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Abstract 
Heart failure is a growing epidemic that affects people nationwide and is disproportionate 
to African Americans. The purpose of this quantitative repeated measures study was to 
determine whether mandibular attachment device (MAD) therapy impacts symptoms of 
heart failure in African American male veterans diagnosed with obstructive sleep apnea 
(OSA). The oxidative stress theory was applied in this study to assess whether MAD 
therapy received from Veterans Affairs (VA) dental clinics impacted heart failure 
symptoms, after controlling for patient body mass index (BMI) levels and smoking status. 
Research questions examined whether MAD had a significant effect on symptoms of 
heart failure in male African American veterans with OSA and whether BMI and 
smoking caused a moderating effect on MAD therapy treating efficacy on symptoms of 
heart failure. Secondary data from the VA was captured through the VA informatics and 
computing infrastructure. Data obtained from 29 records were analyzed using the 
statistical package for the social sciences. The repeated measures multivariate analysis of 
variance and the repeated measures multivariate analysis of covariance were used to 
assess the magnitude of change in heart failure symptoms (ejection fraction, systolic 
blood pressure, diastolic blood pressure, oxygen saturation, brain natriuretic peptide, n-
terminal pro-brain natriuretic peptide, and troponins levels) while controlling for the 2 
covariates. Results showed a positive mean change in systolic blood pressure while using 
the MAD and a negative moderated effect after controlling for BMI at 4-months on 
oxygen saturation. This study will aid positive social change by providing new data that 
can be used by the public health field towards an alternative treatment.  
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Chapter 1: Introduction to the Study 
Introduction 
Obstructive sleep apnea (OSA) is a common respiratory disorder in the United 
States that affects over 25 million adults (American Academy of Sleep Medicine 
[AASM], 2018; Gillespie, Knauret, & Naik, 2015). Adams et al. (2017) indicated that 
over 82% of adult males in the United States remain undiagnosed for OSA. There are 5.9 
million that have been diagnosed with the disease (AASM, 2016). In 2015, those 
diagnosed with OSA had an economic burden of $12.4 billion in the United States 
(AASM, 2016). OSA has been identified as a condition that contributes to heart failure as 
a result of varying amounts of oxygen being received by the body (Chan et al., 2016). 
Heart failure is a disease that impacts 900,000 people in the United States 
annually (American Heart Association [AHA], 2017a). Heart failure symptoms 
frequently occur in those who have OSA occurring in over approximately 50%-80% of 
patients (Abraham et al., 2013). Heart failure is present in 5.7 million people in the 
United States and costs the nation roughly $30.7 billion every year (Centers for Disease 
Control [CDC], 2016). Heart failure is the result of one in four deaths in the U.S. (CDC, 
2017b). 
According to Colvin-Adams, Sharma, and Yancy (2014), African Americans 
appear to be the highest affected ethnic group afflicted with heart failure. Several studies 
reveal that African Americans are disproportionately affected by heart failure, and few 
studies involve African Americans and heart failure (Akinboboye, Jean-Louis, Mitchell, 
Ogedegbe & Olafiranye, 2013; Becker et al., 2014). Continuous positive airway pressure 
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(CPAP) use on those with OSA and heart failure has been effective, though historically 
had low compliance issues, which limits its efficiency (Cistulli et al., 2013). 
Nevertheless, there has been insufficient data to determine whether heart failure 
symptoms are significantly affected by using a mandibular attachment device (MAD), 
which historically has high compliance from those who use the device (Booth, 
Djavadkhani, & Marshall, 2014). 
The following study has examined whether treatment with the MAD effectively 
affects heart failure symptoms in African American male veterans with OSA and whether 
treatment efficacy differs in terms of body mass index (BMI) and smoking status. This 
investigation may result in positive social change for African American male veterans 
diagnosed with OSA and heart failure. In addition, this examination may contribute to the 
increased efficacy and use of MAD treatment. This chapter includes the following: 
background, problem statement, the purpose of the study, research questions, theoretical 
framework, nature of the study, definitions of terms, assumptions, limitations, the scope 
of the review, and significance of this study. 
Background 
Sleep-disordered breathing, such as OSA, has been strongly linked as a 
comorbidity to heart failure (Abraham et al., 2013). Obstructive sleep apnea is the most 
widespread of all sleep disorders (Al-Shorman & Shydfat, 2015) and was four times more 
predominant in men than in women (Ohn & Tin, 2016). An unknown portion of the 
population suffers from sleep apnea without knowing it until confirmed by medical 
professionals (Booth et al., 2014). Approximately 25 million people in the United States 
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have been affected by OSA (AASM, 2018). More than 80% of the cases of moderate to 
severe sleep apnea go undiagnosed until confirmed by medical professionals (American 
Sleep Apnea Association [ASAA], 2017). OSA has significantly been linked to heart 
failure (Barbe, Drager, Lorenzo-Filho, McEvoy & Redline, 2017; Colvin-Adams, 
Sharma, and Yancy, 2014). 
Heart failure is a significant public health concern worldwide and within the 
United States (Lung & Saverese, 2017). In between 2011 to 2014, over 6.5 million of the 
U.S. population had heart failure (Benjamin et al., 2017). Heart failure in the U.S. is 
expected to increase by approximately 46% or roughly 8 million by 2030 (Benjamin et 
al., 2017; Farmakis, Papingiotis & Parissis, 2017; Lung & Saverese, 2017). According to 
Arynchyn et al. (2009), in people of younger ages, heart failure, and higher BMIs are 
present at higher rates in African Americans. African Americans diagnosed with heart 
failure who are less than 50 years old are 20 times more likely to have increased mortality 
than Whites less than 50 years old diagnosed with heart failure (Colvin-Adams et al., 
2014).  
Babson, Bonn-Miller, Del Re & Woodward (2013), using the Veteran Healthcare 
Administration (VHA) database, have demonstrated that OSA has been linked to 
secondary physical complications, including heart failure. The AHA (2017a) indicated 
that high BMI levels and smoking present significant concerns for many Americans 
suffering from sleep apnea and heart failure. Clark, Fonarow, and Horwich (2014) 
revealed that high levels of BMI and being overweight (25-29.9 kg/ m2) or obese (≥ 30 
kg/ m2) are factors that increase the risk of cardiac issues such as heart failure. Smoking 
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impairs endothelial function, increases oxidative stress and vascular inflammation, which 
increases the risk of heart failure (Bauer et al., 2012).  
Heart failure has been linked to multiple indicators, including smoking, obesity, 
hypertension, lack of physical activity, and lifestyle (AHA, 2017a). According to the 
AHA, 2018), an increase in heart failure diagnosis promotes work loss, household 
productivity loss, and encourages premature mortality. Heart failure diagnosis in the 
United States is expected to increase the direct national cost from $30 billion to an 
anticipated $70 billion by 2030 (Greenberg, 2017). 
Treatment of sleep apnea has gained attention as treatment methods have 
expanded to include the use of CPAP, surgery, and oral devices (Gillespie, Knauret, & 
Naik, 2015). Sleep apnea treatment mechanisms have been created to increase airflow 
and reduce gaps in breathing during sleep (Booth et al., 2014). Akinnusi, Anandam, El-
Sohl, Jaoude, & Patil (2013) revealed that sleep apnea treatments relating to the use of 
CPAP have led to reductions in cardiovascular symptoms. A combination of therapies 
that include CPAP coupled with the use of the MAD has been piloted and shown to have 
a significant positive effect on cardiovascular symptoms, though they also display patient 
adherence concerns (Akinnusi, Churder, El-Solh, Lafornara & Moitheennazima, 2011).  
CPAP usage in some studies has shown to be effective against OSA and reducing 
symptoms of heart failure by promoting oxygen, increasing endothelial functioning, 
reducing apnea-hypopnea index (AHI), and lowering blood pressure (Marklund, 
Randerath, & Verbaecken, 2012; Pinto & Sharma, 2018). According to Murariu, Pang & 
Rotenburg (2016), there is a consistent implication across studies over a twenty-year time 
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frame from 1994-2015 of 34.1 % noncompliance with CPAP usage. This high rate of 
non-compliance accentuates the patient need for an alternative treatment for heart failure 
that is similarly effective, cost-effective, noninvasive, and promotes high compliance 
with treatment (Al-Shorman & Shydfat, 2015; Anderson et al., 2016; Bajaj, Kant, & 
Singh, 2017; Marklund et al., 2012). One potential alternative treatment includes the 
MAD. 
The MAD is an oral insertion device received from a dental clinic that moves the 
mandible forward and allows for an increase in airflow when sleeping (Abraham et al., 
2013; Bratton, Gaisl, Kohler, & Wons, 2015). Many of the studies that have used MAD 
to address OSA have primarily included individuals from European or White 
backgrounds as participants. However, African Americans are the racial group most 
affected by OSA (Colvin-Adams et al., 2014). In current practice, the MAD is an 
independent or collaborative method used with and without a CPAP for those who are 
noncompliant with OSA treatment (Abraham et al., 2013). Due to the high patient 
noncompliance rates for the CPAP to treat symptoms of heart failure treatment, the MAD 
may provide an alternative first-line noninvasive option for treatment. Proper use of the 
MAD reduces gaps in breathing, promotes blood flow, and is potentially more cost-
efficient over time compared to the CPAP (Bajaj, Kant, & Singh, 2017; Bennett et al., 
2014; Marklund et al., 2012). The MAD has not explicitly been tested for its efficacy in 
reducing symptoms of heart failure (Abraham et al., 2013; Akinnusi, Anandam, El-Sohl, 
Jaoude, & Patil, 2013; Berge, Gjerde, Lehmann, Johansson, A. & Johansson, A. K., 
2015). However, the MAD may potentially be a non-invasive sleep apnea solution for 
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reducing heart failure symptoms in African Americans with OSA and therefore requires 
further study to assess how the MAD affects symptoms of heart failure (Abraham et al., 
2013; Akinnusi et al., 2013). 
Colvin-Adams et al. (2014) have shown that in the United States, African 
Americans have a higher heart failure prevalence than whites. To further reduce heart 
failure rates among African American males, the goal of this study was to find an 
alternative noninvasive OSA treatment that would significantly reduce symptoms of heart 
failure. This study was necessary to address the gap in the literature, related to CPAP 
noncompliance, which indicates a further need in the public health and medical field for 
an observatory study to identify if the MAD is an alternative first-line treatment for those 
with OSA and heart failure over the age of 20. The need for a further assessment of the 
MADs effect on heart failure symptoms was present due to the unknown cardiovascular 
outcomes resulting from its upper airway stimulation.  
Problem Statement 
Obstructive sleep apnea is commonly undiagnosed and affects veterans nearly two 
times more frequently than other sampled communities (Babson, Bonn-Miller, Del Re & 
Woodward, 2013). Capaldi, Guerrero, and Killgore (2011) found that “redeployed 
combat veterans commonly suffer significant sleep-disordered breathing such as OSA” 
(p. 879).  Approximately 26-36% of veterans served by the VHA have OSA (Casey, 
Knepler, Panos, & Samson, 2012). Of the diagnosed cases of OSA found in veterans 
treated by the VHA, 12-17% of veterans had severe OSA (Casey, Knepler, Panos, & 
Samson, 2012). Additionally, of the 118,105 veterans with OSA served at the Cincinnati 
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Veterans Affairs Medical Center, approximately 13.5% had heart failure (Casey et al., 
2012).  
In between 2007-2009, the prevalence of OSA has increased and is now 
considered a health epidemic that negatively affects African Americans more so than any 
other ethnic race (Bakker et al., 2015). This condition has been strongly linked to 
cardiovascular diseases such as heart failure, and mortality rates continue to climb 
(Colvin-Adams et al., 2014). The use of MAD therapy by patients has shown some 
improvement in vascular functioning and may have similar potential in terms of reducing 
heart failure symptoms (Booth et al., 2014). Nevertheless, there are limited studies that 
have investigated how OSA affects African Americans with heart failure. Currently, 
CPAP machines are the gold standard therapy method for treating OSA (Hwang, 
Mereddy, Parthasarthy, Pepin, & Tamisier, 2018). There appears to be a gap in the 
literature related to the effects of the MAD and cardiovascular symptoms. In a limited 
study by Akinnusi et al. (2013), it has been suggested there may be a possible benefit 
from the MAD on heart failure or cardiovascular disease, however, further analysis was 
needed. 
One in five people in the United States has OSA, while one out of 15 has 
moderate to severe OSA (Bergerhenryent, 2017). African Americans under the age of 25 
and over age 65 are the most affected by OSA (Akinbobye, Jean-Louis, Mitchell, 
Ogedegbe, & Olafiranye, 2013). There remains a debate on the most affected ethnicity 
from OSA between the ages of 26 through 59 years (Akinbobye et al., 2013).  
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In my review of the literature, limited information was identified explicitly 
addressing the use of the MAD to treat OSA and symptoms of heart failure in African 
American males creating a gap in the literature. Duran, George, & Norris (2014) has 
indicated that African Americans appear to be underused in research due to several issues 
including lack of knowledge on behalf of the researcher regarding cultural differences, 
the sensitivity to research among minorities resulting in ineffective communication and 
the lack of consent from African Americans to participate in research. Other issues 
relating to the underuse of African Americans in research include the recruiting of 
minorities requiring extended time before acceptance and participation, the lack of 
consideration from researchers for minorities, and minorities mistrust of researchers 
(Duran, George, & Norris, 2014). Further issues that contribute to the underuse of 
African Americans include both the researcher and the participant’s fear of unintended 
outcomes and lack of confidence due to social repercussions related to stigmas for 
participating in research (Duran et al., 2014). Duran et al. (2014) also indicated that 
barriers involved in the underuse of African Americans in studies may be manifested 
from overt or subtle racism, prejudice, and discrimination from the researcher, 
participant, or community. The focus on African Americans in this study was necessary 
due to the overwhelming number of African Americans who suffer from OSA and heart 
failure and the limitations they experience with regard to treatments that are conducive 
and accessible to meet their needs. This study was conceptualized because of a gap in 
knowledge regarding the isolated use of the MAD as an alternative noninvasive treatment 
for male African Americans veterans diagnosed with OSA and heart failure. 
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Purpose of Study 
The purpose of this quantitative repeated measures study was to examine whether 
MAD therapy impacts symptoms of heart failure in African American male veterans 
diagnosed with OSA. This study has also determined whether treatment efficacy differs 
after controlling for patient BMI levels, including those who are underweight (less than 
18.5 kg/m2), have normal weight (18.5-24.9 kg/m2), are overweight (25-29.9 kg/ m2), 
obese (≥ 30 kg/ m2), or smoke (Downs, Langton, Neyra & Niebuhr, 2016). Secondary 
medical data gathered from the VHA were used to address the research questions. The 
independent variable in this study was the use of the MAD. The dependent variables in 
this study were the symptoms of heart failure (ejection fraction, systolic blood pressure 
[SBP], diastolic blood pressure [DBP], oxygen saturation, brain natriuretic peptide 
[BNP], n-terminal pro-brain natriuretic peptide [NT-proBNP], and troponins levels). 
Identified covariates in this study include BMI and smoking status. 
Research Questions and Hypotheses 
There are three primary research questions that drive this research. The purpose of 
this study was to assess the changes in the values of dependent variables observationally. 
This study used secondary data to evaluate whether the independent variable, the use of 
MAD therapy, impacted the dependent variable, symptoms of heart failure in African 
American male veterans diagnosed with OSA. This study also determined whether 
treatment efficacy differs after controlling covariates, such as BMI levels and smoking 
status. The research questions are: 
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RQ1-Quantitative: Does use of MAD therapy have a statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA? 
H01: Use of MAD therapy does not have any statistically significant effect on the 
symptoms of heart failure (ejection fraction, SBP, DBP, oxygen saturation, BNP, NT-
proBNP, and troponins levels) in male African American veterans diagnosed with OSA. 
Ha1: Use of MAD therapy does have a statistically significant effect on the 
symptoms of heart failure (ejection fraction, SBP, DBP, oxygen saturation, BNP, NT-
proBNP, and troponins levels) in male African American veterans diagnosed with OSA. 
RQ2-Quantitative: What is the moderating effect of BMI on the use of MAD therapy for 
treating symptoms of heart failure in male African American veterans diagnosed with 
OSA? 
H02: BMI levels do not have a statistically significant moderating effect  
on the use of MAD therapy for treating symptoms of heart failure (ejection fraction, SBP, 
DBP, oxygen saturation, BNP, NT-proBNP, and troponins levels) in male African 
American veterans diagnosed with OSA. 
Ha2: BMI levels do have a statistically significant moderating effect on the use of 
MAD therapy for treating symptoms of heart failure (ejection fraction, SBP, DBP, 
oxygen saturation, BNP, NT-proBNP, and troponins levels) in male African American 
veterans diagnosed with OSA. 
RQ3-Quantitative: Does smoking status have a statistically significant moderating effect 
on the use of the MAD therapy for treating symptoms of heart failure in male African 
American veterans diagnosed with OSA? 
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H03: Smoking status (smoker or nonsmoker) does not have a statistically 
significant moderating effect on the use of MAD therapy for treating symptoms of heart 
failure (ejection fraction, SBP, DBP, oxygen saturation, BNP, NT-proBNP, and troponins 
levels) in male African American veterans diagnosed with OSA. 
Ha3: Smoking status (smoker or nonsmoker) does have a statistically moderating 
effect on the use of MAD therapy for treating symptoms of heart failure (ejection 
fraction, SBP, DBP, oxygen saturation, BNP, NT-proBNP, and troponins levels) in male 
African American veterans diagnosed with OSA. 
 This study used the repeated measures multivariate analysis of variance 
(rMANOVA) and repeated measures multivariate analysis of covariance (rMANCOVA) 
to test this correlational study. The principal focus of this research was to use descriptive 
statistics to examine how MAD use affects heart failure symptoms in African Americans 
with OSA, who have various levels of BMI and smoke statuses. The independent variable 
in this study was the use of the MAD. Dependent variables used in this study as 
symptoms of heart failure were ejection fraction, SBP, DBP, oxygen saturation, BNP, 
NT-proBNP, and troponins levels. Body mass index and smoking have been used as 
covariates that may affect the relationship between the use of the MAD and symptoms of 
heart failure in this study. Identification of diagnosis and measurement baselines of heart 
failure and OSA have been gauged by the international classification of disease (ICD-10) 
code diagnosis found in archived records from the medical problem list of the VA 
electronic medical record. Heart failure was assessed by using a ratio level of 
measurement for assessing the magnitude of mean change in the seven dependent 
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variables (ejection fracture, SBP, DBP, oxygen saturation, BNP, NT-proBNP, and 
troponins levels). Obstructive sleep apnea was assessed by reviewing deidentified VA 
archival records containing the identified medical diagnosis of OSA.  The initial 
measurement of the use of MAD treatment in archived records was assumed to begin 
upon receipt of the MAD device from the dental service in the VA electronic record. 
Study results have been utilized to provide information on appropriate outcome use of the 
MAD to the broader African American male population. 
Theoretical Framework 
The theoretical framework used in this study was Denham Harman’s 1972 
oxidative stress theory, which was initially modified from the free radical theory (Birch-
Machin, Bowman & Kandola, 2015; Bisht & Dada et al., 2017; Gladyshev, 2014; Sanz, 
2016). Free radicals are reactive oxygen species (ROS) that can contribute to oxidative 
stress and damage to cellular and DNA structures (Birch-Machin et al., 2015). Oxidative 
stress theory suggests that free radicals induce stress on the mitochondria resulting in its 
dysfunction leading to increased oxidative damage to organs in the body (Goswami & 
Maulik, 2015). The oxidative stress theory suggests that oxidative stress contributes to 
the mechanism of disease progression and heart failure through oxidative damage to the 
cells of the heart resulting in loss of function (Bobak et al., 2015; Bokov et al., 2009; 
Goswami & Maulik, 2015). Oxidative stress theory was applied to this study to explain 
how the MAD might impact symptoms heart of failure before and after controlling for 
patient BMI levels and smoking status by increasing oxygen flow and decreasing the 
stress on the heart. The primary objective of the oxidative stress theory used to explain 
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the effect the MAD has on heart failure is the amount of oxidative stress build-up 
resulting in oxidative damage to lipids, DNA, and proteins in the body that ultimately 
contribute to heart failure (Bokov et al., 2009). This theory was further explored in 
Chapter 2. 
Nature of the Study 
This quantitative nonexperimental study used a repeated measures design. 
Archival data used in this study were collected from the VHA. The targeted population 
was African American male veterans over the age of 20 who obtained treatment in VA 
dental clinics. I assessed secondary data through direct observations of quantitative data 
on mean dependent variable changes. De-identified archived data gathered to measure 
mean dependent variable changes were collected by VA for medical purposes placed in 
medical charts, which include both standardized tests and inquiries.  
A repeated measure test was employed to empirically identify the statistically 
significant changes in heart failure symptoms when using the MAD for the target 
population. As a result, the qualitative design was not appropriate because patient 
observations or opinions were not warranted (Atlasti, 2018). Additionally, the quasi-
experimental design was not appropriate because random assignments, cutoff scores, and 
time-series design were not required (Trochim, 2006). 
Definitions 
Body Mass Index (BMI): A medical determination of a person’s weight in 
kilograms divided by the square of height in meters used to assess weight categories, 
possibly leading to health problems (CDC, 2015a). 
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Brain Natriuretic Peptide (BNP): A medical term that indicates an active 
hormone release in the same molecule that releases Nt-proBNP in reply to changes in 
pressure inside the heart (Cleveland Clinic, 2018b). BNP is a protein produced primarily 
by the left ventricle of the heart (Mangla, 2014).  
Diastolic Blood Pressure: A medical term for the bottom number in a blood 
pressure reading. This number measures the pressure in a person’s blood vessels when 
the heart beats (CDC, 2017d).  
Ejection Fraction: A medical term that describes the percentage of blood leaving 
the two ventricles of the heart chambers during each contraction cycle (Mayo Clinic, 
2018b).  
Heart Failure: A medical term for a chronic progressive cardiovascular disease 
that involves the heart muscle not being able to pump enough blood to supply the body’s 
oxygen and blood needs (AHA, 2017a). 
Mandibular Attachment Device (MAD): One of three approved categories for 
dental sleep devices (Food and Drug Administration [FDA], 2017). MADs are oral 
devices used to move the mandible forward to open airways (Bajaj et al., 2017). 
N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP): A medical term that 
indicates a nonactive prohormone released molecule that releases BNP in reply to 
changes in pressure inside the heart (Cleveland Clinic, 2018b).  
Normal weight: A medical determination calculated according to BMI. A BMI 
ranging from 18.5kg/m2 to 24.9 kg/m2 is considered a normal and healthy weight (CDC, 
2017a). 
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Obese: A medical determination calculated according to high BMI. A BMI above 
30kg/m2 is considered obese, resulting in high prevalence of heart failure (Clark, 
Fonarow, and Horwich, 2014). 
Obstructive Sleep Apnea (OSA): A medical diagnosis for a form of sleep-
disordered breathing that causes repetitive gaps in upper airway breathing during sleep, 
resulting in a diminished airflow (hypopnea) or complete cessation of airflow (apnea; 
Dallas, Holty, Owens, Qaseem, & Shekelle, 2014).  
Overweight: A medical determination calculated according to BMI. A BMI 
ranging from 25 to29.9 kg/m2 is considered overweight, resulting in high prevalence of 
heart failure (Clark et al., 2014). 
Oxygen Saturation (SpO2): A medical term for peripheral oxygen saturation, 
which describes how much oxygen the blood is carrying.  
Oxidative stress: A term to describe the result of reactive oxygen species damage 
to proteins, lipids, nucleic acids as shown in degeneration, aging, and other conditions 
(Huang, Ray, & Tsuji, 2012). 
Reactive Oxygen Species: A term that consists of radical and non-radical oxygen 
species formulated due to an increase or decrease in ROS or an overwhelmed cellular 
antioxidant defense system. The formation of ROS is the result of a partial reduction of 
oxygen, as a result of oxidative stress (Huang et al., 2012). 
Smoking: A term for the inhaling and exhaling of burning tobacco nicotine fumes 
from apparatuses such as cigars, cigarettes, or pipes (National Institute of Health [NIH], 
2020).  
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Systolic Blood Pressure: A medical term for the top number in a blood pressure 
reading. This number measures the pressure in a person’s blood vessels when the heart 
rests between beats (CDC, 2017d).  
Troponins (cTnl and cTnT): A medical term for essential proteins found in the 
blood that produce muscular contractions and provide information on cardiac injuries 
such as acute cardiac syndromes (Jarolim & Mahajan, 2011).  
Underweight: A medical determination calculated according to BMI. A BMI 
below 18.5kg/m2 was considered less than a healthy weight (CDC, 2017a). 
Assumptions 
Assumptions provided were outside of the researcher’s control and assumed to be 
correct. Methods to address these assumptions have been provided and were used to 
maintain the effectiveness of this study. An assumption made in this study consisted of 
using secondary data that was collected and recorded efficiently and accurately. This 
assumption was important to verify there was no missing data that may skew study 
outcomes. To address this assumption, I have checked for accuracy by reviewing the data 
for the identifier variable pertinent to the study and the time frame of the study (Cheng 
and Phillips, 2014). 
Other assumptions made consisted of assuming archived VA electronic record 
data included appropriate information needed to answer the study questions. This 
assumption was important to verify that the research questions being asked could be 
explained by the data being used. To address this specific assumption, I provided 
operational definitions for the independent variables, dependent variables, outcome 
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variables, and covariates to ensure appropriate information was being obtained (Cheng 
and Phillips, 2014).   
Further assumptions were that the quantitative repeated measures study was the 
best method to address the research problem accurately. This assumption was important 
to verify that the study was making the best use of the information provided by the data 
to answer the research question. To address this assumption, I reviewed the criteria for 
the repeated measures design, reviewed the variable data to be used, and developed a data 
plan that included the variables and covariates to be used in the study data set (Cheng and 
Phillips, 2014).  Lastly, another assumption was that smoking consisted of tobacco usage 
unless specifically identified as another smoking substance. To address this assumption, I 
reviewed the smoking data received and verified there were no indications in excess of 
smoking tobacco. Assumptions are important and need to be addressed for the study to 
remain purposeful (Simon, 2011). 
Scope and Delimitations 
Heart failure as a byproduct of OSA in the United States was the focus of this 
study. The purpose of this study was to determine whether treatment using the MAD 
effectively reduces symptoms of heart failure in male African American veterans over 20 
years of age who have been diagnosed with OSA and whether treatment efficacy differs 
after controlling for patient BMI and smoking status. This study does not include 
populations outside of self-identified African Americans. African Americans were used 
in this study due to being underutilized in multiple studies and disproportionately affected 
by heart failure (Bergerhenryent, 2017; Duran et al., 2014).  Study findings could provide 
18 
 
information on alternative non-invasive treatment that will help African American 
veterans over twenty who have acquired the OSA and heart failure diagnosis.  
When considering the study design, I initially considered using the health belief 
model. Browne et al. (2015) indicated that the health belief model’s emphasis was on 
individual awareness, adaptations, and change in health behavior relating to MAD 
effectiveness. After consideration, the oxidative stress theory was selected because it 
suggests oxidative stress to the mitochondria may be due to OSA leading to increased 
oxidative damage in those with heart failure symptoms. This theory has been used in this 
study to explain oxidative stress, oxidative damage, and the effect the MAD intervention 
has on the dependent variables before and after controlling for patient BMI levels and 
smoking status.  
The generalizability of this repeated measures study gathered from secondary data 
allows for statistical inference to be made with fewer VHA records (Jeyabalasingham, 
Lanka, & Ragavan, 2011). A delimitation that I have used within this study was to use 
secondary data to limit my errors when collecting of data error. Other delimitations were 
the use of only including identified African Americans and no other groups to maintain 
the focus of the study. The study was further delimited by the data collection time frame 
between 2016 and 2017. Another delimitation was the use of data only being gathered 
from the VA dental clinics in the U.S. that provided the MAD. Further delimitation in 
this study was the use of 29 archived records that contained the necessary inclusion 
criteria needed for the study. Lastly, another delimitation was the use of the VA 
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informatics and computing infrastructure (VINCI) program due to it being the only 
database to house the VA archived records on the dependent variables in this study.   
Limitations 
Limitations exist within this study involving secondary data from archived 
records. Cheng & Phillips (2014) have argued that limitations of using secondary data 
can consist of existing data not specifically addressing the exact research questions or 
hypothesis’s articulated in a new study due to some variables not being available for 
analysis. Circumstances causing variables not to be available for analysis were due to 
them not being important in the initial collection of secondary data relating to a 
population subgroup, or geographic region (Cheng & Phillips, 2014). Circumstances of 
this type could result in omissions crucial to variable analysis within the study. Therefore, 
limitations in secondary data could result from the data being used, not specifically 
addressing the desired focus of this study or population, resulting in skewed or unusable 
results to answer research questions. 
Cheng & Phillips (2014) have further argued that another limitation using 
secondary data was that confidential data may have been deleted to protect categories 
such as race, age, ethnicity, or other covariate variables. This limitation could result in 
data not reflecting the specific population for the study and excess time being spent 
reviewing the data. According to Cheng & Phillips (2014), researchers collecting data 
may not always be the same person analyzing the data. The change in personnel, 
knowledgebase, and awareness of study distinctions from the researcher could result in 
data inconsistencies. The result of these limitations may be that small specific nuances of 
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information may be missed or glanced over. Cheng & Phillips (2014) have also revealed 
methods to mitigate missed details that include utilizing data from an appropriate 
population, and that covers an accurate geographic location discussed in the study. Other 
methods discussed by Cheng & Phillips (2014) consist of verifying that the secondary 
data used has the correct focus needed for the study and that it utilizes appropriate 
variables that can be resolved through careful examination of relevant documents. 
Significance  
This study was significant because it has the potential to provide useful 
information regarding a possible first-line alternative treatment to the CPAP machine for 
treating people suffering from OSA and heart failure. According to Abraham et al. 
(2009), the use of the MAD in patients resulted in a 52% average improvement apnea-
hypopnea rate <10 for those who use it. Bratton, Gaisl, Kohler, & Wons (2015) indicated 
that there was no difference between MAD use and CPAP use in terms of blood pressure, 
which can be used as a marker for cardiovascular diseases. Though very little data was 
available regarding the impact of the MAD on heart failure among those with OSA, the 
MAD may have the potential for similar efficacy values for treating symptoms of heart 
failure symptoms (Akinnusi et al., 2013; Booth et al., 2014).  
Social Change Implications 
Cistulli et al. (2013) used one-month trials when reviewing the MAD in 
comparison to CPAP treatments relating to cardiovascular functioning. This research 
study supports professional knowledge, practice, and policy by providing a longer-study 
term than has previously been conducted that references the relationships between the use 
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of MAD and changes in heart failure symptoms (Marklund et al., 2012). This research 
can be beneficial to patients wanting to objectively assess the MAD’s impact on heart 
failure symptoms across time in terms of its effectiveness on the underused and under-
assessed African American male U.S. veteran population. Additionally, this study 
supports both the public health and healthcare fields’ professional practice by serving as a 
reference for local, state, and government agencies and medical providers regarding 
whether to request MAD. Casey et al. (2012) indicated that 26-36% of the veteran 
population served by VHA who have OSA, and the 13.5% that have heart failure. 
Findings from the study could be used to promote progressive social change by adding 
new information to the public health and medical field that can be used for medical 
providers, patients, and policymakers to develop a better understanding of MAD 
treatments for OSA and symptoms of heart failure. Moreover, this study could encourage 
patient self-efficacy by providing information that can better equip medical personnel to 
explain and estimate the effect the MAD may have on heart failure symptoms in African 
American male veterans with OSA. 
Findings from the study could be used to contribute knowledge regarding how 
patient’s use of MAD therapy impacts OSA and symptoms of heart failure in African 
American male veterans. The results could provide data that can be used to promote the 
use of a cost-effective alternative treatment as opposed to the cumbersome and often 
expensive CPAP to treat those with both OSA and symptoms of heart failure. The results 
of this study may provide both providers, patients, policymakers, and African American 
male Veterans an awareness of the benefits of the MAD that may trigger a reevaluation 
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of the types of treatment options dental providers, hospitals, and healthcare organizations 
offer. Healthcare professionals could use the information to promote and advocate for 
healthcare policy changes in hospitals, clinics, and agency dental and medical care 
guidelines for the treatment of OSA and heart failure that could encourage insurance 
coverage of the MAD to treat OSA and possibly reduce symptoms of heart failure in 
African American veterans. 
Summary 
In this chapter, I have distinguished that both OSA and heart failure are 
significant public health concerns in the United States. African Americans are severely 
affected by both OSA and heart failure (Ambrosy et al., 2014; Arynchyn et al., 2009; 
Badr, Pranathiageswaran, Rowley, & Severson, 2013; Becker et al., 2014; Colvin-Adams 
et al., 2014; Dudley & Patel, 2016). Heart failure is a rising epidemic amongst minorities, 
though there have been some successful non-pharmacological and limitedly invasive 
methods such as CPAP in place to provide maintenance and control for its reduction 
(Kato, Kasai & Suda, 2014). According to Colvin-Adams (2014), African Americans 
have higher heart failure prevalence, and death rates once admitted to hospitals for heart 
failure than any other ethnic group. Additionally, the rate of heart failure-associated 
deaths and morbidity are highest amongst African Americans (Colvin-Adams et al., 
2014). Forces behind the growing pervasiveness of heart failure include being 
overweight, hypertensive, smoking, obesity, and lifestyle. 
This study looked to assess the MAD effect on heart failure symptoms and the 
two main covariate factors smoking and BMI by establishing quantitative research 
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questions that can be explained within the theoretical framework. A repeated measures 
study design was used to provide clarification regarding the research problem by 
reviewing the same archived variables at different monthly intervals throughout the study 
(Goff, Schwartz &Wilson, 2018). Results from this study possibly could lead to 
alternative methods of treatment that would encourage compliance and improve air intake 
needed to reduce heart failure levels among African Americans. As a result, this study 
may lead to social change, reduce symptoms of heart failure, promote increases in life 
expectancy, life quality through increased airflow, and reduce healthcare costs. Chapter 2 
includes influential and peer-reviewed articles and studies to address the study focus 
relating to literature search strategies, the theoretical foundation, and a literature review 
related to key variables.  
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Chapter 2: Introduction 
Introduction 
This study evaluated whether the use of the MAD significantly reduces heart 
failure symptoms in male African American veterans with OSA above the age of 20 and 
whether treatment efficacy differs in terms of BMI and smoking status. Chapter 2 
includes information on literature search strategies, the theoretical foundation, and a 
literature review related to key variables. This chapter covers the impact that OSA, BMI, 
heart failure, and smoking have had on African Americans as well as current treatment 
methods for OSA and the need for an alternative solution. The current literature review 
covers BMI, smoking, African Americans, BMI and smoking, BMI, smoking and African 
Americans, OSA, heart failure; biomarkers of heart failure, prevalence of heart failure, 
prevalence of OSA and heart failure, race, OSA and heart failure on race, BMI and heart 
failure; smoking and heart failure, oral devices and obstructive sleep apnea, MAD, 
CPAP, CPAP versus MAD, CPAP versus MAD economic cost, summary, and 
conclusion. 
Literature Search Strategy 
Advanced search engines and libraries that were used to access literature and 
databases included Google Scholar, the Florida Agricultural and Mechanical University 
Library, the VA Library, and the Walden University Library. Literature databases used to 
gain access to data, national websites of organizations, peer-reviewed articles, journals, 
online books, reports, and studies, consist of the American Medical Association, BioMed 
Central, Centers for Disease Control, Google Scholar, Horizons, Medline, Medline Plus, 
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NIH Public Access, ProQuest, PubMed, Science Direct, and SpringerLink. Search 
phrases or combination of phrases used to locate literature were African American heart 
failure, BMI, cardiovascular mortality, continuous positive airway pressure, heart failure, 
heart failure risk factors, heart failure mortality, oral devices, MAD, mandibular oral 
device, OSA, overweight, oxidative stress theory, mandibular respiratory device, 
mandibular respiratory splint, obesity, respiratory appliance, sleep medicine, sleep apnea, 
sleep breath, smoking, and veteran. Data and reports used in this study were published 
between 2010 and 2019. This literature review includes 77 seminal and peer-reviewed 
articles. While performing research, there appeared to be contradicting information 
related to CPAP versus MAD efficacy and limited information related to the effect the 
MAD has on African American veterans with heart failure, which supported the necessity 
of this study. Research on evaluating whether the use of the MAD significantly reduces 
heart failure symptoms in male African American veterans with OSA has been limited. 
Partialized information from various studies was used to describe gaps in the literature 
and the need for further observatory evaluations of the study topic that include longer 
study periods.  
Theoretical Foundation 
The oxidative stress theory serves as the theoretical foundation for this study. The 
oxidative stress theory was created by Denham Harman and extracted in 1972 from the 
free radical theory to explain how molecular damage occurs in the body (Birch-Machin et 
al., 2015; Sanz, 2016). The oxidative stress theory was used to indicate how oxidative 
stress affects the mitochondria, leading to increased oxidative damage (Goswami & 
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Maulik, 2015). This theory implies that increased oxygen stress levels caused by OSA 
contribute to heart failure under normal metabolic processes causing oxidative damage to 
macromolecules including lipids, DNA, and proteins resulting in loss of function 
(Lagouge & Larson, 2013).  
The purpose of this theory was used to indicate that oxidative stress on cells was 
the primary cause of the mitochondria being attacked, resulting in oxidative damage to 
the body. This theory was driven by the theoretical belief that the mitochondria generates 
significant amounts of cell energy, consuming over 90% of cellular oxygen, and is a 
target of ROS, ultimately setting the limit on lifespan as a result of a loss of function 
(Lagouge & Larson, 2013). In sum, when oxidative stress attacks mitochondria, it leads 
to increased oxidative damage, which causes a decrease in efficacy and a loss of 
functional integrity (Birch-Machin, Bowman, & Kandola, 2015; Sanz, 2016). Eisele, 
Markart & Schulz (2015) have used the oxidative stress theory among humans with OSA 
in relation to cardiovascular diseases, indicated that there was growing evidence to 
support the pathophysiology of untreated OSA causing oxidative stress resulting in 
morbidity and mortality. Additionally, this study has indicated that OSA treatments such 
as CPAP have been used to effectively reverse these abnormalities (Eisele, Markart & 
Schulz, 2015).  
Studies from Cistulli et al. (2014b) and Marklund, Randerath, & Verbaecken 
(2012) have also displayed that the use of MAD may also advance oxidative stress and 
endothelial function. Due to past studies identifying the usefulness of CPAP as an OSA 
treatment method to address oxidative stress, this study may represent the step necessary 
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to support the additional impact of MAD on heart failure symptoms. The oxidative stress 
theory concept was used to suggest that those who suffer from OSA and heart failure 
related to oxidative stress have potentially impacted mitochondria resulting in oxidative 
damage that possibly affects symptoms of heart failure.  
Bokov et al. (2009) argued that the use of oxidative stress theory on secondary 
data has shown a correlation between increased lifespan, reduced oxidative stress, and 
oxidative damage. Richardson & Schadt (2014) and Bokov et al. (2009), has also 
revealed that experimental manipulations have increased rodent lifespans and displayed a 
reduction in oxidative damage to macromolecules. The oxidative stress theory was used 
in this study to explain how damaged cells that result in increased heart failure symptoms 
are impacted by the MAD while controlling for BMI and smoking status. This theory was 
used to indicate how reducing oxidative stress on heart failure symptoms can be 
associated with lowering oxidative damage, therefore increasing heart function. If 
impactful, the oxidative stress theory could yield useful information relating to the effect 
of the MAD on heart failure symptoms while providing data to suggest the use of 
alternative heart failure treatments. 
Literature Review Related to Key Variables 
Sleep apnea awareness began in the mid-1960s after the first recorded 
polysomnography test, which was used to record apnea episodes during sleep 
(Bahammam, 2011; Resmedica, 2011). Resmedica (2011) has shown that in 1978 in the 
je Remmers study indicated that OSA was identified to occur at the point of the airway 
closure in the oropharynx. Obstructive sleep apnea leads to adverse medical 
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consequences when left unmanaged (Javaheri, Javaheri, & Javaheri, 2013). Unmanaged 
OSA causes large intrathoracic pressure swings, which increase both the left and right 
ventricular pressure, potentially resulting in cardiac arrhythmias, atrial distensions, and 
pulmonary congestion (Javaheri et al., 2013). Additionally, OSA causes multiple sleep 
arousals, which may lead to increased voluntary activity, decreased involuntary activity, 
increased blood pressure, and heart rate during sleep (Javaheri et al., 2013). Obstructive 
sleep apnea also results in oxygen desaturation during sleep, followed by a period of 
recovery where reoxygenation and reduced carbon dioxide occur. As a result of increased 
ventilation causing sympathetic activation resulting in pulmonary arteriolar 
vasoconstriction, pulmonary artery pressure, right ventricular afterload, and abnormal 
enlargement of the heart may occur (Ayas, Badran, & Laher, 2014; Javaheri et al., 2013). 
This recurrent cycle of hypoxia and reoxygenation, known as ROS, results in endothelial 
cell dysfunction (Chen et al., 2017). Obstructive Sleep Apnea contributes to 
approximately 12-53% of heart failure cases (Ayas, Badran, & Laher, 2014). Obstructive 
sleep apnea promotes systematic hypertension and may result in complications involving 
left-sided heart failure and ejection fraction (Ayas et al., 2014; Javaheri et al., 2013).  
Heart failure has been indicated as an epidemic due to its spread across ethnicities 
and its specific effect in the U.S. (Dunlay & Roger, 2014). Common risk factor for heart 
failure includes hypertension, obesity, smoking, physical inactivity, excessive alcohol 
intake, poor diet, hyperlipidemia, atherosclerosis, and diabetes mellitus (Colvin-Adams et 
al., 2014). Diagnosis of this disease is often identified by either a physician, respiratory 
therapist, or dentist. 
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Treatment methodologies for those with OSA resulting in adverse health 
outcomes such as heart failure have expanded over the years, and now depending on the 
level of the diagnosis, may include invasive or noninvasive treatment (Colvin-Adams et 
al., 2014). Economically, untreated OSA potentially translates into healthcare dollars 
over economic cost and are higher for those undiagnosed with OSA (Gillespie et al., 
2015). Non-invasive treatment methods currently involve CPAP use initially (Kasai et al., 
2014). There are several clinical practice guidelines from the American Academy of 
Sleep Medicine and the American Academy of Dental Sleep Medicine [AADSM] 
recommendations for oral device use (Chervin et al., 2015). Practice guidelines for the 
receipt of the MAD suggest that it was provided upon patient request, if the there was a 
sleep physician recommendation or if there was patient intolerance with CPAP, rather 
than no therapy at all (Chervin et al., 2015). Additionally, if provided an oral device for 
OSA, most qualified dentists use a custom titratable oral device over a non-custom 
device, provide oversight, conduct follow-up sleep testing, and request patients return for 
periodic office visits for monitoring (Chervin et al., 2015). 
BMI 
The BMI is a frequently used measurement for assessing body composition 
(Downs et al., 2016). The BMI has been identified by the World Health Organization 
(WHO) in a scale indicating those who have BMI < 18.5 as underweight, those with a 
BMI between 18.5-24.9 as normal, those between 25-29.9 as overweight and those with 
BMI >30 as obese (Downs et al., 2016).  In 2015, 159 million United States adults, 
approximately 69%, were listed as obese or overweight (Arnett et al., 2015). 
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Figure 1. From “Higher BMI Means Higher Risk of Heart Disease and Heart Failure: 
BMI and heart disease have a cause-and-effect connection, not just a link” by J.J. Brown, 
2018 (https://www.everydayhealth.com/heart-failure/living-with/bad-news-if-your-bmi-
is-high-fat-causes-heart-failure/).   
Downs, Langton, Neyra & Niebuhr (2016) reported data from 2011-2012 that has 
indicated that the overweight prevalence of those with a BMI ≥ 25 kg/m2 in the United 
States, ages 20 to 39 is greater than 60%. Obesity is the fifth leading cause of death in the 
world (Dare, Mackey & Pell, 2015). The obesity prevalence of those with a BMI of ≥ 30 
kg/m2 in the United States, ages 20 to 39, is higher than 30% (Downs et al., 2016). 
Dudley & Patel (2016) have shown African Americans compared to all other ethnicities 
have a 51% greater likelihood of obesity even after controlling for age, sex, and 
comorbidities. The prevalence of obesity among African American men in the United 
States in 2012 was 37.1% and 56.6% for African American women (Dudley and Patel, 
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2016). In multiple studies by Dudley & Patel (2016) and Chaturvedi & Marulanda-
Londono (2017), an increased BMI was associated with OSA and suggests an increased 
risk for heart failure. In sum, BMI has a significant effect on African Americans ages 20 
and older in the United States and was a factor for heart failure. 
Smoking 
Both smoking and high BMI are major public health concerns that are increasing 
globally (Dare et al., 2015). Smoking is the inhalation of carcinogenic chemicals from 
tobacco (Institute of Medicine, 2015). There are over 7,000 toxic carcinogens in tobacco 
(Institute of Medicine, 2015). Smoking is the principal cause of preventable mortality in 
the United States (Dixon-Williams, Krishnan & Thornton, 2014). There are 
approximately 5-6 million people who die annually as a result of smoking. Though 
smoking prevalence has dropped in the United States, rates are still as high as 30% in 
some states (Dixon-Williams et al., 2014). Currently, approximately 40 million 
Americans smoke, leaving themselves at risk for premature mortality and morbidity 
(Dixon et al., 2014). Over 29.8 % of those that smoke in the United States are African 
Americans (CDC, 2018b). Smoking is a major contributor of illnesses such as cancer, 
respiratory, heart disease, stroke, and cardiovascular disease (CDC, 2018b; Dare et al., 
2015; Dixon et al., 2014; Institute of Medicine, 2015). 
 Smoking was estimated to cause over 480,000 deaths annually in the United 
States; 160,600 are linked to cardiovascular disease (Institute of Medicine, 2015). A 
single puff of smoke from a cigarette exposes the smoker to over 1015 free-radical 
causing a significant amount of oxidative stress and immediate oxidative damage 
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(Institute of Medicine, 2015). In sum, smoking is a substantial concern for African 
Americans, causing various life-threatening diseases and conditions. Smoking also causes 
oxidative stress resulting in oxidative damage to the body contributing to cardiovascular 
disease. 
African Americans 
According to the United States Census Bureau (2019), in 2018, there were 
approximately 47.8 million African Americans in the United States. Over 13.5% of 
African Americans in the United States are in fair to poor health, while 11.3% of those 
over 65 have no insurance (CDC, 2017b). There are approximately 22.9 million African 
American males in the United States (United States Census Bureau, 2019). Of the 
African Americans living in the United States, there are 21.6% of men that smoke (CDC, 
2017b). Over 88% of African Americans are more likely to have OSA than whites 
(Dudley & Patel, 2016). In an analysis of data from the National Health and Nutrition 
Examination Survey (NHANES), African Americans appear to be more strongly 
associated with hypertension related to cardiovascular disease as a result of the diagnosis 
of OSA than Hispanics or whites (Dudley & Patel, 2016). The leading cause of death in 
African American males as of 2015 was heart disease at a rate of 23.9% (CDC, 2018a). 
Heart disease has been the leading cause of death in African Americans by race, 
ethnicity, and gender since as late as 2013 (Heron, 2017; The National Academic Press, 
2017). In sum, the data provided by the CDC (2018a) and Dudley & Patel (2016) indicate 
the significant impact of heart failure on African American males relative to the 
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population living in America. Therefore, there is a need to utilize African Americans in 
this study as a significantly affected population. 
BMI and Smoking  
Body mass index and smoking are growing health epidemics that have been 
linked to heart failure. There is a complicated relationship between high BMI and 
smoking that may not be completely understood and has had a history of conflicting 
study results (Bush et al., 2011). There also appears to be some reverse causation relating 
to smoking and BMI, suggesting that those who are overweight are more likely to start 
smoking than those not overweight (Dare et al., 2015). Additionally, reports have also 
indicated that fear of weight gain has resulted in former smokers relapsing. Reports from 
this study further indicated that those who have a high BMI and who smoke are more 
likely to be among those who are socioeconomically deprived. Additionally, BMI was 
sometimes derived from self-reported weight and height measurements, which may tend 
to be overestimated and weight underestimated. 
Smoking and BMI have been synonymous through myth and association. Myths 
include the idea that smoking protects the user from weight gain (Dare et al., 2015). The 
study by Dare, Mackay & Pell (2015) was developed to explore the association between 
smoking and BMI > 30 kg/m2 in adult’s age 31 to 69 years. Results showed those who 
currently smoke were less likely to have a high BMI than those who never smoked (Dare 
et al., 2015). However, those who were former smokers were more likely to have a higher 
BMI than those who never smoked (Dare et al., 2015). Nevertheless, obesity increased 
with the amount smoked and that former heavy smokers had a higher BMI than former 
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light smokers (Dare et al., 2015). Therefore, showing that the synonymous myth that 
smoking protects a person from weight gain was overgeneralized (Dare et al., 2015).  
Another study by Plurphanswat & Rodu (2014) showed that smokers have a lower 
BMI and a probability of obesity greater than those who have never smoked. This study’s 
focus was to evaluate the association amongst smokers, selected demographics, and BMI 
on those 25-64 years of age (Plurphanswat and Rodu, 2014). Results indicated that males 
who smoked had a 6.9% lower BMI mean than those who had never smoked or who were 
former smokers (Plurphanswat and Rodu, 2014). Study results have also indicated that 
African Americans and Hispanics had a higher BMI than any other ethnicity within the 
study (Plurphanswat and Rodu, 2014). In sum, multiple studies have shown that there 
may be reverse causation amongst factors of BMI and smoking and that males appear 
consistently more affected by both factors. Therefore, these two characteristics should be 
reviewed as covariates in this study due to the effect they may have on African 
Americans with OSA. 
BMI, Smoking, and African Americans 
Body mass index and smoking are important risk factors that are strongly linked 
to a variety of health concerns for African Americans. In a follow-up prospective cohort 
study by Bethea et al. (2014) on a pooled all-cause analysis of BMI and mortality among 
African Americans from several studies indicated that obesity was linked to a higher risk 
of mortality in African Americans than whites or Asians. The study used a multitude of 
additional studies that included 239,526 participants, from ages 30 to 104 (mean age of 
52 years old), all followed for an average of 11.7 years, half of the participants reported 
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smoking (Bethea et al., 2014). Of the population studied, a third were overweight with a 
BMI between 25-29 kg/ m2, and another third were obese with a BMI over 30 kg/m2. 
Data indicated that being overweight was higher in men than in women (Bethea et al., 
2014). In both male and female African Americans, it was noticed that in subjects whose 
BMI increased, there was an increase in hazard ratios resulting in 11,386 deaths (Bethea 
et al., 2014). There was a more significant effect in women, the closer they were to BMIs 
of 27.4 kg/m2 and the higher men were to BMIs greater than 30 kg/m2 (Bethea et al., 
2014). However, with increased BMI, there was a continuous reduction in smoking. The 
prevalence of those who were overweight and obese was shown to increase drastically 
among African Americans and in recent decades in the United States, are expected to 
continue growing in African Americans (Bethea et al., 2014). 
In a randomized control study by Antoni et al. (2018), it identifies that African 
Americans between 18-65 years of age gained an excessive amount of weight after 
attempting to quit smoking. This study’s main focus was to study the pattern in weight 
gain by participants and study the association between smoking, weight gain, and 
smoking cessation treatment in African Americans (Antoni et al., 2018). This study has 
shown that African Americans experience the highest rate of tobacco-related deaths than 
any other ethnicity and have a higher level of obesity (49.5%) and percentage of those 
who are overweight (76.7%) than whites (Antoni et al., 2018). Additionally, over 80% of 
smokers gain weight in the first three months after they have attempted to quit, followed 
by a smoking relapse (Antoni et al., 2018). Results indicated that there was an overall 
weight increase of 0.62 pounds per month or 4-10 pounds throughout the study for all 
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participants who did not abstain from smoking (Antoni et al., 2018). Those that did 
abstain from smoking gained an increased average of 1.2 pounds per month or 7.26 
pounds throughout the study (Antoni et al., 2018).  
In the study by Gapstur, Hildebrand & Patel (2014), it has indicated that BMI and 
smoking are highly significant in blacks and that those who smoke and are underweight 
or in high weight category pertaining to BMI had a higher risk for mortality. This study 
assessed the risk of mortality according to BMI in both whites and blacks who smoked 
and had a prevalent disease (Gapstur, Hildebrand & Patel, 2014). Results revealed that 
BMI was highest in those who had never smoked or who had a prevalent disease and that 
BMIs in those considered overweight were linked to a significantly high risk of mortality 
(Gapstur et al., 2014). Additionally, smoking was associated with greater mortality in 
blacks with both a prevalent disease and those who smoke (Gapstur et al., 2014). Further 
results have indicated that the absolute mortality rates were higher in blacks than whites 
in each BMI category and that BMI was strongly associated with mortality prior to age 
70 (Gapstur et al., 2014). In sum, the information in the above studies indicates that with 
an increase in BMI, smoking declines. Additionally, there was an indication that weight 
gain was less associated with smoking for those who do smoke and was more likely for 
those that do not smoke contributing to the current public health condition of BMI and 
smoking. As a result of the significance of African Americans affected by these two 
epidemics, this study used both BMI and smoking as covariates on African Americans. 
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OSA 
Obstructive sleep apnea occurs involuntarily and repeatedly when the back of the 
throat collapses on the airway while sleeping, which stops or slows down oxygen from 
entering the lungs (American Lung Association [ALA], 2018). This study has several risk 
factors consisting of gender, age, and those who are excessively overweight (ALA, 
2018). Symptoms of the OSA condition consist of snoring pauses in breathing, daytime 
sleepiness, and difficulty in control medical issues (ALA, 2018). OSA affects 
approximately 24.9 million adults in the United States (Watson, 2016). African 
Americans are 3.5 times more likely to receive OSA than any other ethnicity (Farinde, 
2015). Obstructive sleep apnea appears 2-8 times more in males than females and shows 
a significant increase with age after age 20 through 65 and higher (Ayo-Yusuf, Motloba, 
Solomons & Sethusa, 2015).  
Obstructive sleep apnea has been shown as a significant health issue over the last 
20 years, resulting in various increased health risks, including cardiovascular issues 
(Gillespie et al., 2015). Gillespie et al. (2015) revealed that within the Wisconsin Sleep 
Cohort study, approximately 13 million Americans over age 30 had moderate to severe 
OSA, and 9% were men (Dempsey, Palta, &Young, 1993 as cited in Gillespie et al., 
2015). Additionally, 29.5 million Americans over age 30 have mild to severe OSA, and 
24% are men (Gillespie et al., 2015). As a result of untreated OSA, patients may be at 
risk for cardiovascular morbidities and hypertension as well as all-cause mortality or high 
cardiovascular mortality with a 2.4 relative risk for heart failure (Gillespie et al., 2015). 
Additionally, due to untreated OSA, heart failure was found likely to occur six times or 
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more compared to control having a reduced left ventricular ejection fraction (Gillespie et 
al., 2015).  
Obstructive sleep apnea has also been linked to a fall in oxygen saturation levels, 
vacillating heart rate, and blood pressure (Badr et al., 2013; Booth et al., 2014). However, 
if left untreated, OSA was linked to cardiovascular diseases such as heart failure, stroke, 
and a three to four times higher mortality risk rate (Badr et al., 2013; Booth et al., 2014). 
The link between OSA and heart failure was considered to be due to the continual 
amount of low levels of oxygen being inhaled and getting to the heart, resulting in 
changes in blood pressure and carbon dioxide levels (Cleveland Clinic, 2018a). In sum, 
OSA is an involuntary condition that was likely to occur with increased weight and age. 
This disease also affects African Americans more than any other ethnicity and contribute 
to both heart failure and death. 
Heart Failure 
Heart failure is a condition of OSA and is often called congestive heart failure, 
which occurs when the heart fails to pump blood through the body as effectively as it 
should (AHA, 2018; Mayoclinic, 2018a). The first research on heart failure came about in 
1971 as a result of the Framingham study, which linked to the failing health and 
imminent death of President Franklin D. Roosevelt to heart disease (Gordon, Kannel & 
Schwartz, 1971 as cited in Levy, Mahmood, Vasan & Wang, 2013). The Framingham 
Study indicates an evolving heart failure diagnosis that began in the 1960’s and continues 
to grow to include elevated lipids (troponins), myocardial infarction (which precede 
ejection fraction), and high blood pressure (Gordon, Kannel & Schwartz, 1971 as cited in 
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Levy et al., 2013). This disease is both acute and chronic, resulting in symptoms related 
to difficulty breathing, weakness, swelling, limited movements, irregular heartbeat, and 
chest pains (Mayo Clinic, 2018a).  
The majority of research related to reducing heart failure has focused on 
ethnicities affected, epidemic prevalence, risk factors, diagnosis, and standard treatment 
methodologies. The effect of heart failure is one that has been shown to affect all 
ethnicities, including 6.6 million people in the United States (Colvin-Adams et al., 2014). 
Heart failure has resulted in approximately a 50% death rate within 5 years of receiving 
the disease (CDC, 2016). This disease disproportionately affects African Americans more 
than whites or any other ethnicity (Akinboboye & Cuyjet, 2014). This disease specifically 
affects African Americans at a rate of 4.6 per 1,000 person-years (Colvin-Adams et al., 
2014). Heart failure incidence and prevalence is attributable to an increased burden of 
traditional risk factor amongst African Americans (Albert et al., 2017).  
 Akinboboye & Cuyjet (2014) showed that within 82 African Americans out of 
316 white participants, African Americans had a 50% risk of death and mortality versus 
whites. This affliction has been compacted by the result that the population most affected, 
African Americans, not having experienced the same benefit from treatment as whites 
(Colvin-Adams et al., 2014). The literature review provided in this study indicated that 
the skew in effect on African Americans may be a result of risk factors associated with 
heart failure being considerably more prevalent in African Americans. Nevertheless, 
African Americans are underrepresented in heart failure trials, though the reason is not 
well understood (Albert et al., 2017). The significance of African Americans being 
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underrepresented in studies makes it difficult to draw accurate conclusions about 
ethnicities and races (Clark, Ehlen & Paul, 2016). In sum, heart failure is a result of OSA 
that affects African Americans disproportionately and, in some cases, maybe due to not 
undergoing similar benefits from treatment as other ethnicities and being underutilized in 
trials. 
Biomarkers of Heart Failure 
Kimmenade & Januzzi (2011) argued that heart failure has been indicated as a 
considerable burden on the medical healthcare field and population. The report focuses 
on identifying appropriate biomarkers for elective, supplemental diagnostic for heart 
failure (Kimmenade & Januzzi, 2011). In this study, the researchers identified various 
perspectives on evaluating heart failure, including alternative methods. The researchers 
have created standards of which to evaluate biomarkers such as biomarkers should be 
measurable at a reasonable cost, able to increase knowledge through the use of a clinical 
workup, and be beneficial in the management of cardiovascular disease (Kimmenade & 
Januzzi, 2011). Other quantifiable methods are that biomarkers identify the cause, 
presence, and absence of heart failure while indicating its severity (Kimmenade & 
Januzzi, 2011). Researchers have identified several promising and useful biomarkers in 
identifying heart failure. Specific biomarkers that have proven to be historically practical 
in identifying heart failure symptoms such as BNP and NT-proBNP, which assist in 
identifying vessel stretching, injury, and hypoxia (Kimmenade & Januzzi, 2011). Another 
biomarker that was indicated was t ST2, which identified the myocardial strain and was 
used to monitor heart failure severity (Kimmenade & Januzzi, 2011). Additionally, the 
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researchers have used troponins as a method to assess myocardial necrosis or cell death in 
a failing heart (Kimmenade & Januzzi, 2011).  
In the study by Anand et al., (2017), the focus is on gathering and summarizing 
existing literature on guidance, utility, and availability of heart failure biomarkers. A 
biomarker has been defined as “any substance, structure, or process that can be measured 
in the body or its products and influences or predicts the incidence of outcome or 
disease” (Anand et al., 2017, p. e1055). The researchers found that symptoms of heart 
failure, such as BNP, can accurately diagnose heart failure patients presenting to 
emergency departs with 90% sensitivity. Researchers have indicated that appropriate 
biomarkers form the blood accuracy level, while Nt-proBNP has a higher sensitivity 
ruling out heart failure (Anand et al., 2017). Other heart failure symptoms, such as 
troponins, strongly predict heart failure risk, can detect heart failure severity, assess risk, 
guide therapy, and prevention (Anand et al., 2017). 
Gaggin & Januzzi (2015) sought to provide a distinction between different 
biomarkers as it related to heart failure. This article displays the heart failure biomarkers 
by identifying myocardial stress/injury through markers such as BNP, NT-proBNP, 
proBNP, and troponins, neurohormonal activation through Mid-regional pro-
adrenomedullin (MR-pro ADM), remodeling through the ST2 gene and other 
comorbidities that contribute to heart failure (Gaggin & Januzzi, 2015). Gaggin & 
Januzzi (2015) indicated that the AHA has shown that both BNP and NT-proBNP have 
been recommended for assessing both diagnosis and prognosis. Additionally, troponins 
have received approvals for aiding in identifying the prognosis and the finding of acute 
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myocardial infarction as the preliminary of acute heart failure (Gaggin & Januzzi, 2015). 
Biomarkers displayed have value in informing change from clinical care and also indicate 
if there was an improvement in prognosis. The information yielded from the researchers 
in this article have shown identifiers that can be used to monitor, assess, and benchmark 
heart failure. In sum, identified biomarkers used in this study as dependent variables are 
both viable and reliable to accurately identify and monitor heart failure. 
Prevalence of Heart Failure 
Over 5.7 million are diagnosed with heart failure, costing the nation 30.7 billion 
dollars annually in missed days of work, healthcare, and medications (CDC, 2016). 
Emory Healthcare (2018) has displayed there are over 500,000 new cases of heart failure 
a year. Of those identified with heart failure, 1.4 million are under the age of 60, and 
more than 5% are between the age of 60 and 69 (Emory Healthcare, 2018). Emory 
Healthcare (2018) has displayed that African Americans are 1.5 times more likely to 
develop heart failure than whites. 
In a compendium review article by Colvin-Adams et al. (2014) on information 
about heart failure in African Americans related to management and challenges, it has 
been indicated that heart failure is increasing despite 20 or more years of medical and 
surgical therapies. Colvin-Adams et al. (2014) has shown that as a result of the AHA data 
indicates that African Americans receive heart failure at a rate of 9.1 per 1,000 person-
years versus whites at 6 per 1,000 person-years. This outcome was accompanied by a 
similar result from the artherosclerosis risk in community’s study, which has shown that 
new onsets of heart failure are acquired at a 4.6 per 1,000 person-years in African 
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Americans versus Chinese at 1.0 per 1,000 person-years and whites at 3.5 per 1,000 
person-years ( Bahrami, Bluemke & Kronmal (2008) as cited in Colvin-Adams et al., 
2014). 
In a study by Cheriyath, Guduru, Jadhao, Komanduri & Went (2016), it shows 
that despite population awareness and medical advancements, the same risk factors for 
heart failure continue. Cheriyath et al. (2016) analyzed NHANES data from 2013-2014, 
which explained the changes in the prevalence of the heart failure epidemic. The 
researchers indicated that heart prevalence in Americans is over 23 million, affecting 
1.9% of the population (Cheriyath, Guduru, Jadhao, Komanduri & Went, 2016). Of those 
affected by heart failure, the males appear to be significantly more affected, with a 
prevalence of 1.8% (Cheriyath et al., 2016). Additionally, researchers from this study 
have indicated that heart failure continues to grow at a significant rate, potentially 
attributable to awareness and advancement in diagnosis (Cheriyath et al., 2016). 
Cheriyath et al. (2016) have shown that the primary risk factor consists of coronary artery 
disease and hypertension, those over 65 years old, and increasing obesity. In sum, heart 
failure is an epidemic that considerably affects African Americans more 
disproportionately than other ethnicities, and is increasing at a significant rate. The 
Cheriyath et al. (2016) result provides information indicating the need for this study to 
attempt to find an alternative method to reduce this major health concern. 
Prevalence of OSA and Heart Failure 
Obstructive sleep apnea has been linked to heart failure and estimated to cost 3.4 
billion annually (Akinboboye, Jean-Louis, Mitchell, Ogedegbe & Olafiranye., 2013). In 
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the study by Lombardi, Losurdo, Montano, Parati & Tobaldini (2017), it has been 
indicated that there is increasing evidence to show that there is a relationship between 
OSA and cardiovascular disease, including heart failure and other preliminary measures 
such as hypertension (Lombardi, Losurdo, Montano, Parati & Tobaldini, 2017). 
Lombardi et al. (2017) indicated that severe untreated OSA was linked to both fatal and 
nonfatal cardiovascular events and mortality rates. Heart failure rates in those with 
obstructive sleep apnea have increased from 10% to 20% (Lombardi et al., 2017). Floras 
(2017) has indicated that in 80% of heart failure patients with diminished or preserved 
left ventricular ejection fraction, they experience 5 apnea events per hour and that those 
likely may increase to an OSA rate of 61% in the future. The researchers found that in 
observational studies, which include heart failure therapy patients, there was a doubling 
rate of mortality risk that may occur if OSA is identified and presented (Floras, 2017). 
According to Gillespie et al. (2015), the AHA assessed, the cost of treating heart 
failure in the U.S. in 2015 was approximately 44.6 billion, with other comorbidities 
identified. A study review by Ambrosy et al. (2014), performed a global review of heart 
failure characteristics, management, results, predictors, quality enhancement initiatives, 
regional differences, and limitations regarding available data. The researchers found that 
26 million people globally suffer from heart failure, and 5.7 million people in the United 
States (Ambrosy et al., 2014). Ambrosy et al. (2014) has shown that heart failure was the 
leading cause of hospitalization, with over 1 million people hospitalized annually in 
Europe and the United States and over 670,000 initial cases a year. The researchers 
revealed that those admitted to hospitals for heart failure are between 70 and 75 years old 
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and have a standard deviation of 15 years. However, admission globally is based on the 
standard of living, and those in North America are admitted at an older age than patients 
in other countries (Ambrosy et al., 2014). The researchers indicated that heart failure 
admission in the United States affects females at 40-50% more than males compared to 
the rest of the world (Ambrosy et al., 2014). Ambrosy et al. (2014) has shown that 
African Americans (20%) and Hispanics (7%) appear to be affected more, at a younger 
age and higher prevalence of medical comorbidities than any other ethnicity. Though 
there have been recent developments in drug and device treatment for those with 
ambulatory heart failure, there has been a little progression in its management, which has 
contributed to low in-hospital mortality rates and high risk for readmission post-discharge 
(Ambrosy et al., 2014). In sum, the studies used to show the prevalence of both global 
and domestic OSA and heart failure and how the commonality of these factors has 
grown. The prevalence of this disease can also be seen across ethnicity, age, and sex. 
Therefore, the information provided by Ambrosy et al. (2014), Lombardi et al. (2017), 
and Floras (2017) has displayed a need to explore this growing epidemic in this study as a 
result of the number of potential lives it affects.  
Race 
In a study review by Clark, Ehlen & Paul (2016), it has been indicated that race 
plays a role in sleep-disordered breathing. Clark et al. (2016) haves suggested that 
African Americans experience a higher rate of sleep-disordered breathing than any other 
race, though there have been few studies that compare across different ethnic groups. A 
result from the few studies that have reviewed sleep-disorders across ethnic groups has 
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yielded under-diagnosis of sleep apnea in African Americans, and African Americans are 
afflicted with sleep apnea at younger ages than whites (Clark et al., 2016). Additionally, 
the researchers have indicated that the predictor of sleep apnea in African Americans has 
been both BMI and socioeconomic status (Clark et al., 2016). Lastly, African Americans 
develop OSA and cardiovascular diseases at a higher rate than whites (Clark et al., 2016). 
Dudley &Patel (2016) have shown that within the disparities and genetic risk 
factors of OSA, it has been indicated that there was a racial disparity regarding African 
Americans and OSA. The researchers suggested that African Americans consistently 
have the highest OSA rate out of all ethnicities (Dudley & Patel, 2016). Within the 
Dudley & Patel (2016) study, results have indicated that there may be soft tissue and 
skeletal contributors specific to African Americans with OSA, such as the enlarged 
tongues. Other risk factors that have been linked to racial differences in African 
Americans include the level of obesity (Dudley & Patel, 2016). 
Albert et al. (2017), have shown that there are racial disparities that exist for 
African Americans, including health literacy. Researchers show that incidence rates of 
failure are highest amongst African Americans and that they are the race most likely to be 
hospitalized and develop heart failure (Albert et al., 2017). The researchers indicated that 
African Americans are susceptible to an increased window of opportunity for clinical 
issues that contribute to other diseases, including socioeconomic status (SES), high salt 
intake, high caloric intake, and genetics (Albert et al., 2017). Lastly, Albert et al. (2017) 
have shown that there are some racial disparities that relate to African Americans having 
an increased likelihood to receive emergency room care and utilizing less medical 
47 
 
therapy when needed than whites. In sum, race was important in sleep-disordered 
breathing, which has in some cases, been underdiagnosed in African Americans causing 
the belief that African Americans experience an increased rate of OSA and 
cardiovascular disease more than any other ethnicity due to genetic disposition, health 
literacy, SES, and medical decisions. 
OSA and Heart Failure on Race 
Booth, Djavadkhani, & Marshall (2014) OSA has been identified as a form of 
sleep-disordered breathing. Obstructive sleep apnea is clinically divided into three 
subsections on the apnoea-hypopnea index, including mild 5-15/h, moderate 15-30/h, and 
severe >30/h. Untreated OSA may cause job impairment, vehicle accidents, weight gain, 
and memory problems (Bergerhenryent, 2017). Approximately one in five peoples have 
OSA. African Americans are the highest ethnic group affected, and of those of middle 
age, 9% of women and 25% of men are affected, and 38,000 cardiac deaths are attributed 
to OSA annually, including heart failure (Bergerhenryent, 2017). 
Akinboboye et al. (2013), revealed there was a need for further research on the 
impact amongst OSA and cardiovascular disease, particularly in blacks. The purpose of 
Akinboboye et al. (2013) was to evaluate data that indicates the association of OSA and 
cardiovascular disease (including heart failure) and to assess it for the influence of racial 
differences. The researchers have indicated that previous studies have been conducted on 
non-black populations (Akinboboye et al., 2013). However, reviews from the researchers 
have suggested that there has been a significant prevalence of blacks with OSA under age 
25 and older than age 65 more than other racial groups (Akinboboye et al., 2013). The 
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researchers have also indicated that OSA as a precursor to heart failure has been linked to 
hypertension to blacks and that blacks had a higher baseline level of blood pressure and 
oxygen desaturation, and AHI than whites. Akinboboye et al. (2013) have shown that 
while OSA and cardiovascular disease disparities continue, there were limited research 
studies that have investigated the role of OSA on CVD in minorities or on the interface of 
race on the association of OSA in those with increased cardiovascular risk.  
In the prospective study by Badr, Pranathiageswaran, Rowley, & Severson 
(2013), the focus was on assessing if the severity and mortality of sleep apnea are higher 
in African American patients with OSAHS compared to whites. The researchers have 
performed a prospective study that included data from July 1996 to February 1999 on 512 
patients (244 men and 228 women) greater than 18 years old. Badr et al. (2013) explored 
confounding variables, including gender, age, BMI, and comorbidities. Researchers have 
shown that out 340 African Americans and 172 whites of the same age, the apnea-
hypopnea index was highest among African Americans under 39 years old and those 
between 50 to 59 years old, therefore indicating OSA was higher in African Americans 
than whites (Badr, Pranathiageswaran, Rowley, & Severson, 2013). Badr et al. (2013) 
suggested that race did not predict mortality, and all confounders were found to be 
significant and useful modifiers. The researcher also has displayed the general population 
and subcategories affected by the prevalence of obstructive sleep disorder and the 
potential racial disparities in cardiovascular disease in African Americans (including 
heart failure) in the United States. Badr et al. (2013) indicated that OSA contributes to 
mortality and specifies that increased mortality was higher in those with severe OSA. 
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The article by Abraham et al. (2013) displays the history of sleep-disordered 
breathing in heart failure. Researchers indicated that widely unrecognized commonality, 
an increased relationship of both OSA in heart failure relating to mortality and morbidity 
(Abraham et al., 2013). Abraham et al. (2013) also indicated the increased need for 
suspicion of heart failure and sleep-disordered breathing correlations, the need for 
optimal treatment for this population remains unclear, and the need for further study. In 
sum, OSA and heart failure on race has been indicated to be impactful on the lives of 
African Americans. However, there appears to be a limited amount of studies to quantify 
this pressing issue. Abraham et al. (2013) have also indicated a need to begin to fill the 
gap in the literature regarding the limited amount of studies related to the role of OSA on 
CVD in African Americans.  
BMI and Heart Failure 
Those whose BMI was considered overweight or obese have been identified as a 
factor that increases the risk of cardiac issues including heart failure (Balfour et al., 2015; 
Clark et al., 2014). Clark et al. (2014) indicated that the Framingham study had 581 white 
middle-aged to elderly patients that heart failure rose by 7% in women and by 5 % in 
men for every unit of BMI increased. Albert et al. (2018) looked to evaluate the influence 
of ethnicity on the relationship between BMI and heart failure mortality with ejection 
fraction and heart failure. Albert et al. (2018) indicated that heart failure affects 5.7 
million people, and high BMI/obesity affects 35% of people in the United States. Albert 
et al. (2018) proposed that increased BMI levels are linked to lower mortality in heart 
failure patients. Researchers have indicated that minimal information is known about the 
50 
 
link between BMI and heart failure mortality prevalence among diverse patients (Albert 
et al., 2018). Lastly, Albert et al. (2018) indicated that minorities such as blacks and 
Hispanics had a higher obesity rate than any other ethnicities, potentially contributing to 
cardiovascular disease.  
The study by Christensen et al. (2013) proposed to identify whether factors such 
as inflammation, endothelial dysfunction are associated with BMI and CHF. It has been 
indicated by researchers this study that cardiac natriuretic peptides including, BNP and 
NT-proBNP, are significant heart failure factors that increase impaired outcomes 
(Christensen et al., 2013). These markers have also been determined to be inversely 
associated with BMI and found to be high in patients with cardiac issues (Christensen et 
al., 2013). Additionally, Christensen et al. (2013) have indicated that low BMI was linked 
to a poor outcome relating to heart failure. Researchers have shown that increased NT-
proBNP is a direct effect that was linked to the wasting process or loss of function seen in 
heart failure (Christensen et al., 2013).  
Additionally, Aune et al. (2016) have shown that there was an association 
between those who are overweight, obesity, and heart failure. Researchers have focused 
on clarifying if the relationship amongst general and abnormal adiposity and the risk of 
heart failure (Aune et al., 2016). Aune et al. (2016) indicated that there was a strong 
correlation between BMI, waist circumference, and waist-to-hip ratio, and heart failure. 
Researchers argued that there was an observed relationship between African Americans, 
BMI, and heart failure that was observed; however, it requires further study (Aune et al., 
2016). In sum, researchers have shown that BMI levels are linked to heart failure 
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mortality rate and poor heart failure outcomes and indicated a need to be assessed as a 
covariate BMI on heart failure in this study. 
Smoking and Heart Failure  
Bauer et al. (2012) have argued that there was an association between smoking 
and heart failure. Bauer et al. (2012) focused on assessing if there was an association 
between smoking status and incident heart failure risk on elderly participant health, 
aging, and body composition study. Participants were randomly chosen from zip codes in 
Pittsburgh, PA, and Memphis, Tennessee, from March 1997 to July 1998 (Bauer et al., 
2012). The researchers utilized 2,125 participants over the age of 70 years, 54.2% whites, 
and 46.8% of minorities (Bauer et al., 2012). Researchers also indicated that of the 
participants, 221 were current smokers, and 739 were past smokers. Data has indicated 
after median 9.4 years of follow up, there was a higher significance rate in those that 
currently smoked, who had incidences of heart attacks than any other group. Those who 
currently smoked had 21.9 events per 1,000 persons of heart failure (Bauer et al., 2012). 
Additionally, smoking has also been shown to cause vascular wall inflammation, which 
may contribute to plaque buildup in cardiovascular diseases, including heart failure 
(Bernhard & Messner, 2014). 
Benjamin et al. (2018) revealed that for blacks, there was a significant association 
with cardiac dysfunction. The researcher’s focus in this study was to assess black 
participants who did not have a history of heart failure for coronary heart disease at the 
Jackson Heart Study (Taylor (2005) as cited in Benjamin et al., 2018). Benjamin et al. 
(2018) indicated that smoking was linked to carbon monoxide exposure and reported that 
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it increased the oxidative stress resulting in mitochondrial function, inflammation, 
damage endothelial function. Researchers have indicated that smoking was associated 
with higher BNP, inflammatory cytokines, and cellular death (Benjamin et al., 2018). 
Lastly, Benjamin et al. (2018) identified that in relation to blacks, cigarette smoking was 
a significant risk factor for heart failure symptoms such as left ventricular hypertrophy 
and systolic dysfunction. 
Balfour et al. (2015) focused on identifying a risk prediction equation to utilize in 
primary care to identify patients at high risk for heart failure. The researchers used 6814 
participants, between the ages of 48 to 84 years old, from 2000 to 2002, that were from 
various ethnicities, including African Americans (Balfour et al., 2015). After a 7.1-year 
follow-up, 176 participants developed heart failure. Those who developed heart failure 
had significant characteristics, including being male, elderly, African American, current 
smokers, diabetic, hypertensive, had high BMI, left ventricular ejection fraction and 
increased Nt-proBNP (Balfour et al., 2015). In sum, though the direct evidence for 
linking heart failure and smoking was unknown in various studies, there was a significant 
risk factor associated with smoking as it relates to heart failure. Therefore, the covariate 
of smoking should be assessed in this study.  
Oral Devices and OSA 
Obstructive sleep apnea is an epidemic that affects over 12% of adults in the 
United States (Watson, 2016). This disease causes gasps in breathing during sleep, and 
the repeated slowing down or stopping of oxygen from getting to the lungs due to a 
collapse of the airway (ALA, 2018). As a result of this lack of oxygen to the body, it was 
53 
 
associated with heart failure as a condition of significant OSA (Badr et al., 2013; Booth 
et al., 2014). OSA is a disease that has severe implications for those affected, and there 
have been several measures used to address this health concern to avoid cardiovascular 
disease, motor vehicle accidents, poor neurocognitive performance, and decreased 
mortality (Booth et al., 2014).  
Oral appliance efficacy was chiefly defined as successful by apnea-hypopnea 
index reduction (Cistulli et al., 2014a).  Apnea-hypopnea indexes in patients that are <5 
(identified as OSA resolution), < 10 (very mild disease), or a percentage lessening that 
was clinically significant from baselines of typically 50% are generally considered 
successful (Cistulli et al., 2014a). Oral devices are developed as non-custom-made 
devices (Cistulli et al., 2014a). Custom made devices are cast created from dentition and 
bite registrations by a dentist (Cistulli et al., 2014a; United States Department of Veterans 
Affairs [USDVA], 2018). Long-term effectiveness of oral appliances has been shown to 
stabilize AHI after 1 to 4 years of use, and in those who continue use after five years, 
adherence increase to over 90% (Cistulli et al., 2014a). Researchers have shown that 
efficacy in some studies that gradual titration advancement occurs in three levels that 
consist of 2, 4, 6 mm of overnight oximetry occurring in 25%, 48%, and 65 %, while 
those with severe OSA have shown improvement by 75% (Cistulli et al., 2014a). The 
researchers have also revealed that from a review of collected studies that various oral 
appliance designs have yielded similar effects treating OSA and that two-piece appliance 
considered to improve comfort and wear ability, while more than 82% have chosen 
customized oral devices (Cistulli et al., 2014a). Cistulli et al. (2014a) indicated that data 
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has shown that CPAP and OSA testing yields similar results in trials, though there was 
higher adherence related to the oral appliance. Additionally, researchers suggest that 
there was a benefit in observation and randomized controlled trials that address 
cardiometabolic outcomes as a marker of cardiovascular risk with the use of both oral 
appliance and continuous positive airway pressure (Cistulli et al., 2014a).  
OSA treatments have been used to address both OSA and heart failure (Kasai et 
al., 2014). Oral devices are a relatively new method of non-implantable non-invasive 
medical devices geared to reduce OSA symptoms such as oxygen saturation levels, blood 
pressure, and heart rate (Booth et al., 2014; Chervin et al., 2015). The gold standard 
method for treating OSA was the CPAP (Cistulli et al., 2014a). The CPAP was normally 
used independently during sleep in patients with OSA (Cistulli et al., 2014a). Though the 
CPAP was considered efficacious, it does not consistently result in better health 
outcomes (Cistulli et al., 2014a). Oral appliances have primarily been used as a secondary 
and often tertiary method in combination with CPAP use for non-compliant patients with 
sleep-disordered breathing. Oral devices are available in custom or non-custom made, 
and they can be controlled mechanically or remotely (Cistulli et al., 2014a). Oral 
appliances are divided into three categories: MAD, tongue restraining devices (TRD), 
and combination therapies. In sum, the above studies indicate the need for further and 
observational evaluation of oral devices such as MAD to be considered as a first-line 
treatment for those with OSA and possibly those with heart failure. 
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MAD 
Mandibular attachment devices are oral devices similar to sporting mouth guards 
(Booth et al., 2014). Mandibular attachment devices are removable noninvasive devices 
fitted around the teeth by a dentist in an effort to move the lower jaw and tongue forward 
to increase airflow (Booth et al., 2014). The MAD has been recommended as a second-
line of treatment for those who have mild to moderate OSA, or those who prefer MAD 
than a CPAP. In addition, MAD was also the recommended choice for those who have 
more severe disease and do not comply with the CPAP regimen (Marklund et al., 2012). 
The mandibular attachment device has often been called mandibular attachment splint, 
mandibular repositioning appliance, as well as mandibular repositioning device (Booth et 
al., 2014; Finkel Dental Forum 2015). This treatment has a history of effectiveness on the 
apnea-hypopnea index in this with OSA and displays up to 64% more compliance than 
the CPAP in some studies (Booth et al., 2014). The MAD has been indicated to improve 
vascular functioning, blood pressure, and reduce daytime sleepiness (Booth et al., 2014). 
Tongue restraining devices are similar to the MAD and implanted in the user’s 
mouth orally (Bajaj et al., 2017). The tongue restraining devices has a tongue suppression 
piece used to control and pull the tongue forward and are known to be less comfortable 
than MAD (Bajaj et al., 2017). Combination therapies consist of a custom-made MAD 
that was attached to a CPAP, however, was often used at a much lower pressure setting 
than regular CPAP use (AADSM, 2011). The mandibular attachment device is a 
commonly utilized sleep device, to open the airways by promoting breathing (Bajaj et al., 
2017) 
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The study by Baldini, Ballanti, Cozza & Ranieri (2015) aimed to evaluate a 48-
month long-term efficacy study of MAD in an adult patient with mild to moderate an 
OSA. The researchers used 28 (6 females and 22 male) participants from the Department 
of Orthodontics of the University of Rome Tor Vergata in Rome, averaging 52.2 years of 
age (Baldini, Ballanti, Cozza & Ranieri, 2015). Data was evaluated by using the 
polysomnography and anamnesis results. Baldini et al. (2015) indicated significant 
efficacy using MAD on those with OSA and that 80% of patients displayed a reduction in 
sleepiness, snoring, and sleep discomfort. Researchers have yielded stable effects and 
significant improvement in the long term 48-month study for patients suffering mild to 
moderate OSA. 
The Cistulli et al. (2009) study aimed to assess the mechanism of action in a 
mandibular attachment appraising the outcome on patients who have obstructive sleep 
apneas’ upper airway. This prospective design utilizes 69 mandibular attachment splint 
patients with OSA from a sleep disorder clinic performed during wakefulness. Cistulli et 
al. (2009) indicated that those who participated in the use of mandibular attachment use a 
titratable form, of which acclimation occurred over 6-8 weeks. In those that used the 
mandibular attachment, there was a significant reduction in the apnoea-hypopnea index 
from 27.0+14.7 events/h to 12.5 events/h. There was also an increased distance between 
the hyoid and the posterior nasal spine, and significant increases in total airway volume 
(Cistulli et al., 2009). Due to an increased volume of velopharynx, as well as lower 
anterior facial height hyoid, and a para pharyngeal fat pads being relocated away from the 
airway. Cistulli et al. (2009) revealed x-rays were used to gauge the change in airway 
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opening. Researchers in this study have shown the potential for improved airway by 
using MAD and the basis for potential biomarker improvement. 
In the randomized crossover study by Bishop, Girvan &Verrett (2014), the focus 
was on determining treatment outcomes between two different mandibular appliances and 
patient preferences. Bishop et al. (2014) have carried out this study in the San Antonio 
Texas Veteran Affairs Hospital, using 24 subjects with OSA and compared two popular 
titratable MAD devices in the Klearway vs. TAP3. Researchers have revealed that 18 
participants completed the study, and outcomes were measured using AHI and respiratory 
disturbance index (RDI), oxygen saturation, heart rate levels, and subjective feedback 
(Bishop, Girvan &Verrett, 2014). Bishop et al. (2014) indicated that there were no 
individual statistical differences between the two MAD devices. Nevertheless, TAP 3 
means including scales such as the respiratory disturbance index, and oxygen saturation 
appeared lower than the Klearway device (Bishop et al., 2014). The TAP 3 elite results 
related to RDI improvement were the closest of the two devices to statistical significance, 
with p = 0.559 (Bishop et al., 2014). Bishop et al. (2014) have also shown that neither 
appliance proved significantly more effective over one another in either the AHI category 
of mild, moderate, or severe. There were 72.2% of participants displayed a preference for 
TAP 3 elite versus the Klearway device, indicating that its choice due to its comfort from 
minimal bulk and lack of hardware against the palate (Bishop et al., 2014). 
Researchers have shown that the Veteran Health Care facilities have utilized the 
TAP 3 elite OSA device (Bishop et al., 2014; Department of Veteran Affairs [DVA], 
2015b). In sum, MAD was an oral device used as a secondary treatment on those with 
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OSA or in combination with CPAP, if there was CPAP non-compliance. Researchers in 
multiple studies have shown that the Mandibular attachment devices were beneficial on 
OSA. There have been scarce studies in excess Akinnusi et al. (2013) that explored the 
benefit of MAD on cardiovascular disease and shown it to be beneficial. Of the 
mandibular attachment devices used, TAP3 has been shown to the most used and 
requested by patients with OSA. 
Marklund et al. (2012) suggested there was limited information on the type of 
custom MAD that was most effective on OSA, in excess of titratability. Researchers 
further indicated that there was a greater need for knowledge about MAD outcomes 
related to cardiovascular issues and a need for longer-term studies (Marklund et al., 
2012). Marklund et al. (2012) identified patients that may benefit from MAD treatment 
and its comorbidities to provide patients with optimal alternative therapies. In sum, the 
researchers displayed the purpose of the MAD, its functionality, the significance efficacy 
using MAD on those with OSA. Researchers have also shown that TAP 3 was the MAD 
most preferred by patients and was used by the Veterans Affairs (Marklund et al., 2012). 
Additionally, the gap in the literature suggests the possible benefit of MAD on 
cardiovascular diseases. Therefore, the information provided by the researcher supports 
that a quantitative design was needed to show MAD effectiveness. 
CPAP 
The CPAP is an electronic positive airway pressure device for addressing sleep 
apnea (Pinto & Sharma, 2018). This device forces air through the patient’s airways, 
keeping the air passages to maintain constant breathing during sleeping hours (Pinto & 
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Sharma, 2018). This device was used in patients who do not require invasive ventilation; 
however, they have BMI and OSA concerns or in patients with heart failure (Pinto & 
Sharma, 2018). It was used to successfully extubate patients that might still benefit from 
positive pressure but who may not need invasive ventilation, such as obese patients with 
OSA or patients with congestive heart failure (Pinto & Sharma, 2018). Significant 
complications with CPAP consist of its long acclimation period resulting in irritation and 
uncomfortableness, induced claustrophobic tendencies, or patient embarrassment 
resulting in removal during use and noncompliance (Anderson et al., 2016; Pinto & 
Sharma, 2018). Compliance has also been found to be significantly less in African 
Americans regarding CPAP use more than whites (Anderson et al., 2016). Other concerns 
result in the participants experiencing congestion, nasal drainage, dry mouth, or nasal 
hemorrhages (Pinto & Sharma, 2018). 
CPAP versus MAD 
The Akinnusi et al. (2013) study aimed to assess long-term cardiovascular 
mortality in participants with OSA that utilize CPAP versus a MAD. Akinnusi et al. 
(2013) performed a non-concurrent study that used 570 participants from the Erie County 
Medical Center between February 2002 and January 2004. Researchers utilized four 
comparison groups consisting of a control group without obstructive sleep apnea, an 
untreated MAD group, a CPAP group, and the MAD group. Results indicated cumulative 
cardiovascular mortality in those treated with MAD (P = 0.21). CPAP (P = 0.29) was 
similar, and there was no significant difference between those treated with either MAD or 
CPAP (Akinnusi et al., 2013). However, the use of MAD did result in an AHI, mean 
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titration, and adherence that was higher than that of CPAP users. Akinnusi et al. (2013) 
showed that MAD was comparable and related to treatment. Moreover, the MAD has the 
potential for significant compliance, possibly resulting in the need for reconsideration as 
a primary method. The researchers assessed long-term cardiovascular mortality in 
participants with OSA that utilize CPAP versus MAD. Akinnusi et al. (2013) has also 
shown that MAD was a comparable OSA method, was potentially significant for 
compliance, and has a possible need for reconsideration as a primary method. 
The article by Bratton et al. (2015) focuses on providing a meta-analysis 
comparing MADs to CPAP, placebo, and no placebo groups with alterations in both SBP 
and DBP. Data were gathered from several databases until August 2015, collecting a 
randomized clinical trial of 872 studies, containing over 4,888 patients. There were 51 
reviews used in the final analysis. Treatment comparison was held for CPAP versus 
inactive control, MAD versus inactive control, and CPAP versus MAD while assessing 
biomarkers of the apnea-hypopnea index, oxygen-desaturation index, baseline blood 
pressure, length of follow-up, type of control and blood pressure measurement (Bratton et 
al., 2015). The researcher’s results displayed that of the participants, both MADs and 
CPAP use showed a significant non-discriminatory reduction in blood pressure for both 
SBP and DBP. The Bratton et al. (2015) report displayed a meta-analysis of CPAP usage 
with sleep apnea related to a heart failure marker in blood pressure via BNP levels. 
Bratton et al. (2015) also reported that MAD (reducing PSBO by 2.1 mmHg, DBP by 1.9 
mmHg) was comparable when affecting blood pressure versus CPAP (reducing SBP by 
2.5 mmHg, DBP by 2.0 mmHg). Information provided by the researchers has suggested 
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that MAD was as effective as CPAP usage with Sleep Apnea related to a blood pressure 
via BNP levels. 
Cistulli et al. (2013) focus was to assess if the effect of mandibular attachment 
therapy was similar to the health outcomes of CPAP in a short-term study. The 
researchers used a randomized crossover open-label non-inferiority trial with 126 
participants in three Sleep Centers from Sydney, Australia, over the course of 1 month. 
The participants were 20 years old and older, familiarized with using both CPAP and 
MAD treatments after a two-week wash and re-acclimation phase. Cistulli et al. (2013) 
indicated that the use of MAD was neither inferior nor superior to CPAP results, neither 
treatment lessened baseline blood pressure, self-reported quality of life, nor daytime 
sleepiness. The researchers have provided information that is similar and favorable to 
results related to health outcomes such as neurobehavioral and quality of life within 
participants who suffer from mild to moderate OSA from both CPAP and mandibular 
attachment therapy and a need for further long-term comparative analysis. Cistulli et al. 
(2013) have also shown that not all patients with severe OSA respond well to MAD, 
though a sizeable minority does. Thus, MAD may be an appropriate strategy for severe 
OSA; it may require reconsideration and follow-up studies to assess its efficacy (Cistulli 
et al., 2013). The researchers have verbalized a need for a long-term review, more than 
one month, related to cardiovascular issues with mandibular attachment therapy (Cistulli 
et al., 2013). 
CPAP use has been supported by the benefit of respiration leading to 
cardiovascular outcomes (Bauman et al., 2016; Eisele et al., 2015; Kasai et al., 2014). 
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Limited reports outside of Akinnusi et al., (2013), have supported the use of MAD 
relating to the potential of cardiovascular improvement. Akinnusi et al. (2013) aimed was 
to assess the long-term cardiovascular mortality in participants with severe OSA with 
CPAP or MAD. Over 570 participants with severe OSA were used in this study. Akinnusi 
et al. (2013) provided a non-concurrent cohort study that gathered data from 2002 to 
2004 at the Erie County Medical Center in Buffalo, New York. The researchers indicated 
that after 3-month total participants dwindled to 208 participants, 177 used CPA, and 72 
used fitted with MAD (Akinnusi et al., 2013). Among those treated with CPAP or MAD, 
the lower cardiovascular death rate was associated with users of the CPAP (0.56 per 100 
person-years) closely followed by MAD (0.61 per 100 person-years), indicating no true 
difference in cardiovascular death rate (Akinnusi et al., 2013). Therefore, the Akinnusi et 
al. (2013) report has shown that MAD and CPAP may be equally effective in reducing 
the risk of cardiovascular events in those with severe OSA, and further studies are needed 
to affirm the results. 
Information gathered throughout several studies discussed have indicated that 
CPAP use has been shown as an effective initial treatment for OSA when there was 
compliance. However, other methods such as MAD, which have a history of high 
compliance, have not explicitly been assessed for patients with OSA and heart failure 
(Abraham et al., 2013). In sum, the comparable measure between the CPAP and the 
MAD and the potential for a need for a longer duration to identify the effect MAD may 
have on cardiovascular disease. Therefore, the researcher provided by Akinnusi et al. 
(2013) and Cistulli et al. (2013) should be identified as a reason for the MAD to be 
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considered a testable variable to possibly reduce the symptoms of heart failure in those 
with OSA in this study. 
CPAP versus MAD Economic Cost 
Cistulli & Sutherland (2011) indicated that various oral appliance designs are 
simple to use, inexpensive, and have available techniques that can be applied in office-
based settings. Side effects of oral appliances include increased salivation, mouth 
dryness, tooth pain, gum irritation, headaches, and temporomandibular joint discomfort, 
which decrease around the second month (Cistulli et al., 2014a). Bajaj et al. (2017) has 
shown that MAD was the cheapest treatment modality to address Sleep Apnea at a rate of 
50-160 times cheaper than CPAP but equally as effective. The researchers have also 
suggested the cost of MAD internationally was approximately $1000 and was 
economically more efficient for both populations without electricity and those who 
cannot afford the high cost of CPAP (Bajaj et al., 2017). The American Sleep Association 
[ASA] (2018) has indicated that the CPAP cost an average of approximately $850 to 
$3000, in excess of continual electricity usage. 
 Gillespie et al. (2015) provided a comprehensive literature review of 106 studies 
on the healthcare, workplace, societal consequences, cost, and economic burden of 
prolonged OSA that goes untreated. Gillespie et al. (2015) also yielded data from 
different research studies that have noted that OSA has been associated with various 
health diseases, including heart failure. The researchers have also indicated that if OSA 
was left untreated, it can be medically severe and economically expensive (Gillespie et 
al., 2015). Though CPAP was considered the gold standard, compliance remains an issue 
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as well as the unit’s utility usage cost in addition to the need for insurance coverage 
(Camacho, Certal & Riaz, 2015; Gillespie et al., 2015). Surgeries to address OSA via 
tracheostomies are useful; however, they have significant drawbacks relating to high 
morbidity, long recoveries, and little patient interest (Gillespie et al., 2015).  
Untreated OSA may lead to a more reduced quality of life affecting the patient, 
their family at home, and potentially resulting in a 10% greater chance of workplace 
disability. However, the quality of life level was difficult to calculate or assess due to 
reduced productivity, absenteeism, health care cost, and potential liability in relation to 
the occurrence of accidents (Gillespie et al., 2015). Untreated OSA may lead to 
transportation consequences such as excessive daytime sleepiness, impaired awareness, 
focus, and potential accidents (Gillespie et al., 2015). Gillespie et al. (2015) have shown 
that 810,000 motor vehicle accidents resulted in 1400 deaths that cost approximately 
$15.9 billion, if 70% of those with OSA were treated and were compliant with an airway 
device like CPAP, 500,000 collisions would have been avoided (Davidson et al. (2004) as 
cited in Gillespie et al., 2015). This level of avoidance would have resulted in 1,000 lives 
saved, and the cost would be lowered by 11.1 billion (Gillespie et al., 2015). 
Undiagnosed patients with OSA are estimated to cost $1,950 to $3,899 per patient, per 
year times, the extrapolated number of 29.5 million people from the Wisconsin study. 
This study indicated that even if 60% remained undiagnosed, it would place a 34 to 69-
million-dollar economic burden annually on the health care system (Dempsey, Palta, 
&Young, 1993 as cited in Gillespie et al., 2015). Those diagnosed with OSA, but who are 
untreated, have higher medical costs versus those receiving OSA treatment.  
65 
 
Those diagnosed who are treated are estimated to cost $2,700 to $5,200 less than 
those not receiving OSA treatment (Gillespie et al., 2015). Gillespie et al. (2015) has 
indicated that in some studies, CPAP has been more efficacious in addressing AHI than 
MAD. However, MAD has greater compliance. Additionally, CPAP is covered by 
insurance. However, MAD devices are not covered by insurance, leaving the patient to 
take the brunt of the cost as a deterrent due to the initial cost of the device versus its poor 
suggested efficacy (Gillespie et al., 2015). This approach possible extinguishing hope in 
care or alternative care options. The CDC (2016) indicated that heart failure occurs when 
the heart is unable to pump enough blood and oxygen to support an individual’s other 
organs adequately, though severe, it does not mean your heart has stopped working. In 
sum, OSA and untreated OSA are economically costly and that CPAP can be both 
expensive and continual. However, MAD may be more reasonable and cost-efficient 
overall due to not requiring insurance, maintenance, or utilities. 
Summary and Conclusion 
In this chapter, I have found that higher a BMI level among African Americans 
leads to increased mortality and are found increasingly in African Americans in recent 
decades in the United States. Obstructive Sleep Apnea affects a significant number of the 
population, specifically African Americans, resulting in 38,000 annual heart failure 
deaths (Bergehenryent, 2017). Obstructive Sleep Apnea causes an increased AHI, which 
leads to oxygen desaturation, eventually altering heart rate and blood pressure and 
causing heart failure (Booth et al., 2014). Heart failure continues to rise and is affecting 
African Americans more than Whites and Asians (Colvin et al., 2014). The evidence 
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provided in the literature on the racial disparity regarding the mortality from OSA and 
heart failure affecting African Americans has shown to be significant (Badr et al., 2013). 
Therefore, smoking and BMI should be considered as covariates in this study. 
Body mass index was significantly associated with an increase in heart failure 
(Clark et al., 2014; Del Gobbo et al., 2015). Heart failure was affected considerably by 
both past and current smokers causing impaired endothelial function and oxidative stress, 
which increases heart failure risk (Bauer et al., 2012). Obstructive sleep apnea treatments 
historically have been used to address heart failure (Kasai et al., 2014). Newer treatments 
to address OSA include oral appliances, which reduce oxidative stress levels, blood 
pressure, and heart rates (Booth et al., 2014). The oral appliance has used a lower 
pressure setting than CPAP; however, are similarly effective regarding AHI and 
compliance. Researchers have had limited studies that have addressed oral appliance 
effectiveness on heart failure, and few are suggesting its possible need for further study 
(Akinnusi et al., 2013; Cistulli et al., 2013). The MAD has been well received by patients 
and effective in the respiratory disturbance index. Researchers have been conflicted in 
various studies indicating that MAD was as effective in relation to CPAP use on OSA 
patients (Al-Shorman & Shydfat, 2015; Berge, Gjerde, Lehmann, Johansson, A. & 
Johansson, A. K., 2015; Cistulli et al., 2013). Biomarkers used to identify the 
effectiveness of heart failure symptoms have been indicated as left ventricular ejection 
function, SBP, DBP, oxygen saturation, BNP, NT-proBNP, and troponin levels (Bratton 
et al., 2015; Gaggin & Januzzi, 2015). Cost of MAD appears cheaper overall versus the 
CPAP due to requiring electricity usage. Those diagnosed with heart failure are likely to 
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be male, elderly, African American, smokers, and have high BMI (Balfour et al., 2015). 
The results of the demographics and characteristics of those with heart failure present the 
need for this study’s African American male population over age 20 and its covariates. 
Chapter 3 provides information on the research method, research design and rationale, 
methodology, data collection, and threats to validity.  
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Chapter 3: Research Method 
Introduction 
Obstructive sleep apnea is a public health concern in the United States that 
repeatedly blocks the airway during sleep (NIH, 2017). The prevalence rate for OSA is 
approximately “10% among those age 30-49 and 17% among those 50-70” (Barnet et al., 
2013, p. 1006). Surkin (2013) revealed that 71% of those diagnosed with cardiovascular 
disease have OSA. Obstructive Sleep Apnea has a direct association with heart failure 
(NIH, 2017; Surkin, 2013).  
Heart failure is a common and highly fatal disease if left untreated, and mortality 
rates are 20 times higher for African Americans than any other ethnicity for those under 
the age of 50 (Blair, Huffman & Shah, 2013). The purpose of this study was to determine 
whether treatment using the MAD effectively impacts symptoms of heart failure in 
African American male veterans over 20 years of age who have been diagnosed with 
OSA and whether treatment efficacy differs after controlling for BMI and smoking status. 
In Chapter 3, the design and rationale are discussed. This chapter addresses the study 
variables and justification for research questions and the repeated measures design. The 
operationalization of the conceptual framework focused on translating the oxidative stress 
theory into a measurable outcome within the study. The methodology section includes the 
target population, sampling procedure methods, tools, and software used for analysis, 
handling of secondary archival data, and the operationalization of constructs. Chapter 3 
introduced the data analysis plan and identified threats to validity and ethical concerns 
that may arise, as well as procedures applied in the study to address them. 
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Research Design and Rationale 
This study used a quantitative nonexperimental longitudinal design. The study 
was to evaluate the level of mean change in terms of symptoms of heart failure as a result 
of MAD use, and therefore a quantitative design was most appropriate. A quantitative 
analysis was used to identify if there was a statistically significant impact on the study’s 
dependent variables (ejection fraction, SBP, diastolic blood pressure, oxygen saturation, 
brain natriuretic peptide (BNP), n-terminal pro-brain natriuretic peptide (NT-proBNP), 
and troponins levels) in order to indicate if there was a correlation between MAD use and 
the effect on heart failure symptoms. This study also used a nonexperimental research 
method due to it not requiring the manipulation of the independent variable, there being 
no need for random assignment, and primarily relying on observation and interpretation 
of data from archived files (Hughes, Matt & O’Reilly, 2014; Price, Jhangiani & Chiang, 
2013. This study employed the nonexperimental research method by using observations 
to identify if there were correlations between MAD and symptoms of heart failure. The 
longitudinal design was appropriate in this study due to it allowing for the dependent 
variables in a repeated measures design in a particular case to be followed over a period 
of time (Caruana et al., 2015). This design was most appropriate for this study due to it 
allowing for the assessment of relationships between risk factors and the progress of 
disease and effects of treatment over variable lengths of time (Caruana et al., 2015). 
The repeat measures test relates to the study questions design when identifying if 
there was a significance in MAD use on the main risk factors of heart failure in African 
Americans when controlling such as BMI and smoking over time. The independent 
70 
 
variable in this study was the use of the MAD. The dependent variables in this study were 
symptoms of heart failure (ejection fraction, SBP, DBP, oxygen saturation, BNP, NT-
proBNP, and troponins levels). Body mass index and smoking were covariates to indicate 
how they affect the outcome of the study. Wludyka (2012) has revealed that repeated 
measures studies have been used historically by epidemiologists to comprehend 
correlations between risk factors and the development of diseases as well as treatment 
outcomes over time. The repeated measures design was used as an effective way to assess 
samples of deidentified records involving MAD treatment and create a hypothesis 
regarding why a product or service delivery may or may not appear to correlate.  
Epidemiologists have also used repeated measures studies to assess interventions 
and multiple measurements over various intervals of time for an independent subject 
(Wludyka, 2012). The quantitative repeated measures design can be useful to advance 
knowledge forward in epidemiology as it relates to the MAD as an alternative first-line 
treatment for those with heart failure. The repeated measures design was used because it 
required fewer records for the overall study and could detect effect size within a study 
with a smaller sample size (Jeyabalasingham et al., 2011; Statisticshowto, 2018b). This 
design was also chosen due to its high statistical power and quicker and more efficient 
results (Statisticshowto, 2018b). The rationalization for this design has been based on the 
purpose of the study to examine whether MAD therapy impacts symptoms of heart 
failure in African American male veterans diagnosed with OSA over a six-month 
timeframe. This study attempted to evaluate the level of mean change in symptoms of 
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heart failure as a result of MAD use, and therefore a quantitative study was most 
appropriate. 
Researchers have recommended to further review the use of observational study 
designs to more closely analyze variables including MAD, BMI, and smoking (Arynchyn 
et al., 2009; Babson et al., 2013; Brenner et al., 2015). Additionally, past researchers have 
used cohort studies to assess a form of heart failure variable risk factors associated with 
mortality impact on patients (Akinnusi et al., 2103; Balfour et al., 2015; Bauer et al., 
2012). Though a cohort study can be used to assess cardiovascular disease, it was not 
beneficial to this study due to there being no need for expensive follow-up of a large 
number of subjects for an extended time to address research questions (LaMorte, 2016). 
Berge et al. (2015) used a retrospective study to assess outcome developments of 
patient’s MAD recipients, and the data provided was beneficial relating to significant 
effect at baseline from comorbidities. LaMorte (2016) also revealed that retrospective 
studies frequently have a lack of data on confounding factors if recorded in the past, 
create difficulty identifying the exposed cohort and comparison group, were subject to 
selection bias and if older records were used that have not been maintained the available 
data may be of poor quality. Popat and Sainani (2011) have also indicated that 
retrospective studies have possible low data quality and a lower level of generalizability 
in relation to cross-section studies due to the limited volume of hospitals, clinics, and the 
potential for a limited level of participation. 
Other experimental study designs were not chosen because the research does not 
require participants or the altering of independent or dependent variables. Price et al. 
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(2013) have revealed that a quasi-experimental design allows for the manipulation of the 
independent variable or control the assignment of the treatment conditions. Quasi-
experimental designs were not chosen due to there not being a need to manipulate 
variables or covariates. Experimental designs were not chosen because there being was 
no need for random assignment in this study. Moreover, an experimental design was not 
selected due to the study not requiring an overly expensive design for an issue that can be 
inexpensively addressed (Popat and Sainani, 2011). The experimental design was also not 
chosen due to it not always being generalizable, ethical, or feasible (Popat and Sainani, 
2011). A repeated measures design was chosen because of its capability of assessing the 
prevalence of risk factors and outcomes over time (Chambers, Graeme, Hickey, Mokhles 
& Kolamunnage, 2018). Other benefits of this study may include its inexpensiveness, 
short turnover, output clarity, increased generalizability, and valid evaluations of the 
prevalence of risks (Chambers et al., 2018; Popat and Sainani, 2011). Additionally, the 
repeated measures design was linked to the research questions in this study due to its 
ability to assess changes in values of dependent variables and to evaluate if treatment 
with MAD effectively reduces heart failure symptoms in African American veterans with 
OSA and whether treatment efficacy differs by BMI and smoking status. 
Methodology 
 In this section, I indicated how the study was implemented. This section includes 
a description of the population, sampling, sampling procedure, the sampling frame 
including the inclusion and exclusion criteria, power analysis, data collection, use of 
archival data, data analysis plan, threats to validity, and ethnic procedures. 
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Population 
As of 2016, there were approximately 20 million veterans who were served 
nationally by the VHA Population Projection Model (DVA, 2016b). Data has shown that 
over 50% of Veterans live in 10 states within the United States, of which Florida was 
within the top three. Within the state of Florida, there were approximately 1.6 million 
veterans, including nearly 91% or 1,452,024 males and 09% or 142,193 females (DVA, 
2016a). Of the Florida veteran population, there were approximately 180,315 black or 
African Americans (DVA, 2016a). The target population of this study was African 
Americans over the age of 20 years living in the United States. Study data from archived 
files include those registered at the VHA and diagnosed with OSA and heart failure. Data 
from archived files consisted of those who have been issued MAD and have 
polysomnography results indicating sleep apnea within the past year. The approximate 
Veteran population size consisted of 23 de-identified archived records. 
Sampling and Sampling Procedures 
Sampling is an essential method of selecting a representative part of a population 
for the purpose of determining characteristics of the entire population (Emerson, 2015; 
Statistics Solutions, 2017). Purposeful sampling was used to screen deidentified medical 
records for: African Americans registered with the VHA who are diagnosed with OSA 
and heart failure and were 20 years of age and older. Data regarding dependent and 
independent variables were assessed from medical problem lists, primary care doctor, 
nurse, respiratory, dental, cardiology notes, and labs. Those sampled were ages twenty 
and older, using MAD and have polysomnography results indicating sleep apnea within 
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the past year and six-month polysomnography test after receipt of the MAD. Other 
inclusion criteria consisted of de-identified records data from archived files on those who 
have been seen by VHA respiratory clinics and been referred to dental services from a 
MAD. Records were excluded if they did not meet the inclusion criteria. The approach of 
using non-probability sampling can be viewed as economical, though there were practical 
reasoning for its application (Dever and Valliant, 2014). 
A benefit of the purposeful sampling strategy was its ability to target a population 
that meets the inclusion criteria, its accessibility, geographical proximity, and the fact that 
it has the secondary data needed for the study (Alkassim, Etikan & Musa, 2016). Variable 
data was downloaded from the VA VINCI onto a password encrypted isolated hard drive 
for storage. Study data to address mean changes in variables was computed using the 
VINCI’s Statistical Package for the Social Sciences (SPSS)/PSPP (USDVA, 2016).  
Sample Size/Power Analysis 
Ergin, Kibar & Konak (2016) have shown that a G*Power analysis serves as a 
free and independent power analysis to conduct an estimated requisite sample size. A 
G*Power analysis incorporates multiple testing types, including an f-test, which was used 
in this analysis to appropriately calculate a generalizable sample (Statistics Solutions, 
2018). According to G*Power, an appropriate significance level or (α) alpha error 
probability of 0.05, indicates that there was a 5% or less chance of a type I error rejecting 
the null hypothesis (G Power, 2017). Additionally, the lowest power probability of 0.80 
indicates that there was an 80% chance or better that there would be no chance of type I 
error (G Power, 2017; Lakens, 2013; Taylor, 2011). The effect size was used to measure 
75 
 
the distance between the null and alternative hypothesis and in an f-test would be 
between the lower limit of 0.10, the medium limit of .25, and the largest limit of .40 (G 
Power, 2017). A commonly used effect size would be located at the middle limit, which 
would be an f of 0.25 (G Power, 2017).  
Without appropriate Veterans Affairs data, it may be inappropriate to identify an 
actual expected number of records that meet the eligibility criteria for the study. 
Aaronson et al. (2015) using MANOVA and MANCOVA relating to OSA, and cardiac 
status issues have yielded effect sizes ranging from as low as .20 to as high as .80. 
Therefore, historically used values that were placed into the G power software to identify 
an appropriate sample size consisted of using a medium effect size of 0.25, an alpha error 
probability of 0.05, a power probability of 0.80, number of groups of 1, number of 
measurement (dependents) of 7 and correlation among measures 0.5 resulting in 
approximately 23 de-identified archived files to have at least an 80% power probability. 
Table 1 
 
Power Analysis 
Options: F tests Manova: Repeated measures, within factors 
Analysis: A priori: Compute required sample size 
 Input Identified G-Power Measurement 
Effect size f 0.25 
α err prob 0.05 
Power (1-β err prob) 0.80 
Number of groups 1 
Number of measurements 7 
Corr among rep measures 0.5 
Output  
                  (table continues) 
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Non-centrality parameter λ 20.1250000 
Critical F 2.6986599 
Numerator df 6.0000000 
Denominator df 17.0000000 
Total sample size 23 
Actual power 0.8175114 
Pillai V 0.4666667 
Data Collection 
Data were gathered via nonprobability purposeful sampling from archived from 
the Veterans Health Care Administration Dental Clinics records that met the diagnosis 
and inclusion criteria. Archived records from the Veterans Affairs agency were chosen 
due to the agency’s ability to address Veteran needs. The Veterans Affairs mission is 
related to putting veterans first, by honoring the commitment of President Abraham 
Lincoln to care for the Veteran, his widow, and orphan, and balancing resources and the 
patients’ needs (Dasheiff & Finn, 2009; DVA, 2015a). This study does not require or 
involve the recruitment of subjects as all information was collected from existing 
archived secondary data. The archived data utilized in this study from the Veterans 
Affairs electronic record was scrubbed of Patient Health Information (PHI) identifiers by 
the agency prior to receipt and used by the researcher.  
The Veterans Affairs electronic record was the Veterans Integrated System and 
Technology Architecture (VISTA) based interface, which was used by VA clinicians 
called the Computerized Patient Record System (CPRS) (Brandt et al., 2017; Espadas et 
al., 2011). The electronic record included veterans who were served at VHA hospitals 
and Community-Based Outpatient Clinics (CBOCs) throughout the U.S. (Department of 
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Veterans Affairs Office of Inspector General, 2015). Computerized patient record system 
files incorporate all Veterans serviced within Veterans Affairs Hospitals. The 
Computerized Patient Record System (CPRS) has been used since the 1980s by the VA 
and identifies patients serviced in the various independent disciplines, units, and clinics 
within the local veteran affairs agency (Agha et al., 2014; Espadas et al., 2011). Storage 
of this electronic patient data was updated nightly from VISTA/CPRS and was contained 
in VA VINCI, which was an integrated national database and toolkit for the analysis of 
sensitive healthcare data in a secure computer environment (Brandt et al., 2017; USDVA, 
2014).  
Data for this study were captured after receiving approval from the Walden 
University Internal Review Board (IRB) #09-11-18-0235165. Once approval was gained, 
this study was submitted to the Gainesville, Florida Veterans Affairs office of Human 
Research Protection Process (HRPP). I have contacted the Veterans Affairs office of 
HRPP and have been notified that I was unable to receive a signed letter of cooperation 
from the VA granting authority to this researcher to access the needed study information 
until the proposal was completed and it had been approved by Walden University IRB. 
This researcher completed document requirements then submitted the request for review 
by the Veterans Affairs office of HRPP. The HRPP encompassed approvals by VA 
identified Internal Review Boards, Research and Development, and National Data 
Systems. Requirements to gain access to the veteran affairs data consisted of completing 
documents such as the: conflict of interest, abstract form, responsible request and project 
information sheet, research and development information system investigator data, safety 
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cover sheet, medical center support form, new study submission coversheet, data 
management and access plan, protocol form, scope of practice for research staff form, 
data access request tracker application, VHA research addendum form, authorization for 
use and release of individually identifiable health information collected for VHA 
research, and the research protocol safety evaluation form. 
Once approval was provided by the Veterans Affairs HRPP, this researcher 
logged onto the secured VINCI site on a dedicated North Florida South Georgia VA 
computer and specified the search under the dental department. De-identified data sets 
were accessed from VINCI by performing a query on records that meet the inclusion 
criteria. Data from collected records were observationally screened for appropriate 
inclusion criteria indicated in the study. Collected data was then uploaded, and statistical 
analysis was performed via VINCI’s SPSS/PSPP. The analysis for the study research 
questions were addressed through the rMANOVA and rMANCOVA tests. Data 
highlighted and accessed was primarily based on the independent variable, the use of 
MAD on African American male veterans. The dependent variables in this study were the 
symptoms of heart failure (ejection fraction, SBP, DBP, oxygen saturation, BNP, NT-
proBNP, and troponins levels). Identified covariates in this study include BMI and 
Smoking status. Additionally, as a result of the accessing data from archived secondary 
data, informed consent was not needed, nor was there a need to provide follow-up or exit 
interviews. Storage and analysis of data were housed in a VINCI workspace. Once the 
statistical analysis has been completed, statistical reports would be downloaded to this 
researcher’s password encrypted external hard drive and was stored in a secured room 
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within the VA, behind a locked door, and inside of a locked file cabinet of which this 
researcher has the only key. Data results were transferred from this secured password 
encrypted hard drive and displayed as usable research analysis within this study to be 
potentially displayed in a medical journal (i.e., PubMedCentral) or a Veterans centered 
journal within one year of the studies completion. 
Use of Archival Data 
Secondary data is a reanalysis of data that has been collected for an alternative 
purpose (Cheng & Phillips, 2014). Data were accessed from the North Florida South 
Georgia Veterans Affairs hospital after I obtained VHA IRB and Walden University IRB 
approval. Data were provided by the VHA Office of Research and Development’s 
VINCI. Data were downloaded onto an isolated and password encrypted computer hard 
drive, then uploaded into SPSS/PSPP. Time to collect secondary data and the cost of 
acquiring data was minimal in comparison to primary data collection methods, and the 
data was usually cleaned by professional staff.  
Instrumentation and Operationalization of Constructs 
The secondary archival data used in this study to ascertain de-identified veteran’s 
medical data was collected by the VINCI database from the VA. The VINCI has 
collected data from the Veterans Affairs agency since 2000 (Agha et al., 2014). The 
VINCI was a database warehouse that allows research to facilitate the analysis of VHA 
data in a private and data secured setting (USDVA, 2014). The VINCI can be accessed 
remotely through a desktop from anywhere within the VA network inside of its own 
project site (USDVA, 2014). This database program allows the use of datasets through 
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structured queries language (SQL) queries and extractions from VISTA/CPRS and was 
compatible with SPSS/PSPP (USDVA, 2014). This database was not a published 
instrument and was not publicly available and requires approval from the Veterans 
Affairs Internal Review Board.  
BNP. BNP levels have been indicated in three scale levels, from those <100pg/ml 
were considered ordinary, ruling out heart failure (Mangla, 2014). Those between 
100pg/ml to 400pg/ml warranted further investigation, due to there being a 95% chance 
of heart failure and in those greater than 400pg/ml, heart failure was likely (Mangla, 
2014). 
Diastolic blood pressure. Pressure levels have been indicated in three scale 
levels: normal < 80 mmHg, at-risk (prehypertension) 80-89 mmHg, and high >90mmHg 
(CDC, 2017d). 
Ejection fraction. The left ventricle is the main chamber pumping oxygenated 
blood through to the body. Ejection fractions were typically measured only in the left 
ventricle and have been indicated in two scale levels 55 percent < were considered 
normal, and 50 percent > were considered reduced/borderline (Mayo Clinic, 2018b). 
NT-proBNP. NT-proBNP levels have been indicated in scale levels including 
those who were <125/ pg ml aged 0-74 years old, and <450pg/ml aged 75-99 years old 
were considered normal. Those over 450pg/ml for those under 50 years old, and > 
900pg/ml for those over 50 years old were considered unstable (Cleveland Clinic, 
2018b). 
Oxygen saturation. Normal oxygen saturation scale levels were considered 
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between 95%-100%, those between 94%- 91% require evaluation and treatment, and 
those who have less than 90% were considered to have a low oxygen saturation level 
leading to hypoxemia indicating the patient was having a clinical emergency (WHO, 
2011). 
Systolic blood pressure. Pressure levels have been indicated in three scale levels: 
normal < 120 mmHg, at-risk (prehypertension) 120-139 mmHg, and high >140mmHg 
(CDC, 2017c). 
Troponins. Those with troponin levels < 0.03 were considered normal, those with 
levels between 0.03-0.09 were considered to have a medium risk or unstable angina, and 
those 0.1 were thought to indicate a myocardial infarction (Alosert et al., 2009). 
Instrumentation and Operationalization of Variables 
Heart failure. Heart failure symptoms were assessed as dependent variables by 
reviewing significant heart failure markers. Heart failure markers consisted of left 
ventricular ejection function (LVEF), SBP, DBP, oxygen saturation, BNP, NT-proBNP, 
and troponins levels for appropriate measurement indications (Balfour et al., 2015; 
Gaggin & Januzzi, 2015; Gilliespie et al., 2015). These markers were observationally 
assessed from test results of secondary data using observed medical notes from a 
physician, nursing, and cardiology notes, labs, and consults.  
Table 2 
Symptoms of Heart Failure 
Symptom Level of Measurement Source of data 
left ventricular ejection function Ratio  (Anavekar et al., 2012) 
                  (table continues) 
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systolic blood pressure  Ratio (Chin, 2016) 
diastolic blood pressure  Ratio (Chin, 2016) 
oxygen saturation  Ratio  (Gastel et al., 2016) 
BNP Ratio  (Clavel et al., 2016) 
NT-proBNP  Ratio  (Enseleit et al., 2012) 
troponins levels Ratio  (Enseleit et al., 2012) 
 
OSA. Obstructive sleep apnea was observationally assessed from secondary data 
by verifying OSA ICD-10 code diagnosis found in the medical problem list of the VA 
electronic medical record, which has been inputted as a diagnosis by a licensed physician. 
BMI. Body mass index levels within archived files were observationally assessed 
from secondary data using medical notes. BMI categories were assigned according to 
guides established by the CDC. The CDC (2017a) has identified those less than 18.5kg/ 
m2 as underweight, those 18.5-24.9 kg/ m2 as normal, those 25-29.9 kg/ m2 as overweight 
and those equal to or greater than 30kg/ m2 as obese. BMI level data from archived files 
were observationally assessed in research question two as a covariate using medical 
notes. The rMANCOVA was used due to its ability to potentially meet all the 
assumptions, therefore, increasing validity and reliability. 
Smoking. Smoking status data within archived files was observationally assessed 
in research question three. This study used archived records that included nicotine labs 
from secondary medical data. The covariate smoking was coded using 0 for no and 1 for 
yes. The rMANCOVA was used due to its ability to potentially meet all the assumptions, 
therefore, increasing validity and reliability (Lund and Lund, 2013b). 
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Data Analysis Plan 
A correlational design using repeated measures within factor study was obtained 
from secondary data collected through VHA, due to the inexpensiveness, accessibility, 
availability of the data. Benefits of the repeated measures within factor was that it 
eliminates individual differences and has a test type that has high sensitivity (Nimmo-
Smith, 2009). Other benefits of this study design include the ability to conduct research 
with few records available while allowing statistical inference to be made with data from 
archived files, and its ability to allow for the study to be conducted quicker and with 
greater efficiency (Jeyabalasingham et al., 2011). Lastly, this study type allowed for the 
researcher to monitor the changes in records over time.  
The data analysis for this study consisted of descriptive statistics and pre-data 
screening procedures to eliminate and address all missing data. Descriptive statistics were 
used to describe the sample data obtained from VHA records. The reported statistics 
included frequency counts, measures of variability, and measures of dispersion.  
The pre-data screening consisted of assessing for missing data and testing statistical 
assumptions. Missing data was assessed through visual scanning of the data and 
frequency counts by this researcher. The amount of missing data determines what actions 
to take with regard to the missing data. Screening for missing data allows for this 
researcher to identify missing values in a dataset to reduce the possible hindrances in the 
outcome of a study (Kang et al., 2013). Screening for missing data was important because 
the lost data could cause bias in the estimation of parameters (International Business 
Machines, n.d.a.; Kang et al., 2013). It was important to screen for missing data as 
84 
 
incomplete study values can provide misleading results (International Business Machines, 
n.d.a.; Kang et al., 2013). Missing data could also reduce statistical power (Hawkes, 
Mendelson, Su & Yan, 2016; Kang et al., 2013). Lastly, missing data can complicate 
theories by not being able to use complete cases (International Business Machines, n.d.a.; 
Kang et al., 2013). Testing statistical assumptions were important before conducting 
statistical procedures because it validates the test being used to ensure accurate results 
(Lund & Lund, 2013a; Lund & Lund, 2013b). 
The rMANOVA analysis was deemed to be valid when the seven assumptions 
were met, which include that two or more dependent variables were continuous. 
Variables were assessed as continuous variables if they were interval or ratio (Lund and 
Lund, 2018). Another measure was that the independent variable possesses two or more 
categorical related groups (Lund and Lund, 2018).  Groups were considered related when 
they were measured at all time points or all receive treatment (Lund and Lund, 2018). 
This assumption was addressed by the measurement of MAD use at the three different 
monthly intervals.  
Additional measures were to have an average sample size. This assumption was 
addressed by using a Gpower analysis to determine the appropriate sample size. This 
assumption was addressed by having a larger number of records in each group than the 
number of dependent variables (Lund and Lund, 2018). Other fitting measures of 
appropriateness were that there were no significant univariate or multivariate outliers. 
This assumption was assessed by using z-scores of +3.29 to identify extreme univariate 
outliers (Steyn, 2018). The Mahalanobis distance calculation was used to suggest 
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possible multivariate outliers (Garson, 2012; Lund and Lund, 2013a; Pennsylvania State 
University, 2019). Also, a measure of appropriateness was that there was multivariate 
normality. This assumption was assessed by using the Q-Q plots to assess the differences 
in the data from a normal distribution and Shapiro-Wilk test of normality on each 
dependent variable for each of the group’s independent variable (Lund and Lund, 2018; 
Statistics Solutions,2019a). This test was recommended for studies with small sample 
sizes up to n=2000 (Garson, 2012).  
Moreover, another measure was that there was a linear relationship between each 
dependent variable for each group of the independent variable (Lund and Lund, 2018; 
Statistics Solutions, 2013). This assumption was assessed by using a Pearson correlation r 
table to assess the linear relation between variables (Kent State University, 2019; 
StatTrek, 2019).  Another measure was that there were one or more continuous 
covariates. Variables were assessed as continuous variables if they were interval or ratio 
(Lund and Lund, 2013b). Lastly, another measure was that there was no multicollinearity. 
This assumption was assessed by evaluating the Pearson correlation. A study by Lee et al. 
suggests that values between 0.5 and 0.8 suggest no multicollinearity. Several researchers 
have proposed that greater than 0.8 were considered to have multicollinearity (Lee et al., 
2016; Negreiros, 2018). As a result, VIF values greater than 0.9 were considered 
evidence of multicollinearity between variables. 
The rMANCOVA analysis was a form of the RM analysis of variance 
(ANCOVA) considered appropriate when the four assumptions were met, which include 
that there was homogeneity of variance and covariance (Griffith, 2015; Mertler & 
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Vannatta, 2002; Statistics Solutions, 2013). The homogeneity of covariance was assessed 
by using a Box M test of equality of covariance to test whether two or more covariances 
were homogenous (Garson, 2012; Statisticshowto, 2018a). Homogeneity of variances 
was tested with Mauchly’s test of sphericity (Horn, n.d.). Moreover, another measure was 
that there was a linear relationship between each dependent variable for each group of the 
covariate variable (Lund and Lund, 2018; Statistics Solutions, 2013). This assumption 
was assessed by a Pearson correlation r table to assess the linear relationship between 
variables (Kent State University, 2019; StatTrek, 2019).  Lastly, another appropriate 
measure was that there must be multivariate normality (Griffith, 2015). This assumption 
was assessed by using the Q-Q plots to assess the differences in the data from a normal 
distribution and the Shapiro-Wilk test of normality on each dependent variable for each 
of the group’s independent variable (Lund and Lund, 2013b). This test was recommended 
for studies with small sample sizes up to n=2000 (Garson, 2012). 
RQ1: Does use of MAD therapy have a statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA? 
H01: Use of MAD therapy does not have any statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA. 
Ha1: Use of MAD therapy does have a statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA. 
The independent variable for this research question was the use of the MAD. The 
dependent variables were measures of heart failure symptoms (ejection fraction, SBP, 
DBP, oxygen saturation, BNP, NT-proBNP, and troponins levels). Changes in symptoms 
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of heart failure were assessed by looking at the changes in the data at the second, fourth, 
and sixth month follow up after treatment with the MAD began. The rMANOVA 
procedure was used to test the follow-up measures of heart failure and determine if the 
use of MAD has a statistically significant effect on heart failure symptoms in male 
African American Veterans with OSA. The use of the rMANOVA allowed me to assess 
the magnitude of changes in values for the seven dependents variables while controlling 
for the inflation of Type I error. Independent and dependent data from archived files were 
evaluated using scatterplots and correlation tables. A scatterplot was used to test the 
assumption that there was a linear relationship between each dependent variable and the 
independent variables (Lund & Lund, 2013a). Correlation tables were used to identify the 
significance of the change in dependent variables means.  
RQ2: What is the moderating effect of BMI on the use of MAD therapy for 
treating symptoms of heart failure in male African American veterans diagnosed with 
OSA? 
H02: BMI levels do not have a statistically significant moderating effect  
on the use of MAD therapy for treating symptoms of heart failure in male African 
American veterans diagnosed with OSA. 
Ha2: BMI levels do have a statistically significant moderating effect on the use of 
MAD therapy for treating symptoms of heart failure in male African American veterans 
diagnosed with OSA. 
The independent variable in the study was the use of the MAD. The dependent 
variables were the measures of heart failure symptoms (ejection fraction, SBP, DBP, 
88 
 
oxygen saturation, BNP, NT-proBNP, and troponins levels). The covariate was the level 
of BMI. The rMANCOVA was used to examine whether BMI moderates the impact of 
MAD therapy on symptoms of heart failure. The rMANCOVA allowed me to assess the 
magnitude of changes in values for the seven dependent variables while controlling for 
the inflation of type I error. Incremental analysis reviews were performed at the end of 
the second, fourth, and sixth months of the study to compare study results. Independent 
and dependent data from archived files were evaluated using a scatterplot and correlation 
table. A scatterplot was used to test the assumption that there was a linear relationship 
between dependent variables, independent variables, and between the covariate BMI, as 
well as each of the dependent variables, and the independent variable (Lund & Lund, 
2013b). Correlation tables were used to identify the significance of the change in 
dependent variables. 
RQ3: Does smoking status have a statistically significant moderating effect on the 
use of MAD therapy for treating symptoms of heart failure in male African American 
veterans diagnosed with OSA? 
H03: Smoking status does not have a statistically significant moderating effect on 
the use of MAD therapy for treating symptoms of heart failure in male African American 
veterans diagnosed with OSA. 
Ha3: Smoking status does have a statistically moderating effect on the use of 
MAD therapy for treating symptoms of heart failure in male African American veterans 
diagnosed with OSA. 
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The independent variable in the study was the use of the MAD. The dependent 
variables were the outcomes of heart failure symptoms (ejection fraction, SBP, DBP, 
oxygen saturation, BNP, NT-proBNP, and troponins levels). The covariate was smoking. 
The rMANCOVA was used to examine whether smoking status moderates the impact of 
MAD therapy on symptoms of heart failure levels at the end of the second, fourth, and 
sixth months of the study to compare study results. The rMANCOVA allowed me to 
assess the magnitude of changes in values for the seven dependent variables while 
controlling for the inflation of Type I error. Independent and dependent data from 
archived files were evaluated using a correlation table and scatterplot format. A 
scatterplot was used to test the assumption that there was a linear relationship between 
dependent variables, independent variables, and between the covariate smoking, as well 
as each dependent variable and the independent variable (Lund & Lund, 2013b). 
Correlation tables were used to identify the significance of the change in dependent 
variables. 
Threats to Validity 
External validity describes the ability for the findings to be generalizable to the 
target population (Crawford and Khorsan, 2014). Heart failure affects 5.7 million people 
in the United States (CDC, 2016). Casey et al. (2012) has shown that OSA affects 
between 26-36% of veterans, due to there being a relative sample size it may aid in the 
external validity of the study. This study was a repeated measures study using a 
purposeful convenience sample of African Americans over the age of 20, using MAD, 
who have been diagnosed with OSA and heart failure within the past year. Threats to the 
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external validity may include the fact that there cannot be a cause-effect relationship in 
this study design, however, that there may be correlation pending the sample was large 
enough to be representative (Carlson and Morrison, 2009). Another threat to external 
validity may include purposeful convenience sampling due to the potential selection of 
records (Dudovskiy, 2019). Though the number of African American veterans using 
MAD who have heart failure in this sampling method was unknown, theoretically, to 
minimize this threat, the best technique was to focus on the distinctive characteristics of 
the target population. Therefore, to minimize these threats, there was one researcher to 
review the data to verify that the actual data needed for the study was present and that to 
ensure no missing data values and to identify possible misclassification.  
Patten (2012) has revealed that threats to external validity applying to the 
secondary data in this study include: (a) interaction effects of selection and experimental 
variables, (b) specificity of variables, (c) and multiple treatment interferences. Interaction 
effects of selection and experimental variables indicate that certain groups may be more 
affected by treatment due to the makeup of the group (Rommel-Esham, 2010). The study 
results regarding African American Veterans may not be applicable to other 
demographics or females as a result of other patients not having the benefits of VA 
healthcare access, and the opportunity for alternative treatment coverage. Specificity of 
variables occurs when the variables were so unique to the study that it lessens the ability 
to generalize (Georgia Southern University, n.d.). De-identified data used in the study 
from archived files may be affected due to the receipt of MAD in a sterile healthcare 
environment, possibly being quite different from the natural home environment in which 
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the device was used during sleep. Patten (2012) has indicated that multiple treatment 
interferences occur when there was more than one treatment given to a group, due to it 
potentially having the opportunity to effect each other. Multiple treatment interferences 
may consist of records having other medical impairments or carryover effects to the 
treatment being offered in this study that cause counter interactions that make it hard for 
results to be associable. Additionally, archived records used in the study from the target 
population may also involve other health conditions (diabetes, cancer, etc.) or treatments 
that may cause a simultaneous form of impairment to the study. However, it was hard to 
generalize the conflict of simultaneous forms of health condition or treatments being 
received by the study population because the researcher has no control and cannot control 
for extraneous variables. 
Threats to internal validity include maturation and mortality (Flannelly et al., 
2018). Maturation results in bodily changes that occur over time within the study 
(Flannelly et al., 2018). Throughout the course of the study, results may indicate a 
maturation change in BMI, smoking, and level of severity of heart failure symptoms 
(Flannelly et al., 2018). Mortality indicates any failure of data from archived files that do 
not to complete the study (Flannelly et al., 2018). Due to the longevity of the study, rates 
of attrition may occur as a result of death, non-compliance, and drop out. To address this 
concern, queries in VINCI were ran to identify the number of records at the beginning of 
the study and to determine the percentage of attrition within the target population.  
Threats to conclusion validity may be due to the random heterogeneity of 
respondents, which addresses diversity among respondents and determining the 
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likelihood if a relationship exists. This validity concern may be present due to only 
having African American Veterans in this study, which may result in it not being 
generalized to the overall population. In sum, this study does not address the female sex 
or other ethnicities in excess of African Americans. An effort to improve conclusion 
validity has been implemented by having good statistical power in the study over 
.80.  The current study power in this study was 0.8175114. 
Ethical Procedures 
Ethical epidemiological practice was maintained in this study. Data collected 
from secondary data provided by the VA agency did not require informed consent. I, as 
the primary data collector of secondary data, required approval from both the Walden 
University IRB and VA identified IRBs. Additionally, VA HRPP face-to-face training, 
VA via University of Florida’s IRB-01 Health Insurance Portability and Accountability 
Act (HIPAA) for Research, local IRB training, the NIH Office of Extramural Research 
Protecting Human Research Participants, and the Collaborative Institutional Training 
Initiative (CITI) training certificates were completed by me before handling any personal 
healthcare information as a measure of data security. Once approval was gained, I was 
able to review de-identified data in VINCI. All data, however, was scrubbed and redacted 
for personal identifying information to make anonymous in relation to name, social 
security number, address, phone numbers, physician names, and other safeguards for 
those records who were utilized. Linkage of data was associated via a codex, followed by 
gender, ethnicity, and categorical diagnosis. Data collected was housed on a password 
encrypted isolated hard drive and only displayed and calculated via the VINCI’s 
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SPSS/PSPP. Due to the use of de-identified data, I was the only researcher in this 
secondary data study, and there was no need for dissemination of PHI due to no 
identifying marks or interventions activities for refusal or withdrawal. Therefore, upon 
completion and publication of this study, data will be stored for a minimum of five years 
before being deleted and destroyed to prevent any accidents or lapses in security that 
would allow any PHI to escape (University of Florida, 2014). 
Summary 
This study used a quantitative repeated measures design to assess if there was a 
significant reduction in heart failure symptoms through MAD use among African 
American Veterans with OSA who were age 20 or older and whether treatment efficacy 
differs in terms of BMI and smoking status. This study uses secondary data collected 
from the VHA to address the three research questions. Chapter 4 includes the statistical 
results of the data for this study using SPSS/PSPP. 
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Chapter 4: Results  
Introduction 
This quantitative correlational study was conducted to determine whether MAD 
therapy impacts symptoms of heart failure among African American male veterans 
diagnosed with OSA. The independent variable consisted of the use of the MAD. The 
dependent variables were symptoms of heart failure (SBP, DBP, oxygen saturation, BNP, 
NT-proBNP, and troponins levels). Data analyzed in this study were obtained from the 
VA VINCI database and performed using a correlational design. Data analysis was 
conducted through a repeated measures test and calculated using SPSS version 25. The 
rMANOVA and rMANCOVA analysis were used to test the hypotheses in this study. 
The research questions and associated hypotheses were: 
RQ1: Does use of MAD therapy have a statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA? 
H01: Use of MAD therapy does not have any statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA. 
Ha1: Use of MAD therapy does have a statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA. 
RQ2: What is the moderating effect of BMI on the use of MAD therapy for 
treating symptoms of heart failure in male African American veterans diagnosed with 
OSA? 
H02: BMI levels do not have a statistically significant moderating effect  
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on the use of MAD therapy for treating symptoms of heart failure in male African 
American veterans diagnosed with OSA. 
Ha2: BMI levels do have a statistically significant moderating effect on the use of 
MAD therapy for treating symptoms of heart failure in male African American veterans 
diagnosed with OSA. 
RQ3: Does smoking status have a statistically significant moderating effect on the 
use of MAD therapy for treating symptoms of heart failure in male African American 
veterans diagnosed with OSA? 
H03: Smoking status does not have a statistically significant moderating effect on 
the use of MAD therapy for treating symptoms of heart failure in male African American 
veterans diagnosed with OSA. 
Ha3: Smoking status does have a statistically moderating effect on the use of 
MAD therapy for treating symptoms of heart failure in male African American veterans 
diagnosed with OSA. 
The rMANCOVA analysis was used to examine whether the use of MAD therapy 
impacted measures of symptoms of heart failure levels in the second, fourth, and sixth 
months of the study. The rMANCOVA allowed me to assess the magnitude of changes in 
values for the dependent variables while controlling for the inflation of type I error. 
Chapter 4 includes the results of the completed data analysis. This chapter addresses the 
data collection process, results of data analysis, discussion of results, evaluation of 
statistical assumptions, and discussion of the statistical analysis.  
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Data Collection 
Data used in this quantitative nonexperimental longitudinal study were supplied 
by the VHCA’s VINCI program. In this study, secondary data was used, and it did not 
require recruitment or response rates. Data were initially requested for this study from the 
VA VINCI on April 9, 2019. The VINCI program data was provided to me by an 
assigned VA approved and certified principal investigator. The assigned VA principal 
investigator completed all VA-required training between July 24 and August 17, 2018, to 
certify her ability to handle secondary data from the federal government. Initially, I 
requested data on the Orlando Veterans Affairs Healthcare system and the North Florida/ 
South Georgia Veterans Affairs Healthcare system from the North Florida/South Georgia 
Veterans Affairs Healthcare systems and was notified by the VA that this request was too 
specific, and would not yield more than a small number of results due to the MAD not 
being provided at every station. Therefore, I was provided data from veterans’ healthcare 
facilities across the United States of America that used the MAD between 2005 and2019. 
Data has been queried by VINCI from SQL, converted to Excel, sent to the assigned VA 
approved principal investigator, and supplied to me on the initial date of June 5, 2019. I 
was provided access to the data through a designated VA computer within a designated 
workspace, using a VA- encrypted username and password login so that I could review 
the data related to the study.   
The data I received from the VA principal investigator was in Excel format and 
contained the following information: station location, race, sex, date of birth, OSA 
diagnosis, OSA diagnosis date, MAD receipt date, dependent variable dates collected and 
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dependent variables data from the second, fourth, and sixth months relating to ejection 
fraction, SBP, DBP, oxygen saturation, BNP, NT-proBNP, and troponins levels. Data by 
the VA approved principal investigator did contain PHI in the form of a unique identifier 
via the patient-internal control numbers (ICN) with no real or scrambled social security 
numbers.  The data set was supplied to me without any code to connect the ICN to the 
patient. Once I received the data set, I immediately analyzed it for the appropriate 
population, geographic location, correct focus of study, and appropriate variables. I then 
scrubbed it of its PHI relating to the Patient ICNs using the anonymization technique of 
suppression. Suppression is a technique to reduce the risk of identification for 
participants by removing identifying markers and assigning it an appropriate variable 
(Benschop, Machinguata & Welch, 2018; Nayaki, Simi & Sudheep, 2017). The ICN data 
was suppressed by deleting the ICN column and providing each set of data in that column 
with an individual variable identification number in SPSS to de-identify the data set. Data 
collected was then observationally screened for accuracy and appropriate inclusion 
criteria relating to study variables. All data that did not meet the study criteria were 
excluded from the study, including non-African Americans, OSA diagnosis dates, heart 
failure diagnosis dates, dependent variables dates, and cases containing insufficient data 
due to not being relevant to the study questions.  
There were 1634 cases initially provided in the data sample. Of 1634, 23 cases 
were stricken from the study due to not meeting the criteria related to ethnicity. Within 
the 1611 cases remaining, 1582 cases were removed, due to insufficient data across the 
variables and intervals of interest for the study.  
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Within the 29 cases, I utilized the compute variables box and a syntax code of 
COMPUTE age = CTIME.DAYS(formdate-birthdate)/365.25 to convert the given date of 
birth with the date the data was received to calculate a given age for each case. 
Verification of age conversion uniformity consisted of going into the variable view tab 
and verifying that the date box was set to date, month, and year (dd.mm.yyyy). 
Calculated ages were used to represent cases of African American male veterans who 
used the MAD device. A means imputation was performed within the 29 cases, due to 
each case having variations of missing data within the dependent variables and the 
covariate of BMI. This method was used to assign a scale mean on the missing data 
within dependent variables to “maximize the data collected and minimize the effects of 
the missing data” (Harris, 2013, p. 90). According to Harris (2013), this approach does 
not modify the value of the data because it inputs scale means that do not alter the general 
mean; however, it reduces the number of dropped cases from the analyses.  
Repeated measures MANOVA assumptions were assessed observationally for 
adequate sample size, dependent variables measured as ratio levels, and the independent 
variable consisted of two or more categorical independent groups. Other rMANOVA 
assumptions were assessed through SPSS statistical analysis testing. The rMANOVA 
assumptions consisted of identifying if there was multivariate normality and determining 
if there were linear relationships between each pair of dependent variables within each 
group of the independent variables. Additional rMANOVA assumptions were comprised 
of verifying there were no univariate or multivariate outliers, and that there was no 
multicollinearity.  
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The rMANCOVA assumptions were assessed by observationally inspecting that 
two or more dependent variables that were measured in interval or ratio levels, and that 
the one independent variable consists of two or more categorical, independent groups. 
Further rMANCOVA assumptions consisted of visually assessing that one or more 
covariates were continuous variables and that there was independence of observations. 
Other rMANCOVA assumptions were assessed through SPSS statistical analysis testing 
which included determining if there were linear relationships between each pair of 
dependent variables within each group of the independent variable, and determining if 
there were linear relationship between the covariate and each dependent variables within 
each group of the independent variable. Lastly, additional rMANCOVA assumptions 
consisted of assessing the homogeneity of variances and covariances, multivariate 
normality, determining there were no significant univariate outliers in the independent 
variable groups in term of each dependent variable and no multivariate outliers in the 
groups of the independent variables in terms of each dependent variable. Data that met 
the study’s inclusion criteria were then statistically analyzed in SPSS using the 
rMANOVA to assess the magnitude of changes in values for the seven dependent 
variables relating to heart failure while controlling for the inflation of type I error. Data 
that met the study’s inclusion criteria were also statistically analyzed in SPSS using the 
rMANCOVA to examine whether BMI and Smoking moderates the impact of MAD 
therapy on symptoms of heart failure and to assess the magnitude of changes in values for 
the seven dependent variables while controlling for the inflation of type I error.   
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Discrepancies 
The discrepancies in the data collection plan differed from the method identified 
in chapter 3 in several ways as a result of the VA requirements, access to data, and access 
to data analysis tools. Initially, in Chapter 3, I did not include the use of a principal 
investigator due to being notified by the VA that one may not be needed. However, a VA 
trained, and certified principal investigator was indeed required, assigned, and provided 
by VA. The VA principal investigator was educated on the study, its structure, and its 
needed data components and provided monitoring of the study data. Initially, my study 
criteria included data gathered within the past year. Thought the initial data review 
timeframe was from 2016-2017, as a result of a combination of data not being available, 
limited sample size, and need for inclusion criteria to be met, I was provided data from 
the last 14 years from 2005-2019. Within this data, useable data from the timeframe of 
2016-2017 was not sufficient or applicable. There were a few populations’ discrepancies, 
which were included in the study. A discrepancy was that I was not able to gather data 
primarily from the Veterans Affairs Healthcare systems due to being notified by the VA 
that the request was too specific and would not yield more than a significantly limited set 
of results due to the device not being widely used at every station. I, however, was 
provided data from Veterans Health Care facilities across the country that were trained 
and able to utilize this device. 
Other discrepancies related to polysomnography results indicating sleep apnea 
within the past year was changed as a result of notification from VA that these tests were 
utilized in several ways including community outsourcing through community care, 
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watches, and overnight polysomnography test all would be difficult to capture 
longitudinally, and therefore the OSA diagnosis of ICD-9 code 327.23 and ICD-10 code 
G47.33 were used. Data containing PHI in the form of Patient ICN with no real or 
scrambled social security numbers and no connecting code were provided to me from the 
VA Principal Investigator; however, it was anonymized via suppression. Originally, I 
indicated that archived data utilized in this study would be scrubbed of Patient Health 
Information (PHI) identifiers by the agency prior to my receipt and used by the 
researcher. Additionally, a password encrypted hard drive was not needed due to VA 
providing an isolated password encrypted computer that logged onto a secured site of 
which data was not able to be removed, printed, downloaded, or saved from the VINCI 
workstation. Moreover, the PSPP software was not able to be used in this study as an 
analysis tool in VINCI due to it not being able to perform rMANOVA or the 
rMANCOVA analysis. Therefore, SPSS was provided by the VA.  
Further discrepancies were related to several additional forms, processes, and 
documents needed to gain access to the data from the HRPP. The HRPP encompassed 
approvals by Gainesville, Florida, VA, and identified the following entities: the Internal 
Review Board from the University of Florida, the VA WOC program, VA Research and 
Development, and the VA National Data Systems. Requirements to gain access to the 
Veteran Affairs data consisted of completing forms such as the: Gainesville’s VA 
academic affiliation agreement with Walden University, face-to-face VA research 
SharePoint training, and the completion of the North Florida / South Georgia SharePoint 
form. Additional VA requirements consisted of completing training such as the: 
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Collaborative Institutional Training Initiative (CITI) on human research for good clinical 
practice, CITI on VA human subject’s protection training, CITI on VA office of research 
and development biosecurity, government ethics training, ethics most wanted, VA 
privacy and information security awareness and rules of behavior, and VA privacy and 
HIPAA.  
VA documents required to gain access to data consisted of completing forms such 
as the: VA abstract, authorization form for use and release of individually identifiable 
health information collected for VHA research, certification of licensure form, coversheet 
subcommittee on research safety, data management and access plan (DMAP), data use 
agreement (DUA) between VHA and federal entity, privacy, confidentiality, and 
information security source checklist for research. Additional documents that required 
completion in order to gain access to the VA data were the declaration for federal 
employment form, DUA VHA limited data set, education verification form, HRPP memo 
research staff only, HRPP new study submission sharepoint introduction training, human 
research subject protection, human subject research pre-review checklist. Continual 
documents needed per VA to gain data access were the employment verification form, 
new investigator form, privacy review, privacy security data, protocol form, research and 
development information system investigator data, research financial conflict of interest 
statement,  research protocol safety evaluation form, safety cover sheet, scope of practice, 
VA10-9012 if protocol used a drug, and VA and Walden affiliation agreement.   
Requirements from the Gainesville, Florida VA Without Compensation (WOC) 
program also consisted of completing: a packet checklist, appointment position 
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description, appointment patient contact statement, appointment experience working with 
animals, appointee intellectual property agreement, appointment mandatory training 
instruction, appointment information manager and personal identity verification sponsor. 
Additional required documents needed to gain WOC status needed to gain access to the 
VA data were the certification of licensure, VA declaration of federal employment, ethics 
most wanted training, intellectual property agreement, information system security 
officer (ISSO) review/approval letter, myIRB study submission form, personal resume,  
real social security number access form, registration or bar membership form, scope of 
practice for research staff,  scope of practice for CPRS access, and scope of work form. 
Continual documents needed for WOC were the VA clinical studies center education 
verification form, VA national rules of behavior form, verification of license and 
certifications, VA talent management system training, VA assigned VA principal 
Investigator, VA privacy HIPAA training, VA privacy and information security 
awareness and rules of behavior training, without compensation application, and the 
Department of Homeland Security employment eligibility verification.  
Training needed from the University of Florida consisted of the completion of the 
myIRB SharePoint form and training that included CITI human research -good clinical 
practice, CITI VA human subjects protection, CITI mandatory IRB training-biomed, 
CITI VA ORD biosecurity training, completing virtual private network (VPN) access, 
completed associate affiliation assurance, IRB01 local training, IRB01 local training 
refresher, NIH extramural education and UF HIPAA and privacy – research, and UF 
gatorlink registration. The following documents were needed to gain access to VINCI: 
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the ISSO referral letter, VINCI registration, complete data access request tracker (DART) 
application, research request memo, research study IRB approval letter, research and 
development committee approval letter. Additional completed documents needed for 
VINCI were the IRB approval of waiver of HIPAA-compliant authorization, research 
protocol, corporate data warehouse (CDW)-domain checklist, real SSN access request, 
vital status rules of behavior, national data system (NDS) data use agreement, research 
privacy review checklist, receive VA VINCI link and password, VINCI assigned sequel 
assistant, and CDW request forms prior to receiving access to data.   
After approval to access the data was provided by the VA office HRPP, I logged 
onto the provided secured VINCI site on a dedicated VA computer. Additional changes 
in this study consisted of the study sample changing from de-identified data to a limited 
data set with no real or scrambled social security numbers that have limited PHI in the 
form of non-identifiable ICN. Data was accessed from VINCI by performing a query on 
records that meet the inclusion criteria. Additional data was excluded from the study data 
set due to not meeting the inclusion criteria and not being relevant to the study analysis. 
Excluded data that did not meet the study criteria included the following: dates of 
diagnosis for OSA and heart failure, and dates of collection for symptoms of heart failure, 
BMI, and smoking status. Furthermore, several dependent variables were removed from 
the study due to not having sufficient data across the 2nd, 4th, and 6th monthly intervals, 
including ejection fraction, BNP, proBNP, and troponin. The remaining three dependent 
variables include SBP, DBP, and oxygen saturation. Lastly, within the covariate of 
smoking status, a means imputation was not able to be performed using this variable due 
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to inconsistent data, there being no uniform depiction of smoking type within the variable 
and the mean imputation yielding undistinguishable half measures across the 2nd, 4th, and 
6th month interval.  
Demographics 
Table 4 includes the archived records of 29 African American male Veterans, 
from 16 VA health care systems, nationally, who were between the ages of 43 to 84 years 
old. The independent variables consisted of data collected at the 2nd, 4th, and 6th month 
on the use of the MAD. The dependent variables consisted of symptoms of heart failure 
(SBP, DBP, oxygen saturation). The covariate was BMI. 
Results 
Descriptive Statistics 
Demographic data. Table 3 presents a summary of descriptive statistics for the 
demographic data. The mean age documented in the records was 62.83 years, and the 
standard deviation as 8.97 years. The ages ranged from 43 to 84 years of age.  
Frequency counts were performed to acquire baseline descriptive statistics on the 
demographic data and data provided within the sample data set. There were 29 valid list 
wise and archived African American male Veterans records. The frequency counts in 
Table 4 shows that the most frequently occurring age was 66 years and older. 
Table 3 
Descriptive Statistics 
                  (table continues) 
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Black or African 
American  N 
            
Rang
e Minimum 
Maximu
m Sum Mean 
Std. 
Dev. 
age 29 41 43 84 1822 62.83 8.969 
Valid N 
(listwise) 
29 
      
 
Table 4 
Frequency Statistics for Age  
 Frequency Percent 
Valid 
Percent Cumulative Percent 
Valid under 45 2 6.9 6.9 6.9 
46-55 2 6.9 6.9 13.8 
56-65 10 34.5 34.5 48.3 
66-and older 15 51.7 51.7 100.0 
Total 29 100.0 100.0  
 
Table 5 presents a summary statistic for the data collected on dependent variables 
at the 2nd, 4th, and 6th months after the use of the MAD began. Data collected in the 2nd 
month shows the range of SBP levels were from 107 mmHg to 165 mmHg, with an 
average SBP level amount of 127.32 (SD = 14.597. Diastolic blood pressure levels 
ranged from 58 mmHg to 121 mmHg, with an average DBP level of 76.95 (SD = 
11.159).  Oxygen saturation levels ranged from 93% to 99%, with an average oxygen 
saturation level of 97.00 (SD = 1.035). The BMI levels ranged from 26 kg/m2 to 46 
kg/m2, with an average BMI level amount of 34.89 (SD = 4.028).   
Also exhibited in Table 5, data collected in the 4th month, SBP levels ranged from 
105 mmHg to 171 mmHg, with an average SBP level amount of 133.18 (SD = 12.084). 
The most frequent SBP level amount was 133 mmHg. Diastolic blood pressure levels 
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ranged from 60 mmHg to 95 mmHg, with an average DBP level amount of 81.53 (SD = 
7.026.  The range of oxygen saturation levels were from as low as 86% to as high as 
100%, with an average oxygen saturation level amount of 96.92 (SD = 2.337. Systolic 
blood pressure levels ranged from 114 mmHg to 156 mmHg, with an average SBP level 
amount of 136.73 (SD = 9.155). Diastolic blood pressure levels ranged from 51 mmHg to 
97 mmHg, with an average DBP level amount of 80.60 (SD = 8.451. Oxygen saturation 
levels ranged from 94% to 100. Lastly, the range of BMI levels was from 27 kg/m2 to 46 
kg/m2, with an average BMI level of 34.07 (SD = 3.360).  
 
Table 5 
Summary Descriptive Statistics for Dependent Variables across Bimonthly Intervals for 6 
months 
Variable  N Min Max Sum Mean SD 
Systolic Blood Pressure 
  2 months 29 107 165 3692 127.31 14.59 
  4 months 29 105 171 3862 133.17 12.08 
  6 months 29 114 156 3965 136.73 9.15 
 
Diastolic Blood Pressure 
  2 months 29 58 121 2231 76.94 11.15 
  4 months 29 60 95 2364 81.52 7.02 
  6 months 29 51 97 2337 80.60 8.45 
Oxygen Saturation 
  2 months 29 93 99 2813 97.00 1.03 
  4 months 29 86 100 2811 96.91 2.33 
  6 months 29 94 100 2824 97.36 .93 
BMI 
  2 months 29 26 46 1012 34.88 4.02 
  4 months 29 20 46 998 34.39 4.04 
  6 months 29 27 46 988                      34.07 3.35 
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Testing Statistical Assumptions 
Sample size. Within both the rMANOVA and rMANCOVA assumptions, 23 
cases were considered to have an adequate sample size according to the G*Power 
analysis, which was calculated on a medium effect size of f = 0.25, α err prob = 0.05, 
Power (1-β err prob) = 0.80. This sample size was met due to there being 29 cases 
utilized in the study, with no missing cases. 
Independent variables. The independent variable in this study was the use of the 
MAD, which was present in two or more independent groups, i.e., in the 2nd, 4th, and 6th 
month, therefore, this assumption was met. 
Dependent variables. All the dependent variables in this study were on a ratio 
level of measurement; therefore, this assumption was met. 
Covariates. This study did have one covariate in BMI. The covariate BMI was 
presented as a continuous ratio variable in this study in three different monthly interval 
measurements in the 2nd, 4th, and 6th months. Therefore, this assumption has been met. 
 Outliers. SPSS produced a z-score table used in assessing the z-scores of +3.29 to 
identify extreme univariate outliers (Steyn, 2018). In Appendix A, the SPSS produced a 
z-score table, that shows five outliers identified ranging from as low as -4.67 to as high as 
3.96. Due to there being no universal best choice to address the outliers that exist in the 
Z-score table, I performed a visual inspection to determine the nature of the outliers 
(Pum, 2019).  Results from the visual inspection that all suspected values were truly 
possible values for the variables included in the data set. Therefore, the univariate outlier 
assumption was met. 
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In addition, mahalanobis distance was used to test for multivariate outliers in the 
data (Statistics Solutions, 2019b). The mahalanobis distance statistic was a common, 
sensitive, and robust method for detecting multivariate outliers (Deng, Jiang, Li, L. & Li, 
X., 2019). It was based on the Rocke estimator, by using the threshold set in the chi-
square distribution using a p<.001 to identify a critical value (Deng et al., 2019). 
According to the chi-square value table, the maximum allowable critical value for the 
Mahalanobis distance for 3 variables was 16.266 (Palay, 2016). It can be suggested that 
there were outliers within the set of data if the identified critical value result was more 
than the maximum critical value of 16.266.  
In Appendix B, the residuals statistics table shows that the Mahalanobis distance 
mean was 8.690 (SD=7.004), while the maximum critical value was 23.021.  Due to the 
outlier assumption being violated, therefore, a commonly used correction was executed. I 
performed a visual inspection of the dependent variables in the data for appropriateness 
(Beaton et al., 2019). Results have shown that all possible outliers were within the normal 
range for dependent variable data. Therefore, the assumption for no multivariate outliers 
was met.  
Linear relationships. According to Lund and Lund (2018), the linear relationship 
between each dependent variable for each group of the independent variable was needed 
for the assumption to be valid.  Due to the correlation tables’ ability to assess the degree 
to which a relationship is linear, a scatterplot was not used in this linear relationship 
analysis (Lund & Lund, 2018). The test assessed linear relationships between heart 
failure symptoms, i.e., SBP, DBP, oxygen saturation, and MAD use via the use of a 
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Pearson Correlation table (Kent State University, 2019; StatTrek, 2019). The Pearson 
correlation r was used when both variables were measured on an interval or ratio scale to 
indicate the magnitude and direction of a linear relationship between variables (Kent 
State University, 2019; StatTrek, 2019). According to NAME OF AUTHOR (YEAR), 
Pearson correlation r values were between -1 and 1. Additionally, the further the Pearson 
correlation r value was from zero, the stronger the linear relationship between two 
variables was considered (University of Texas, 2015).  
 In Table 6, a Pearson’s r test was computed to assess the relationship between the 
independent variable of MAD use at 2nd, 4th, 6th months on the dependent variables of 
SBP, DBP, and oxygen saturation. The sample size for all variable samples were n=29. 
There appears to be a statistically significant, positive linear relationship between 2-
month SBP and 2-month DBP (r=.661, p=.000), 4-month SBP and 4-month DBP (r= 
.693, p=.000), 4-month SBP and 4-month oxygen saturation (r= .576, p=.001),  4-month 
DBP and 4-month oxygen saturation (r= .607, p=.000), and 6-month SBP and 6-month 
DBP (r=.662, p=.000). Overall, there appears to be a significantly strong linear 
relationship between MAD use and SBP, DBP, and oxygen saturation. Therefore, 
indicating that as one variable increased, the other increased.  
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Table 6  
 
Correlations 
 
 @2moSystolic_BP       @2moDiastolic_BP                      @2moO2           @4moSystolic_BP     @4moDiastolic_BP 
@2moSystolic_B
P 
Pearson Correlation 1 .661** .118 .105 .096 
Sig. (2-tailed)  .000 .541 .586 .620 
@2moDiastolic_
BP 
Pearson Correlation .661** 1 .164 -.171 .007 
Sig. (2-tailed) .000  .396 .376 .970 
@2moO2 Pearson Correlation .118 .164 1 -.093 -.069 
Sig. (2-tailed) .541 .396  .630 .721 
@4moSystolic_B
P 
Pearson Correlation .105 -.171 -.093 1 .693** 
Sig. (2-tailed) .586 .376 .630  .000 
@4moDiastolic_
BP 
Pearson Correlation .096 .007 -.069 .693** 1 
Sig. (2-tailed) .620 .970 .721 .000  
@4mo_O2 Pearson Correlation -.121 -.074 .031 .576** .607** 
Sig. (2-tailed) .532 .702 .874 .001 .000 
@6moSystolic_B
P 
Pearson Correlation .191 .068 .118 .274 .238 
Sig. (2-tailed) .320 .724 .543 .150 .213 
@6moDiastolic_
BP 
Pearson Correlation .083 .090 .079 .170 .213 
Sig. (2-tailed) .668 .644 .683 .378 .266 
@6mo_O2 Pearson Correlation .166 .176 .198 -.208 -.009 
Sig. (2-tailed) .390 .362 .304 .278 .962 
(table continues)
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    @4mo_O2                   @6moSystolic_BP                    @6moDiastolic_BP                       @6mo_O2 
@2moSystolic_BP Pearson Correlation -.121 .191 .083 .166 
Sig. (2-tailed) .532 .320 .668 .390 
@2moDiastolic_BP Pearson Correlation -.074 .068 .090 .176 
Sig. (2-tailed) .702 .724 .644 .362 
@2moO2 Pearson Correlation .031 .118 .079 .198 
Sig. (2-tailed) .874 .543 .683 .304 
@4moSystolic_BP Pearson Correlation .576** .274 .170 -.208 
Sig. (2-tailed) .001 .150 .378 .278 
@4moDiastolic_BP Pearson Correlation .607** .238 .213 -.009 
Sig. (2-tailed) .000 .213 .266 .962 
@4mo_O2 Pearson Correlation 1 .019 .003 -.082 
Sig. (2-tailed)  .923 .990 .673 
@6moSystolic_BP Pearson Correlation .019 1 .662** .360 
Sig. (2-tailed) .923  .000 .055 
@6moDiastolic_BP Pearson Correlation .003 .662** 1 -.095 
Sig. (2-tailed) .990 .000  .625 
@6mo_O2 Pearson Correlation -.082 .360 -.095 1 
Sig. (2-tailed) .673 .055 .625  
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
a. Cannot be computed because at least one of the variables is constant. 
b. All Dependent Variables Sample N=29 
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In Table 7, among the 2-month BMI correlation, there appears to be a positive 
significant linear relationship with 2-month SBP (r= .359, p= .056).  In the 4-month BMI 
correlation, there appears to be a positive linear relationship with 4-month SBP (r=.601, 
p=.001), 4-month DBP (r=.492, p=.007), and 4-month oxygen saturation (r= .660, 
p=.000).  Lastly, in the 6-month BMI correlation, there appears to be a positive linear 
relationship 2-month SBP (r= .428, p= .020), 4-month SBP (r=.461, p=.012), and 6-
month SBP (r=.470, p=.010). Overall, due to all values being between -1 and 1, there 
appears to be a significant linear relationship between MAD use and BMI on SBP, DBP, 
and oxygen saturation. Overall, the linear assumption was met. 
Table 7  
 
Correlations 
 
 @2moBMI_1_1 @4mo_BMI_1_1 @6mo_BMI_1_1 
@2moSystolic_BP_1 Pearson Correlation .359 .195 .428* 
Sig. (2-tailed) .056 .310 .020 
@2moDiastolic_BP_1 Pearson Correlation .160 .001 .024 
Sig. (2-tailed) .406 .995 .901 
@2moO2_1_1 Pearson Correlation -.028 .157 .088 
Sig. (2-tailed) .886 .416 .652 
@4moSystolic_BP_1 Pearson Correlation .175 .601** .461* 
Sig. (2-tailed) .364 .001 .012 
@4moDiastolic_BP_1 Pearson Correlation -.051 .492** .096 
Sig. (2-tailed) .792 .007 .620 
@4mo_O2_1_1 Pearson Correlation .045 .660** .011 
Sig. (2-tailed) .817 .000 .954 
@6moSystolic_BP_1 Pearson Correlation .320 .205 .470* 
Sig. (2-tailed) .090 .285 .010 
@6moDiastolic_BP_1 Pearson Correlation .242 .163 .361 
Sig. (2-tailed) .205 .397 .054 
                  (table continues) 
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@6mo_O2_1_1 Pearson Correlation .027 -.082 -.082 
Sig. (2-tailed) .889 .673 .672 
@2moBMI_1_1 Pearson Correlation 1 .368* .632** 
Sig. (2-tailed) 
 
.050 .000 
@4mo_BMI_1_1 Pearson Correlation .368* 1 .486** 
Sig. (2-tailed) .050  .008 
@6mo_BMI_1_1 Pearson Correlation .632** .486** 1 
Sig. (2-tailed) .000 .008  
 
Multicollinearity. In Tables 7 and 8, I assessed the lack of multicollinearity 
assumption by evaluating the Pearson Correlation.  Research has shown that Pearson 
correlation values up to 0.8 suggest no multicollinearity, and those greater than 0.8 were 
considered to have multicollinearity (Lee et al., 2016; Lund and Lund, 2013a; Negreiros, 
2018). According to the data in correlations tables, there were no correlations 0.8, 
indicating no multicollinearity. Overall, the assumption of lack of multicollinearity has 
been met.  
Multivariate normality. Due to having a sample size under n=2000, the test used 
on this assumption was the Shapiro-Wilk test of normality on each dependent variable for 
each of the group independent variable (Garson, 2012; Lund & Lund, 2013a).  In Table 8, 
according to the Shapiro-Wilk test for normality of the three dependent variables and one 
covariate, all have a significance level less than .05, indicating that there was a non-
normal distribution and that the assumption was violated (Northern Arizona University, 
n.d.). Due to the violation of multivariate normality, a known correction has been 
performed. According to Mordkoff (2016), it has been suggested that “N’s of 10 or more 
were almost always enough to correct for any problems,” such as outliers. This correction 
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was considered sufficient even though the unproven sample sizes around 30 have been 
suggested to be a rule of thumb to meet the central limit theorem (Mordkoff, 2016). 
Therefore, multivariate normality was appropriate.  
Table 8 
Tests of Normality 
 
 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
@2moSystolic_BP_1 .259 29 .000 .820 29 .000 
@2moDiastolic_BP_1 .257 29 .000 .792 29 .000 
@2moO2_1_1 .362 29 .000 .693 29 .000 
@4moSystolic_BP_1 .253 29 .000 .873 29 .002 
@4moDiastolic_BP_1 .259 29 .000 .877 29 .003 
@4mo_O2_1_1 .431 29 .000 .507 29 .000 
@6moSystolic_BP_1 .296 29 .000 .833 29 .000 
@6moDiastolic_BP_1 .328 29 .000 .822 29 .000 
@6mo_O2_1_1 .362 29 .000 .707 29 .000 
@2moBMI_1_1 .305 29 .000 .806 29 .000 
@4mo_BMI_1_1 .293 29 .000 .736 29 .000 
@6mo_BMI_1_1 .293 29 .000 .777 29 .000 
 
a. Lilliefors Significance Correction 
 
Due to the conservative nature of the Shapiro-Wilks test, it has been indicated that 
it should not be the lone determining factor of normality (Northern Arizona University, 
n.d.). Additionally, understanding what multivariate normality looks like was important. 
Quantile-quantile (Q-Q) plots, located in Appendix C-N, were used to address the 
differences that the variables may have in relation to a normal distribution (Statistics 
Solutions, 2019a). Research suggests that Q-Q plot curve interpretations should be 
identified as one of six categories: normally distributed, convex (skewed left), concave 
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(skewed right), convex-concave (heavy-tailed), concave-convex (light-tailed), or a 
bimodal (separated cluster) distribution (Ruppert, 2011).   
Another Q-Q plot displayed in Appendix C at 2-months SBP appears to be a 
positive skewed concave-convexed distribution with several outliers between 120-140 
and 160-170. Within the Q-Q plots in Appendix D at 2-months, diastolic blood pressure 
appears to be a positively skewed convex-concaved distribution with one outlier between 
120-125. The Q-Q plots in Appendix E at 2-months oxygen saturation appears to be a 
positively skewed convex-concaved distribution with one outlier between 93-94.  
 The Q-Q plots in Appendix F at 4-months SBP appear to be a positively skewed 
convex-concaved distribution with several outliers between 100-105 and 165-175. Also, 
the Q-Q plot in Appendix G, at four months diastolic blood pressure, appears to be a 
positively skewed convex-concaved distribution with several outliers between 60-67. 
Within the Q-Q plot in Appendix H, at 4th months oxygen saturation appears to be a 
positively skewed convex-concaved distribution with several outliers between 80-85 and 
possible 93-95.  
Also, within the Q-Q plot in Appendix I, at 6-months SBP appears to be a 
positively skewed convex-concaved distribution with several outliers between 115-120, 
120-125, and 135-140. Furthermore, the Q-Q plot in Appendix J at 6-months diastolic 
blood pressure appears to be a positively skewed convex-concaved distribution with 
several outliers between and 50-53. Lastly, the Q-Q plot in Appendix K at 6-months 
oxygen saturation appears to be a positive skewed convex-concaved distribution with two 
outliers between 94, 97, and 100.   
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In Appendix L, the Q-Q plot at 2-month BMI appears to be a positively skewed 
convex-concaved distribution with several outliers between 25-28, 33-35, 35-38, and 44-
46. Within Appendix M, the Q-Q plot at 4-month BMI appears to be a positively skewed 
convex-concaved distribution with several outliers between 19-20, 30-35, 35-38, and 45-
47. Lastly, in Appendix N, the Q-Q plot at 6-month BMI appears to be a positively 
skewed convex-concaved distribution with several outliers between 25-27, 34-38, and 46-
48. Overall, multivariate normality does appear violated. Therefore, the corrective action 
of performing a visual inspection was implemented, and all assumed outlier values were 
identified as possible values and included in the data set (Ramzan, Ramzan, & Zahid, 
2013). Therefore, the multivariate normality assumption was met. 
Homogeneity of Variance and covariance. The test was initially noted to be 
evaluated by using the Box’s M test of Equality of Covariance Matrices, however, due to 
it not computing and there being fewer than two non-singular cell covariance matrices, 
the Levene’s test of equality of error variances was used. According to Garson, p-values 
in the Levene’s test was considered significant at <.05 (Garson, 2012). The Levene’s test 
of equality of error variances result has shown a non-statistically significant result for all 
the dependent variables indicating homogeneity of variance and covariance except for 4 
months diastolic blood pressure p-value of .004, and 4-months oxygen saturation which 
had a p-value of .005 (Northern Arizona University, n.d.). Overall, results show that two 
variables indicate statistically significant outcomes. Therefore, the significance of these 
results has shown a noticeable difference between the variable variances. Due to 
multivariate normality being violated, commonly used corrections have been reviewed, 
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and studies have suggested changing to a robust Levene’s significance level of <.001 
(Allen & Bennett, 2008; Gastwirth, Gel, & Miao, 2009; Han & Zhu, 2014). Therefore, 
correcting the number of significant results to zero, meeting the homogeneity of variance 
and covariance assumption.  
Table 9 
 
Levene’s Tests of Equality of Error Variance 
 
 
 
F df1 df2 Sig. 
@2moSystolic_BP_1 .861 3 25 .474 
@2moDiastolic_BP_1 1.145 3 25 .350 
@2moO2_1_1 1.547 3 25 .227 
@4moSystolic_BP_1 .980 3 25 .418 
@4moDiastolic_BP_1 5.656 3 25 .004 
@4mo_O2_1_1 5.496 3 25 .005 
@6moSystolic_BP_1 2.391 3 25 .093 
@6moDiastolic_BP_1 1.485 3 25 .243 
@6mo_O2_1_1 2.375 3 25 .094 
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups.a 
a. Design: Intercept + @2moBMI_1_1 + @4mo_BMI_1_1 + @6mo_BMI_1_1  
 
Results 
RQ1: Does use of MAD therapy have a statistically significant effect on the 
symptoms of heart failure in male African American veterans diagnosed with OSA? 
The independent variable in this study was the use of the MAD. The dependent 
variables were data collected using secondary data at the 2nd, 4th, and 6th month on the 
results of SBP, DBP, and oxygen saturation. Overall, within the dependent variable 
demographics, there was an increase in the SBP mean values while using the MAD 
device over the three interval months. There was also an increase in the DBP mean value 
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from the 2nd to the 4th month and a slight decrease in the 6th month. Additionally, there 
was a decrease in the oxygen saturation mean value from the 2nd to the 4th month, 
followed by a slight increase in the 6th month. Lastly, there was a very slight mean 
decrease in the covariate BMI from the 2nd month through the 6th month. I ran the 
rMANOVA test to assess the magnitude of the change in the mean values for measures 
related to symptoms of heart failure as a result of MAD use across the time span of 6 
months. Results related to this test were provided below. 
The first symptom to be reported were the values for SBP. Results from the 
Mauchly’s test of sphericity indicated that sphericity assumption was not violated as the 
result was not statistically significant at χ2(2) =3.72, p=.155. It was noted that the 
variances dated across the three time periods were equal. Therefore, values for the 
sphericity assumed line were used to assess the statistical significance of the results. A 
summary of the rMANOVA for SBP was presented in Table 10. The data revealed a 
statistically significant result [F (2, 56) = 5.341, p = .008]. The observed power statistic 
reveals that the differences in the mean scores were large enough to be detected with an 
82.00% probability. A review of the descriptive statistics revealed that mean SBP while 
using MAD increased from 127.31mmHg in the 2nd month, to 133.17 mmHg in the 4th 
month to 136.73 mmHg in the 6th month. Therefore, indicating that there was a 
significant difference in the effect of MAD use on SBP. 
Table 10 
Test of Within-Subjects Effects for Systolic Blood Pressure 
 
 
                  (table continues) 
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Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares Df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
factor1 Sphericity 
Assumed 
1311.660 2 655.830 5.341 .008 .160 10.681 .820 
Greenhouse-
Geisser 
1311.660 1.772 740.405 5.341 .010 .160 9.461 .784 
Huynh-Feldt 1311.660 1.882 696.769 5.341 .009 .160 10.054 .802 
Lower-bound 1311.660 1.000 1311.660 5.341 .028 .160 5.341 .607 
Error(factor
1) 
Sphericity 
Assumed 
6876.690 56 122.798 
     
Greenhouse-
Geisser 
6876.690 49.603 138.634 
     
Huynh-Feldt 6876.690 52.710 130.463      
Lower-bound 6876.690 28.000 245.596      
a. Computed using alpha = .05 
 
 
 
The second symptom to be reported were the values for diastolic blood pressure. Results 
from the Mauchly’s test of sphericity indicated that sphericity assumption was not 
violated as the result was not statistically significant at χ2(2) =3.76, p=.152. It was noted 
that the variances in the data across the three time periods were equal. Therefore, values 
for the sphericity assumed line was used to assess the statistical significance of the 
results. A summary of the rMANOVA for diastolic blood pressure was presented in table 
11. The data revealed a non-statistically significant result [F (2, 56) = 2.28, p = .111]. 
The observed power statistic reveals that the differences in the mean scores were large 
enough to be detected with a 44.50% probability.  
Table 11 
Test of Within-Subjects Effects for Diastolic Blood Pressure 
 
                  (table continues) 
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Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
factor1 Sphericity 
Assumed 
340.273 2 170.136 2.282 .111 .075 4.565 .445 
Greenhouse-
Geisser 
340.273 1.770 192.269 2.282 .118 .075 4.039 .416 
Huynh-Feldt 340.273 1.880 180.957 2.282 .115 .075 4.292 .430 
Lower-bound 340.273 1.000 340.273 2.282 .142 .075 2.282 .309 
Error(facto
r1) 
Sphericity 
Assumed 
4174.245 56 74.540 
     
Greenhouse-
Geisser 
4174.245 49.554 84.237 
     
Huynh-Feldt 4174.245 52.652 79.281      
Lower-bound 4174.245 28.000 149.080      
a. Computed using alpha = .05 
 
 
 
The third symptom to be reported was the values for oxygen saturation. Results 
from the Mauchly’s test of sphericity indicated that the sphericity assumption was 
violated as the result was statistically significant at χ2(2) =16.78, p=.000. It was noted 
that the variances dated across the three time periods were not equal. Subsequently, 
values for the Greenhouse-Geisser correction were used to assess the statistical 
significance of the results. A summary of the rMANOVA for oxygen saturation was 
presented in table 12. The data revealed a non-statistically significant result [F (1.36, 
38.27) = .671, p = .462]. The observed power statistic revealed that the differences in the 
mean scores were detected with a 13.70% probability.  
Table 12 
Test of Within-Subjects Effects for Oxygen Saturation 
 
                  (table continues) 
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Measure:   MEASURE_1   
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
factor1 Sphericity 
Assumed 
3.277 2 1.638 .671 .515 .023 1.342 .157 
Greenhouse-
Geisser 
3.277 1.367 2.397 .671 .462 .023 .918 .137 
Huynh-Feldt 3.277 1.413 2.318 .671 .467 .023 .949 .139 
Lower-bound 3.277 1.000 3.277 .671 .420 .023 .671 .124 
Error(factor
1) 
Sphericity 
Assumed 
136.682 56 2.441 
     
Greenhouse-
Geisser 
136.682 38.278 3.571 
     
Huynh-Feldt 136.682 39.578 3.453      
Lower-bound 136.682 28.000 4.881      
a. Computed using alpha = .05 
 
 
 
Results from the Pairwise Comparison test were provided below. Due to the small 
sample size, the Bonferroni test was used to limit Type 1 error across the pairwise 
comparison test (Horn, n.d.). The data revealed a statistically significant difference 
between the 2nd month SBP and 6th month SBP, p =.009. There were no statistically 
significant differences between either of the three periods among DBP or oxygen 
saturation.  
Table 13 
Pairwise Comparison Test  
Measure 
(I) 
factor1 
(J) 
factor1 
Mean 
Difference (I-
J) 
Std. 
Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
SBP 1 2 -5.861 3.332 .268 -14.345 2.623 
3 -9.418* 2.911 .009 -16.830 -2.005 
2 1 5.861 3.332 .268 -2.623 14.345 
                  (table continues) 
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3 -3.557 2.415 .456 -9.707 2.593 
3 1 9.418* 2.911 .009 2.005 16.830 
2 3.557 2.415 .456 -2.593 9.707 
DBP 1 2 -4.582 2.441 .213 -10.797 1.633 
3 -3.653 2.485 .458 -9.980 2.675 
2 1 4.582 2.441 .213 -1.633 10.797 
3 .929 1.814 1.000 -3.690 5.549 
3 1 3.653 2.485 .458 -2.675 9.980 
2 -.929 1.814 1.000 -5.549 3.690 
O2sat 1 2 .083 .469 1.000 -1.111 1.278 
3 -.364 .232 .386 -.955 .228 
2 1 -.083 .469 1.000 -1.278 1.111 
3 -.447 .481 1.000 -1.671 .777 
3 1 .364 .232 .386 -.228 .955 
2 .447 .481 1.000 -.777 1.671 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
In conclusion, the rMANOVA was conducted to test the mean change in 
symptoms of heart failure as a result of MAD use.  The results have shown that there was 
a significant mean difference between the intervention and the dependent variable. The 
dependent variable SBP was found to be significantly affected. 
RQ2: What is the moderating effect of BMI on the use of MAD therapy for 
treating symptoms of heart failure in male African American veterans diagnosed with 
OSA? 
The independent variable in this study was the use of the MAD. The dependent 
variables were data collected using secondary data at three different monthly interval 
measurements of the 2nd, 4th, and 6th month on the results of SBP, DBP, and oxygen 
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saturation. The covariate was BMI. I ran the rMANCOVA test to assess the magnitude of 
change in the mean values for measures related to symptoms of heart failure as a result of 
MAD use across the time span of 6 months while controlling for the covariates BMI. 
Results related to this test were provided below. 
The first symptom to be reported were the values for SBP. Results from the 
Mauchly’s test of sphericity indicated that sphericity assumption was not violated as the 
result was not statistically significant at χ2(2) =4.27, p=.118. It was noted that the 
variances dated across the three time periods were equal. Therefore, values for the 
sphericity assumed line were used to assess the statistical significance of the results. A 
summary of the rMANCOVA for SBP was presented in Table 14. The data revealed no 
statistically significant results within SBP [F (2, 50) = .640, p = .531], SBP *2moBMI 
[F(2, 50) = .944, p = .396], SBP *4moBMI  [F(2, 50) = 2.516, p = .091], and SBP 
*6moBMI [F(2, 50) = .025, p = .976].  
Table 14 
Test of Within-Subjects Effects for Systolic Blood Pressure and the Covariate of BMI 
 
 
Measure:   MEASURE_1   
Source 
Type III 
Sum of 
Squares Df 
Mean 
Square F 
 
Sig. Partial Eta 
Squared 
Noncent 
Paramet
er 
Observ
ed 
Powera 
SBP Sphericity 
Assumed 
154.748 2 77.374 .640 .531 .025 1.280 .151 
Greenhouse-
Geisser 
154.748 1.719 90.005 .640 .509 .025 1.101 .143 
Huynh-Feldt 154.748 2.000 77.374 .640 .531 .025 1.280 .151 
Lower-bound 154.748 1.000 154.748 .640 .431 .025 .640 .120 
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SBP * 
@2moBMI_1_
1 
Sphericity 
Assumed 
228.137 2 114.068 .944 .396 .036 1.888 .204 
Greenhouse-
Geisser 
228.137 1.719 132.689 .944 .385 .036 1.623 .191 
Huynh-Feldt 228.137 2.000 114.068 .944 .396 .036 1.888 .204 
Lower-bound 228.137 1.000 228.137 .944 .341 .036 .944 .154 
SBP * 
@4mo_BMI_1
_1 
Sphericity 
Assumed 
608.143 2 304.072 2.516 .091 .091 5.032 .481 
Greenhouse-
Geisser 
608.143 1.719 353.710 2.516 .100 .091 4.326 .443 
Huynh-Feldt 608.143 2.000 304.072 2.516 .091 .091 5.032 .481 
Lower-bound 608.143 1.000 608.143 2.516 .125 .091 2.516 .332 
SBP * 
@6mo_BMI_1
_1 
Sphericity 
Assumed 
5.937 2 2.968 .025 .976 .001 .049 .053 
Greenhouse-
Geisser 
5.937 1.719 3.453 .025 .962 .001 .042 .053 
Huynh-Feldt 5.937 2.000 2.968 .025 .976 .001 .049 .053 
Lower-bound 5.937 1.000 5.937 .025 .877 .001 .025 .053 
Error(SBP) Sphericity 
Assumed 
6042.598 50 120.852 
     
Greenhouse-
Geisser 
6042.598 42.983 140.580 
     
Huynh-Feldt 6042.598 50.000 120.852      
Lower-bound 6042.598 25.000 241.704      
a. Computed using alpha = .05 
 
 
The second symptom to be reported was the values for diastolic blood pressure 
(DBP). Results from the Mauchly’s test of sphericity indicated that sphericity assumption 
was not violated as the result was not statistically significant at χ2(2) =5.15, p=.076. It 
was noted that the variances dated across the three time periods were equal. Therefore, 
values for the sphericity assumed line was used to assess the statistical significance of the 
results. A summary of the rMANCOVA for diastolic blood pressure was presented in 
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table 15. The data revealed no statistically significant results within DBP [F (2, 50) = 
.310, p = .735], DBP*2moBMI [F(2, 50) = 1.156, p = .323], DBP*4moBMI  [F(2, 50) = 
1.980, p = .149], and DBP*6moBMI [F(2, 50) = 1.015, p = .370].  
Table 15 
Test of Within-Subjects Effects for Diastolic Blood Pressure and the Covariate BMI 
 
 
Measure:   MEASURE_1   
Source 
Type III 
Sum of 
Squares Df 
Mean 
Square F 
 
Sig. Partial Eta 
Squared 
Noncent 
Paramet
er 
Observ
ed 
Powera 
DBP Sphericity 
Assumed 
44.981 2 22.491 .310 .735 .012 .621 .097 
Greenhouse-
Geisser 
44.981 1.676 26.834 .310 .696 .012 .520 .093 
Huynh-Feldt 44.981 1.998 22.508 .310 .734 .012 .620 .097 
Lower-bound 44.981 1.000 44.981 .310 .582 .012 .310 .084 
DBP * 
@2moBMI_1_
1 
Sphericity 
Assumed 
167.566 2 83.783 1.156 .323 .044 2.312 .243 
Greenhouse-
Geisser 
167.566 1.676 99.964 1.156 .317 .044 1.938 .223 
Huynh-Feldt 167.566 1.998 83.847 1.156 .323 .044 2.311 .243 
Lower-bound 167.566 1.000 167.566 1.156 .293 .044 1.156 .179 
DBP * 
@4mo_BMI_1
_1 
Sphericity 
Assumed 
286.972 2 143.486 1.980 .149 .073 3.960 .390 
Greenhouse-
Geisser 
286.972 1.676 171.196 1.980 .157 .073 3.319 .355 
Huynh-Feldt 286.972 1.998 143.595 1.980 .149 .073 3.957 .390 
Lower-bound 286.972 1.000 286.972 1.980 .172 .073 1.980 .273 
DBP * 
@6mo_BMI_1
_1 
Sphericity 
Assumed 
147.085 2 73.542 1.015 .370 .039 2.030 .217 
Greenhouse-
Geisser 
147.085 1.676 87.745 1.015 .359 .039 1.701 .200 
Huynh-Feldt 147.085 1.998 73.598 1.015 .370 .039 2.028 .217 
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Lower-bound 147.085 1.000 147.085 1.015 .323 .039 1.015 .163 
Error (DBP) Sphericity 
Assumed 
3623.161 50 72.463 
     
Greenhouse-
Geisser 
3623.161 41.907 86.457 
     
Huynh-Feldt 3623.161 49.962 72.518      
Lower-bound 3623.161 25.000 144.926      
a. Computed using alpha = .05 
 
The third symptom to be reported were the values for oxygen saturation (O2sat). 
Results from the Mauchly’s test of sphericity indicated that the sphericity assumption was 
violated as the result was statistically significant at χ2(2) =6.936, p=.031. It was noted 
that the variances dated across the three time periods were not equal. Therefore, values 
for the Huynh-Feldt correction were used to assess the statistical significance of the 
results. A summary of the rMANCOVA for oxygen saturation was presented in table 16. 
The data revealed a statistically significant result O2sat *4moBMI [F (1.89, 47.39) = 
16.83, p = .000]. The observed power statistic reveals that the differences in the mean 
scores were large enough to be detected with a 99.80% probability. Data revealed no 
statistically significant results within O2sat [F (1.89, 47.39) = 2.61, p = .087], O2sat 
*2moBMI [F (1.89, 47.39) = .222, p = .790], and O2sat *6moBMI [F (1.89, 47.39) = 
2.60, p = .087].  
Table 16 
Test of Within-Subjects Effects for Oxygen Saturation and the Covariate BMI 
 
 
Measure:   MEASURE_1   
                  (table continues) 
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Source 
Type III 
Sum of 
Squares Df 
Mean 
Square F 
 
 
Sig. 
Partial Eta 
Squared 
Noncent 
Paramet
er 
Observ
ed 
Powera 
O2Sat Sphericity 
Assumed 
8.452 2 4.226 2.611 .083 .095 5.223 .497 
Greenhouse-
Geisser 
8.452 1.599 5.287 2.611 .097 .095 4.175 .439 
Huynh-Feldt 8.452 1.896 4.458 2.611 .087 .095 4.950 .482 
Lower-bound 8.452 1.000 8.452 2.611 .119 .095 2.611 .343 
O2sat * 
@2moBMI_1_
1 
Sphericity 
Assumed 
.718 2 .359 .222 .802 .009 .444 .083 
Greenhouse-
Geisser 
.718 1.599 .449 .222 .752 .009 .355 .080 
Huynh-Feldt .718 1.896 .379 .222 .790 .009 .421 .082 
Lower-bound .718 1.000 .718 .222 .642 .009 .222 .074 
O2sat * 
@4mo_BMI_1
_1 
Sphericity 
Assumed 
54.490 2 27.245 16.834 .000 .402 33.669 1.000 
Greenhouse-
Geisser 
54.490 1.599 34.083 16.834 .000 .402 26.914 .998 
Huynh-Feldt 54.490 1.896 28.742 16.834 .000 .402 31.915 .999 
Lower-bound 54.490 1.000 54.490 16.834 .000 .402 16.834 .976 
O2sat * 
@6mo_BMI_1
_1 
Sphericity 
Assumed 
8.445 2 4.223 2.609 .084 .095 5.218 .496 
Greenhouse-
Geisser 
8.445 1.599 5.282 2.609 .097 .095 4.171 .439 
Huynh-Feldt 8.445 1.896 4.455 2.609 .087 .095 4.946 .482 
Lower-bound 8.445 1.000 8.445 2.609 .119 .095 2.609 .342 
Error(O2sat) Sphericity 
Assumed 
80.920 50 1.618 
     
Greenhouse-
Geisser 
80.920 39.969 2.025 
     
Huynh-Feldt 80.920 47.395 1.707      
Lower-bound 80.920 25.000 3.237      
a. Computed using alpha = .05 
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In conclusion, the rMANCOVA was conducted to test the mean change in 
symptoms of heart failure as a result of MAD use while isolating for BMI.  The result 
showed that there was a significant mean difference between the intervention and 
dependent variable oxygen saturation when controlling for BMI at the 4-month. 
Summary 
The focus of my research was to assess change in the mean values for dependent 
variables effected by the use of MAD therapy while isolating for BMI. Based upon the 
analysis of the data, for RQ1, the alternative hypothesis was accepted due to there being a 
positive mean change that was specifically indicated in the dependent variable SBP. 
Additionally, in RQ2, the alternative hypothesis was accepted due to results indicated that 
MAD use was shown to have a significant negative effect on oxygen saturation in the 4th 
month when controlling for BMI. Therefore, the alternative hypothesis was accepted.  
Lastly, within the RQ3, data was observationally assessed to be insufficient due to having 
significant amounts of missing data and, therefore was not able to be determined. 
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Chapter 5: Discussions, Conclusions, Recommendations   
Introduction 
The purpose of this quantitative correlational study was to determine whether 
MAD therapy impacted symptoms of heart failure in African American male veterans 
over 20 years old diagnosed with OSA by using the rMANOVA. This study determined 
that treatment efficacy differs after controlling for patient BMI levels by using the 
rMANCOVA. Within the rMANOVA, it was revealed there was a mean change in SBP 
while using the MAD. This study’s findings indicate that SBP was affected by the use of 
MAD among those with OSA and may benefit African American male veterans with 
OSA. Within the rMANCOVA, it was determined that MAD use treatment efficacy was 
negatively moderated after controlling for an obese BMI after 4 months pertaining to the 
oxygen saturation level. In Chapter 5, I discuss interpretations of the findings, limitations 
of the study, recommendations, implications, and provide a conclusion.  
Interpretation of the Findings 
The results of my study should be considered when trying to relay information to 
improve the heart failure biomarkers of oxygen saturation and SBP.  The archival data in 
my study did provide comparable information as shown by Dudley and Patel (2016), 
which argued that BMI among male African Americans was significantly high. Within 
the study by Cistulli et al. (2009), reports indicated that the upper airway was affected by 
the use of oral mandibular devices on patients. Results of my study yielded a statistically 
significant negative result on the dependent variable oxygen saturation in male African 
American veterans who used the MAD, when controlling for an obese BMI.  
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According to Booth et al. (2014), the MAD has been suggested to possibly 
improve blood pressure.  Throughout my study, changes in the mean values of SBP were 
seen in African Americans male veterans while using MAD therapy. The result of my 
study extended knowledge to the public health and healthcare disciplines that was 
previously not available by providing information that aids in analyzing the effect that 
MAD therapy has on heart failure symptoms among the African American populations 
related to those with OSA, heart failure, and BMI. Furthermore, my study allowed for 
information to be gained regarding the effects MAD therapy has on heart failure 
symptoms and identified which biomarkers were susceptible to change when using the 
MAD device within a 6-month timeframe.  
In relation to the oxidative stress theory, study results have suggested that 
oxidative damage to lipids, DNA, and proteins may be reduced as a result of MAD 
therapy. The possible change in oxygen flow may be evidence of the statistical changes 
in SBP levels, which may suggest reductions in attacks on mitochondria by potentially 
limiting ROS. This potential change may allow for increased cardiovascular function 
resulting in decreased heart failure symptoms as a result of a decrease in BMI. 
Limitations of the Study 
Limitations in this study may have been due to the use of secondary data as well 
as the lack of complete data provided in the initial study sample. Cheng and Phillips 
(2014) have indicated that limitations may consist of secondary data not always having 
been collected by the same person, which may have led to inconsistent routines or 
knowledge bases to verify data. Secondary data usage may have also served as a 
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limitation in the study due to the initial medical provider who collected the data possibly 
having biases, brain fatigue, or brain overload, resulting in possible inaccurate 
information being recorded (Cheng and Phillips, 2014). Within the initial queried sample 
from VINCI there was a significant amount of missing data for many of the study 
variables resulting in data being limited. Limited data present in my study resulted in 
removing 1582 African American archived records that may have been used to provide 
more validity to the study if not for missing data. The limitation in archived records may 
have affected the potential generalizability of the study, even though the study did display 
adequate power and sample size (Davis-Kean, Jager & Maslowsky, 2015). Additionally, 
limitations due to missing data resulted in having RQ3 removed. These limitations were 
difficult to address due to having no control over extraneous variables. 
In addition to the possible limitations involved in purposeful convenience 
sampling, there were no cause-effect relationships between variables, several of the 
assumptions for both rMANOVA and rMANCOVA were violated, and there was a 
possible decrease in validity and reliability.  Limitations in purposeful sampling included 
susceptibility to judgment error, low reliability, high potential for bias, and the inability 
of findings to be generalized (Dudovskiy, 2019). Due to the use of purposeful sampling, 
there may be a limitation in external validity due to the lack of sample randomization 
(Crawford and Khorsan, 2014). Another limitation of the study may be its correlational 
design. Correlational designs may show that there is a relationship between variables; 
however, they cannot imply causal effect (Rohrer, 2018). Causal effect indicates that one 
action causes another (Australian Bureau of Statistics, 2013). As a result of the use of 
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secondary data, a causal effect may not be clear due to data possibly having 
uncontrollable variables, including human error, exposure to unknown factors that may 
alter results, and the potential for biases before receiving.  
Some initial dependent variables in the study displayed missing data, resulting in 
a means imputation; however, if missing data was initially provided at the beginning of 
the study, it may have enhanced the study validity, and possibly increased the low 
generalizability within this study (Davis-Kean, Jager, & Maslowsky, 2015). Therefore, 
the results of the study may not be generalizable to the larger African American male 
veteran study population due to the small sample size.  This study may not be 
generalizable due to having used only African American male veterans who were over 20 
years old, which may make it difficult to generalize results to any other group, gender, or 
race. Conclusion validity was the level to which a reasonable deduction was reached in 
terms of relationships of variables through statistical analysis observation. Conclusion 
validity must also be considered as a limitation due to having a violation of multivariate 
normality assumptions that may have led to an incorrect relationship inference (Indiana, 
n.d.). Conclusion validity may have been mitigated by using an appropriate statistical 
power of at least 80% (Hoare & Hoe, 2012). Within this study, there were possible 
unknown extraneous variables in the data that may have included the possible attrition of 
participants in the form of non-compliance or drop out of the study. According to 
Amankwaa (2016), trustworthiness involves credibility, transferability, dependability, or 
confirmability. The National Coordination Office for Networking and Information 
Technology Research and Development (2016), indicated the trustworthiness of data by 
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federal agencies are required by the federal government due to the Information Quality 
Act of 2001. Due to the data being securely gathered, maintained, and provided by the 
VA, there were no concerns involving a lack of trustworthiness.  
Recommendations 
This study began to bridge the gap in the literature regarding the effect the MAD 
has on heart failure symptoms as well as the moderating effect of BMI. This study 
analysis did not, however, answer all the questions pertaining to the effects that MAD has 
on the scope of heart failure. I recommend further research be done to confirm the results 
of this study. Research may also be needed that uses larger sample sizes with more access 
to heart failure biomarkers. Further investigation should be done as a comparative 
analysis on the effect that MAD therapy has on heart failure symptoms across studies. 
Future research might include identifying how the MAD effects heart failure symptoms 
through a pre and posttest. Recommendations for practice might also include a bimonthly 
analysis of how MAD use effects heart failure symptoms in African American veteran 
women vs. men. Another recommendation would be to study the effect that the MAD has 
on different levels of BMI in African American veterans over age 20.  
Additionally, another recommendation would be to perform this study on non-
veteran African Americans, other minorities, and races. This study was primarily focused 
on African American male veterans in the U.S. and may benefit from further research 
abroad on other minority foreign military veterans, such as India who one of the world’s 
largest military services (Statista, 2019). Lastly, additional research might include an 
exploration into why the MAD is currently not covered by insurance companies for OSA 
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patients. A higher number of African Americans suffer from OSA, more than any other 
race (Clark et al., 2016).   
Implications 
The potential impact from this study to create positive social change may be felt 
at the family and individual levels for caregivers and patients with OSA and heart failure 
patients wanting information on the benefits of MAD use. Organizationally this data can 
be used for health agencies and departments wanting to know the benefits of MAD use 
OSA in relation to heart failure symptoms prior to the prescription of the other devices or 
medications. Societally, the results of this study on possible SBP improvement may be 
used by the general public to help promote the need for an alternative cost-effective OSA 
health solution that does not require electricity usage or excess equipment. This study 
may also benefit society due to the information it has obtained on MAD use over the 
extended six month time period. Results from this study may also be beneficial, 
providing information as to what interval measure the device was most useful in relation 
to symptoms of heart failure. Information captured in this study may also be beneficial 
societally by knowing the potential limitations that can be caused when using the MAD 
and having a high BMI. Regarding policy, this study adds more information to the 
policymaking arena on the uses of MAD and its effectiveness on OSA as well as its 
benefit on symptoms of heart failure, i.e., SBP. Results from this study can be utilized by 
both the public health and medical field to further indicate the benefits of MAD treatment 
on OSA and heart failure. Currently, insurance companies do not cover the MAD as an 
alternative treatment for OSA, and results from this study can be used as a reference for 
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policies to be written by agencies and lawmakers at the local, state level, and federal 
levels regarding insurance coverages. 
Conclusion 
Heart failure symptoms in those with OSA were found to be a destructive 
epidemic that affects 24.9 million Americans and 4.1 million African Americans every 
year, of all ages, genders, and ethnicities but especially those who are African American, 
males, and Veterans (Capaldi, Guerrero & Killgore, 2011; Dudley & Patel, 2016; United 
States Census Bureau, 2017; Watson, 2016). This epidemic has many different 
parameters and has historically occurred involuntarily, gone unnoticed for the better part 
of a century and in some cases, continues to go untreated due to lack of knowledge, 
finances, insurances, or resources (ALA, 2018; Gillespie et al., 2015). This gap in the 
literature has guided me to inspect whether MAD therapy impacts the symptoms of heart 
failure in African American male veterans diagnosed with OSA. This study has also 
determined whether MAD treatment efficacy differs after controlling for patient BMI 
levels, however, it was unable to assess the MAD effects of those who smoke. This study 
sought to shine a light on specific questions regarding the use of the MAD. My overall 
goal was to better understand the effect the MAD therapy has on heart failure symptoms 
in African American Veterans in hopes of extending the public health knowledge base 
regarding this non-invasive treatment for the benefit of those most affected. Though there 
remains much more research to be done, I hope the results provided in this study can lay 
the groundwork for others to continue research and to further understand the benefit of 
the MAD.  
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Appendix A: Z-score Univariate Outliers 
 
Z@2mo 
SBP 
Z@2mo
DBP 
Z@2mo
O2 
Z@4mo 
SBP 
Z@4mo 
DBP 
Z@4m
o_O2 
Z@6mo 
SBP 
Z@6mo 
DBP 
Z@6mo
_O2 
.11538 .72160 1.93218 -.92492 -.50233 .00000 .13835 .75733 .00000 
-.36417 -1.07060 -.96609 .73020 -.92931 .89148 -2.48309 -1.84600 -3.59255 
-.50118 -.71216 .00000 .00000 .00000 .00000 -2.37386 -3.50267 .67967 
.00000 .00000 .00000 .56469 1.34792 .03566 -1.50005 .40233 -.38838 
.00000 .00000 .00000 .06815 .06698 -.82016 .79371 .40233 .00000 
.18389 .27355 .00000 .00000 .00000 .00000 .00000 .00000 .00000 
-.50118 -.08489 .00000 -.51114 .35163 .00000 .00000 .00000 .00000 
.32090 .99043 .00000 -.01460 .63629 .00000 .00000 .00000 .00000 
2.30760 3.94755 .00000 .00000 .00000 .00000 .00000 .00000 .00000 
-1.04924 -.98099 .00000 3.13012 .92094 1.31939 1.12139 .40233 .67967 
.00000 .00000 .00000 .23366 .77861 .46357 .79371 .87567 .00000 
2.58162 .00472 .96609 1.80602 .35163 .00000 2.10443 .87567 .67967 
.00000 .00000 .00000 -2.33177 -3.06422 -
4.67134 
.00000 .00000 .00000 
-1.39177 -1.69787 .96609 .00000 .00000 .00000 .00000 .00000 .00000 
.00000 .00000 .00000 .73020 1.91723 .00000 .02913 -.66267 .00000 
-.22715 -1.16021 .00000 .00000 .00000 .00000 .00000 .00000 .00000 
1.00597 .27355 .00000 .00000 .00000 .00000 -.08010 -.78100 .00000 
-.77521 .81121 1.93218 .06815 .35163 1.31939 .00000 .00000 .00000 
.00000 .00000 .00000 -1.33870 -.21768 .46357 .79371 -1.37267 2.81578 
.00000 .00000 .00000 -1.33870 -.78699 .03566 -1.71850 .04733 .67967 
-.63819 -.98099 -.96609 1.14398 1.91723 .89148 1.44907 1.94067 -1.45644 
.00000 .00000 .00000 .00000 .00000 .00000 -.18933 1.23067 -1.45644 
.00000 .00000 .00000 .00000 .00000 .00000 .00000 .00000 .00000 
-1.11774 .00472 .96609 -.92492 -1.07164 .03566 .00000 .00000 .00000 
-1.32326 -.71216 .00000 -1.09043 -2.06793 .03566 .00000 .00000 .00000 
.00000 .00000 .00000 .00000 .00000 .00000 1.12139 1.23067 .67967 
2.51312 1.16965 .00000 .00000 .00000 .00000 .00000 .00000 .67967 
-.84372 -.17450 -3.86437 .00000 .00000 .00000 .00000 .00000 .00000 
-.29566 -.62255 -.96609 .00000 .00000 .00000 .00000 .00000 .00000 
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Appendix B: MAD Residuals Statistics 
 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value 45.098 81.485 62.833 7.181 29 
Std. Predicted Value -2.470 2.597 .000 1.000 29 
Standard Error of Predicted 
Value 
1.211 6.036 3.553 1.455 29 
Adjusted Predicted Value 41.686 88.335 62.373 8.792 29 
Residual -11.059 9.278 .000 5.372 29 
Std. Residual -1.696 1.423 .000 .824 29 
Stud. Residual -2.084 1.904 .011 1.059 29 
Deleted Residual -20.696 26.907 .460 10.079 29 
Stud. Deleted Residual -2.310 2.060 .000 1.112 29 
Mahal. Distance .000 23.021 8.690 7.044 29 
Cook's Distance .001 1.340 .123 .280 29 
Centered Leverage Value .000 .822 .310 .252 29 
 
a. Dependent Variable: Factor1 
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Appendix C: rMANOVA Q-Q Plot for SBP @ 2-months 
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Appendix D: rMANOVA Q-Q Plot for DBP @ 2-months 
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Appendix E: rMANOVA Q-Q Plot for O2sat @ 2-months 
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Appendix F: rMANOVA Q-Q Plot for SBP @ 4-months 
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Appendix G: rMANOVA Q-Q Plot for DBP @ 4-months 
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Appendix H: rMANOVA Q-Q Plot for O2sat @ 4-months 
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Appendix I: rMANOVA Q-Q Plot for SBP @ 6-months 
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Appendix J: rMANOVA Q-Q Plot for DBP @ 6-months 
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Appendix K: rMANOVA Q-Q Plot for O2sat @ 6-months 
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Appendix L: rMANCOVA Q-Q Plot for BMI @ 2-months 
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Appendix M: rMANCOVA Q-Q Plot for BMI @ 4-months 
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Appendix N: rMANCOVA Q-Q Plot for BMI @ 6-months 
 
